Uptake of Genetic Testing
~ Genetics of Breast & Ovarian Cancer

Papers dealing with demographics of testing, timing of testing, numbers of patients tested (or not tested) in given programs, overall population trends in testing, barriers to and facilitators of uptake/testing, etc.

List was last updated on Nov 28, 2021 @ 10:43 pm.


    • Disparities in Genetic Testing for Heritable Solid-Tumor Malignancies.
    • Dillon J, Ademuyiwa FO, Barrett M, Moss HA, Wignall E, Menendez C, Hughes KS, Plichta JK.
    • Surg Oncol Clin N Am. 2022 Jan;31(1):109-126. doi: 10.1016/j.soc.2021.08.004. Epub 2021 Oct 19.
    • Review
    • Survey Reveals Groups, Strategies to Focus Awareness Efforts for Cancer Germline Testing.
    • Kanski A.
    • Precision Oncology News. Biomarkers. BRCA. 2021 Nov 23.
    • News
    • Conference Session Highlight: I'm Not White, Can I Still Have a Mutation?
    • Stallings E, Goldberg D.
    • FORCE. Blog. 2021 Nov 19.
    • Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context.
    • Kolinsky MP, Niederhoffer KY, Kwan EM, Hotte SJ, Hamilou Z, Yip SM, Chi KN, Wyatt AW, Saad F.
    • Can Urol Assoc J. 2021 Nov 18. doi: 10.5489/cuaj.7621. Epub ahead of print.
    • Feasibility of a Traceback Approach for Using Pathology Specimens to Facilitate Genetic Testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study Protocol.
    • Kauffman TL, Prado YK, Reyes AA, Zepp JM, Sawyer J, White LL, Martucci J, Salas SB, Vertrees S, Rope AF, Weinmann S, Henrikson NB, Lee SS, Feigelson HS, Hunter JE.
    • J Pers Med. 2021 Nov 13;11(11):1194. doi: 10.3390/jpm11111194.
    • Access to Information and Support is the Key to Education for the Deaf Community.
    • Lesser D.
    • FORCE. Blog. 2021 Nov 10.
    • Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study.
    • Furniss CS, Yurgelun MB, Ukaegbu C, Constantinou PE, Lafferty CC, Talcove-Berko ER, Schwartz AN, Stopfer JE, Underhill-Blazey M, Kenner B, Nelson SH, Okumura S, Law S, Zhou AY, Coffin TB, Rodriguez NJ, Uno H, Ocean AJ, McAllister F, Lowy AM, Lippman SM, Klein AP, Madlensky L, Petersen GM, Garber JE, Goggins MG, Maitra A, Syngal S.
    • Cancer Prev Res (Phila). 2021 Nov;14(11):1021-1032. doi: 10.1158/1940-6207.CAPR-20-0642. Epub 2021 Oct 8.
    • Research to reduce inequities in cancer risk services: Insights for remote genetic counseling in a pandemic and beyond.
    • Lee R, Frick M, Joseph G, Guerra C, Stewart S, Kaplan C, Dixit N, Tsoh JY, Flores S, Pasick RJ.>
    • J Genet Couns. 2021 Oct 23. doi: 10.1002/jgc4.1525. Epub ahead of print.
    • ASO Author Reflections: Germline Testing for All Patients With Breast Cancer: Has the Time Finally Come?
    • Mittal A, Pramanik R.
    • Ann Surg Oncol. 2021 Oct 15. doi: 10.1245/s10434-021-10880-8. Epub ahead of print.
    • Genetic Counseling, Screening and Risk-Reducing Surgery in Patients with Primary Breast Cancer and Germline BRCA mutations: Unmet needs in Low- and Middle- Income Countries.
    • Moukadem HA, Al Masry A, Atwani RW, Kreidieh F, Khalil LE, Saroufim R, Daouk S, Dalle IA, El Saghir NS.
    • Eur J Breast Health. 2021 Oct 13. doi: 10.4274/ejbh.galenos.2021.2021-5-1. [Epub ahead of print]
    • Communication processes about predictive genetic testing within high-risk breast cancer families: a two-phase study design.
    • Blomen CL, Pott A, Volk AE, Budäus L, Witzel I.
    • Sci Rep. 2021 Oct 11;11(1):20178. doi: 10.1038/s41598-021-98737-8.
    • Invitae, Outcomes4Me Collaborate to Improve Breast Cancer Genetic Testing Access.
    • [No author given]
    • GenomeWeb. Diagnostics. 2021 Oct 8.
    • Study: Genetic testing for inherited mutations may be helpful for all people with advanced or metastatic cancer.
    • [No author given]
    • FORCE. XRAY. 2021 Sep 30.

    Related:

    Original research:

    Therapeutic Implications of Germline Testing in Patients With Advanced Cancers.

    • Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing.
    • Wang Y, Golesworthy B, Cuggia A, Domecq C, Chaudhury P, Barkun J, Metrakos P, Asselah J, Bouganim N, Gao ZH, Chong G, Foulkes WD, Zogopoulos G.
    • J Med Genet. 2021 Sep 23:jmedgenet-2021-108054. doi: 10.1136/jmedgenet-2021-108054. Epub ahead of print.
    • Management of breast cancer patients with BRCA gene mutations in Lebanon of the Middle East: perspectives and challenges.
    • El Saghir NS, Ghanem H, El Karak F, Farhat F, Ghosn M, Makdessi J, Chouaib K, Debs J, Tabchy AB.
    • Hosp Pract (1995). 2021 Sep 22:1-5. doi: 10.1080/21548331.2021.1974678. Epub ahead of print.
    • Commentary
    • Genetic testing in women with early-onset breast cancer: a Traceback pilot study.
    • Augustinsson A, Nilsson MP, Ellberg C, Kristoffersson U, Olsson H, Ehrencrona H.
    • Breast Cancer Res Treat. 2021 Sep 16:1–9. doi: 10.1007/s10549-021-06351-z. Epub ahead of print.
    • Feasibility of genetic testing for cancer risk assessment programme in Nigeria.
    • Adejumo PO, Aniagwu TIG, Awolude OA, Oni AO, Ajayi OO, Fagbenle O, Ogungbade D, Kochheiser M, Ogundiran T, Olopade OI.
    • Ecancermedicalscience. 2021 Sep 7;15:1283. doi: 10.3332/ecancer.2021.1283.
    • Pretest Genetic Education Video Versus Genetic Counseling for Men Considering Prostate Cancer Germline Testing: A Patient-Choice Study to Address Urgent Practice Needs.
    • Russo J, McDougall C, Bowler N, Shimada A, Gross L, Hyatt C, Kelly WK, Calvaresi A, Handley NR, Hirsch IH, Izes JK, Lallas CD, Mann M, Mark JR, Mille PJ, Preate Jr D, Trabulsi EJ, Tsang M, Chandrasekar T, Weiner PR, Gomella LG, Giri VN.
    • JCO Precis Oncol. 2021;5:1377. doi: 10.1200/PO.21.00238. Epub 2021 Sep 1.
    • Cascade Genetic Testing for Hereditary Cancer Risk: An Underutilized Tool for Cancer Prevention.
    • Whitaker KD, Obeid E, Daly MB, Hall MJ.
    • JCO Precis Oncol. 2021;5:1387. doi: 10.1200/PO.21.00163. Epub 2021 Sep 1.
    • Review
    • Implementation of Multigene Germline and Parallel Somatic Genetic Testing in Epithelial Ovarian Cancer: SIGNPOST Study.
    • Chandrasekaran D, Sobocan M, Blyuss O, Miller RE, Evans O, Crusz SM, Mills-Baldock T, Sun L, Hammond RFL, Gaba F, Jenkins LA, Ahmed M, Kumar A, Jeyarajah A, Lawrence AC, Brockbank E, Phadnis S, Quigley M, El Khouly F, Wuntakal R, Faruqi A, Trevisan G, Casey L, Burghel GJ, Schlecht H, Bulman M, Smith P, Bowers NL, Legood R, Lockley M, Wallace A, Singh N, Evans DG, Manchanda R.
    • Cancers (Basel). 2021 Aug 27;13(17):4344. doi: 10.3390/cancers13174344.
    • Patient-Reported Outcomes following Genetic Testing for Familial Hypercholesterolemia, Breast and Ovarian Cancer Syndrome, and Lynch Syndrome: A Systematic Review.
    • Hendricks-Sturrup RM, Joseph L, Lu CY.
    • J Pers Med. 2021 Aug 27;11(9):850. doi: 10.3390/jpm11090850.
    • Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas.
    • Somasegar S, Weiss AS, Norquist BM, Khasnavis N, Radke M, Manhardt E, Pennil C, Pennington KP, Eckert MA, Chryplewicz A, Lengyel E, Swisher EM.
    • Gynecol Oncol. 2021 Aug 24:S0090-8258(21)01315-9. doi: 10.1016/j.ygyno.2021.08.017. Epub ahead of print.
    • Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
    • Arun BK, Peterson SK, Sweeney LE, Bluebond RD, Tidwell RSS, Makhnoon S, Kushwaha Ac.
    • Cancer. 2021 Aug 23. doi: 10.1002/cncr.33866. Epub ahead of print

    Related:

    Editorial:

    Population screening to identify women at risk for hereditary breast cancer syndromes: The path forward or the road not taken?

    • "Being proactive, not reactive": exploring perceptions of genetic testing among White, Latinx, and Pacific Islander Populations.
    • Chavez-Yenter D, Vagher J, Clayton MF, Rindler M, Shukovich M, Kaphingst KA.
    • J Community Genet. 2021 Aug 20. doi: 10.1007/s12687-021-00542-3. Epub ahead of print.
    • Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology Clinics.
    • Sturgill EG, Misch A, Lachs R, Jones CC, Schlauch D, Jones SF, Shastry M, Yardley DA, Burris III HA, Spigel DR, Hamilton EP, McKenzie AJ.
    • JCO Precis Oncol. 2021;5:1297. doi: 10.1200/PO.20.00469. Epub 2021 Aug 19.

    Related:

    Press: NGS Use for Breast Cancer Increases Sixfold in Community Oncology Clinics, Study Finds. (Precision Oncology News)

    • Genetic epidemiology of BRCA1- and BRCA2-associated cancer across Latin America.
    • Herzog JS, Chavarri-Guerra Y, Castillo D, Abugattas J, Villarreal-Garza C, Sand S, Clague-Dehart J, Alvarez-Gómez RM, Wegman-Ostrosky T, Mohar A, Mora P, Del Toro-Valero A, Daneri-Navarro A, Rodriguez Y, Cruz-Correa M, Ashton-Prolla P, Alemar B, Mejia R, Gallardo L, Shaw R, Yang K, Cervantes A, Tsang K, Nehoray B, Barrera Saldana H, Neuhausen S, Weitzel JN.
    • NPJ Breast Cancer. 2021 Aug 19;7(1):107. doi: 10.1038/s41523-021-00317-6.
    • Study: Frequency of inherited mutations linked to breast cancer are similar in Black and white women.
    • [No author given]
    • FORCE. XRAY. 2021 Aug 13.

    Related:

    Original research:

    Comparison of the Prevalence of Pathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United States.

    • Following NCCN guidelines within one hospital system in the United States: Comparison between cancer centers and genetic counselor utilization.
    • Powell K, Rakestraw J, Gupta S, Shou W, Lee K, Leitner O.
    • J Genet Couns. 2021 Aug 9. doi: 10.1002/jgc4.1495. Epub ahead of print.
    • Update: Breast cancer disparities in Black Americans.
    • [No author given]
    • FORCE. XRAY. 2021 Aug 5.

    Related:

    Progress Report: Cancer Disparities Progress Report 2020: Achieving the Bold Vision of Health Equity for Racial and Ethnic Minorities and Other Underserved Populations. (AACR, American Association for Cancer Research)

    • A report on the 73th Annual Congress of the Japan Society of Obstetrics and Gynecology International Workshop for Junior Fellows: Risk-reducing surgery for hereditary breast and ovarian cancer.
    • Hirayama T, Inayama Y, Odajima S, Yamanaka A, Sekine M, Terao Y, Koide K, Kuwabara Y, Yahata H, Yanaihara N, Nagase S, Kobayashi Y, Sekizawa A.
    • J Obstet Gynaecol Res. 2021 Aug 1. doi: 10.1111/jog.14952. Epub ahead of print.
    • Conference news
    • Overview of Prostate Cancer Genetic Testing.
    • Chandrasekar T, Kelly WK, Gomella LG.
    • Urol Clin North Am. 2021 Aug;48(3):279-282. doi: 10.1016/j.ucl.2021.04.002. Epub 2021 Jun 10.
    • Review
    • Risk-Stratified Approach to Breast Cancer Screening in Canada: Women’s Knowledge of the Legislative Context and Concerns about Discrimination from Genetic and Other Predictive Health Data.
    • Alarie S, Hagan J, Dalpé G, Faraji S, Mbuya-Bienge C, Nabi H, Pashayan N, Brooks JD, Dorval M, Chiquette J, Eloy L, Turgeon A, Lambert-Côté L, Paquette JS, Walker MJ, Lapointe J, Granados Moreno P, Blackmore K, Wolfson M, Broeders M, The PERSPECTIVE I&I Study Group, Knoppers BM, Chiarelli AM, Simard J, Joly Y.
    • J Pers Med. 2021 Jul 27;11(8):726. doi: 10.3390/jpm11080726.
    • Barriers to family history knowledge and family communication among LGBTQ+ individuals in the context of hereditary cancer risk assessment.
    • Rolf BA, Schneider JL, Amendola LM, Davis JV, Mittendorf KF, Schmidt MA, Jarvik GP, Wilfond BS, Goddard KAB, Ezzell Hunter J.
    • J Genet Couns. 2021 Jul 23. doi: 10.1002/jgc4.1476. Epub ahead of print.
    • Genetic Landscape of Male Breast Cancer.
    • Campos FAB, Rouleau E, Torrezan GT, Carraro DM, Casali da Rocha JC, Mantovani HK, da Silva LR, Osório CABT, Moraes Sanches S, Caputo SM, Santana Dos Santos E.
    • Cancers (Basel). 2021 Jul 15;13(14):3535. doi: 10.3390/cancers13143535.
    • Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer.
    • Hamilton JG, Symecko H, Spielman K, Breen K, Mueller R, Catchings A, Trottier M, Salo-Mullen EE, Shah I, Arutyunova A, Batson M, Gebert R, Pundock S, Schofield E, Offit K, Stadler ZK, Cadoo K, Carlo MI, Narayan V, Reiss KA, Robson ME, Domchek SM.
    • Genet Med. 2021 Jul 13. doi: 10.1038/s41436-021-01262-2. Epub ahead of print.
    • Success Factors and Barriers in Combining Personalized Medicine and Patient Centered Care in Breast Cancer. Results from a Systematic Review and Proposal of Conceptual Framework.
    • Giulio de Belvis A, Pellegrino R, Castagna C, Morsella A, Pastorino R, Boccia S.
    • J Pers Med. 2021 Jul 13;11(7):654. doi: 10.3390/jpm11070654.
    • Patient ethnicity and cascade genetic testing: a descriptive study of a publicly funded hereditary cancer program.
    • Braley EF, Bedard AC, Nuk J, Hong Q, Bedard JEJ, Sun S, Schrader KA.
    • Fam Cancer. 2021 Jul 7. doi: 10.1007/s10689-021-00270-0. Epub ahead of print.
    • Influence of payer coverage and out-of-pocket costs on ordering of NGS panel tests for hereditary cancer in diverse settings.
    • Lin GA, Trosman JR, Douglas MP, Weldon CB, Scheuner MT, Kurian A, Phillips KA.
    • J Genet Couns. 2021 Jul 7. doi: 10.1002/jgc4.1459. Epub ahead of print.
    • Comparison of the Prevalence of Pathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United States.
    • Domchek SM, Yao S, Chen F, Hu C, Hart SN, Goldgar DE, Nathanson KL, Ambrosone CB, Haiman CA, Couch FJ, Polley EC, Palmer JR; CARRIERS Consortium.
    • JAMA Oncol. 2021 Jul 1;7(7):1045-1050. doi: 10.1001/jamaoncol.2021.1492.

    Related:

    Research news: Study: Frequency of inherited mutations linked to breast cancer are similar in Black and white women. (FORCE. XRAY)

    Research news: UPenn Study Finds Similar Rates of Risk Mutations Among Black, White Breast Cancer Patients. (Precision Oncology News)

    • Challenges and Opportunities in Engaging Primary Care Providers in BRCA Testing: Results from the BFOR Study.
    • Pace LE, Tung N, Lee YS, Hamilton JG, Gabriel C, Revette A, Raja S, Jenkins C, Braswell A, Morgan K, Levin J, Block J, Domchek SM, Nathanson K, Symecko H, Spielman K, Karlan B, Kamara D, Lester J, Offit K, Garber JE, Keating NL.
    • J Gen Intern Med. 2021 Jun 25. doi: 10.1007/s11606-021-06970-8. Epub ahead of print.
    • Expanding the search for germline pathogenic variants for breast cancer. How far should we go and how high should we jump? The missed opportunity!
    • Abdel-Razeq H.
    • Oncol Rev. 2021 Jun 24;15(1):544. doi: 10.4081/oncol.2021.544.
    • The evolving role of germline genetic testing and management in prostate cancer: Report from the Princess Margaret Cancer Centre International Retreat.
    • Clark R, Kenk M, McAlpine K, Thain E, Farncombe KM, Pritchard CC, Nussbaum R, Wyatt AW, de Bono J, Vesprini D, Bombard Y, Lorentz J, Narod S, Kim R, Fleshner N.
    • Can Urol Assoc J. 2021 Jun 22. doi: 10.5489/cuaj.7383. Epub ahead of print.
    • Framing Effects on Decision-Making for Diagnostic Genetic Testing: Results from a Randomized Trial.
    • Dwyer AA, Shen H, Zeng Z, Gregas M, Zhao M.
    • Genes (Basel). 2021 Jun 20;12(6):941. doi: 10.3390/genes12060941.
    • A Retrospective 5-Year Single Center Study Highlighting the Risk of Cancer Predisposition in Adolescents and Young Adults.
    • Jordan F, Huber S, Sommer S, Schenkirsch G, Frühwald MC, Trepel M, Claus R, Kuhlen M.
    • Cancers (Basel). 2021 Jun 17;13(12):3033. doi: 10.3390/cancers13123033.
    • Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?
    • Dunn C, Gately L, Gibbs P.
    • JAMA Oncol. 2021 Jun 17. doi: 10.1001/jamaoncol.2021.1904. Epub ahead of print.
    • Letter, Comment

    Related:

    Letter, Reply:

    Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?-Reply.

    Original research:

    Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.

    • Disparity in Access to Oncology Precision Care: A Geospatial Analysis of Driving Distances to Genetic Counselors in the U.S.
    • Bellaiche MMJ, Fan W, Walbert HJ, McClave EH, Goodnight BL, Sieling FH, Moore RA, Meng W, Black CM.
    • Front Oncol. 2021 Jun 16;10:689927. doi: 10.3389/fonc.2021.689927.
    • Therapeutic Implications of Germline Testing in Patients With Advanced Cancers.
    • Stadler ZK, Maio A, Chakravarty D, Kemel Y, Sheehan M, Salo-Mullen E, Tkachuk K, Fong CJ, Nguyen B, Erakky A, Cadoo K, Liu Y, Carlo MI, Latham A, Zhang H, Kundra R, Smith S, Galle J, Aghajanian C, Abu-Rustum N, Varghese A, O'Reilly EM, Morris M, Abida W, Walsh M, Drilon A, Jayakumaran G, Zehir A, Ladanyi M, Ceyhan-Birsoy O, Solit DB, Schultz N, Berger MF, Mandelker D, Diaz LA Jr, Offit K, Robson ME.
    • J Clin Oncol. 2021 Jun 16:JCO2003661. doi: 10.1200/JCO.20.03661. Epub ahead of print.
    • Mutations in BRCA-related breast and ovarian cancer in the South African Indian population: A descriptive study.
    • Combrink HM, Oosthuizen J, Visser B, Chabilal N, Buccimazza I, Foulkes WD, van der Merwe NC.
    • Cancer Genet. 2021 Jun 15;258-259:1-6. doi: 10.1016/j.cancergen.2021.06.002. Epub ahead of print.
    • Germline Genetic Testing for All Patients With Cancer?
    • Nelson R.
    • Medscape Oncology. 2021 Jun 15.
    • Impact of changing guidelines on genetic testing and surveillance recommendations in a contemporary cohort of breast cancer survivors with family history of pancreatic cancer.
    • Wang A, Everett JN, Chun J, Cen C, Simeone DM, Schnabel F.
    • Sci Rep. 2021 Jun 14;11(1):12491. doi: 10.1038/s41598-021-91971-0.
    • Community research collaboration to develop a promotores-based hereditary breast cancer education program for Spanish-speaking Latinas.
    • Almeida R, Lopez-Macha A, Dugatkin T, Joseph G, Duron Y, Hurtado de Mendoza A, D Graves K, Fejerman L.
    • Health Educ Res. 2021 Jun 11:cyab011. doi: 10.1093/her/cyab011. Epub ahead of print.
    • The role of psychosocial factors in Black women's self-efficacy in receiving genetic counseling and testing.
    • Ding H, Sutton AL, Hurtado-de-Mendoza A, Sheppard VB.
    • J Genet Couns. 2021 Jun 4. doi: 10.1002/jgc4.1439. Epub ahead of print.
    • Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I).
    • Brooks JD, Nabi HH, Andrulis IL, Antoniou AC, Chiquette J, Després P, Devilee P, Dorval M, Droit A, Easton DF, Eisen A, Eloy L, Fienberg S, Goldgar D, Hahnen E, Joly Y, Knoppers BM, Lofters A, Masson JY, Mittmann N, Paquette JS, Pashayan N, Schmutzler R, Stockley T, Tavtigian SV, Walker MJ, Wolfson M, Chiarelli AM, Simard J.
    • J Pers Med. 2021 Jun 4;11(6):511. doi: 10.3390/jpm11060511.
    • Out-of-pocket and private pay in clinical genetic testing: a scoping review.
    • Grant P, Langlois S, Lynd LD; GenCOUNSEL Study, Austin JC, Elliott AM.
    • Clin Genet. 2021 Jun 3. doi: 10.1111/cge.14006. Epub ahead of print.
    • Review
    • Cancer genetic testing in marginalized groups during an era of evolving healthcare reform.
    • Modell SM, Allen CG, Ponte A, Marcus G.
    • J Cancer Policy. 2021 Jun;28:100275. doi: 10.1016/j.jcpo.2021.100275. Epub 2021 Feb 16.
    • A Collaborative Model to Implement Flexible, Accessible and Efficient Oncogenetic Services for Hereditary Breast and Ovarian Cancer: The C-MOnGene Study.
    • Lapointe J, Dorval M, Chiquette J, Joly Y, Guertin JR, Laberge M, Gekas J, Hébert J, Pomey MP, Cruz-Marino T, Touhami O, Saint-Pierre AB, Gagnon S, Bouchard K, Rhéaume J, Boisvert K, Brousseau C, Castonguay L, Fortier S, Gosselin I, Lachapelle P, Lavoie S, Poirier B, Renaud MC, Ruizmangas MG, Sebastianelli A, Roy S, Côté M, Racine MM, Roy MC, Côté N, Brisson C, Charette N, Faucher V, Leblanc J, Dubeau ME, Plante M, Desbiens C, Beaumont M, Simard J, Nabi H.
    • Cancers (Basel). 2021 May 31;13(11):2729. doi: 10.3390/cancers13112729.
    • Disparity in Access to Oncology Precision Care: A Geospatial Analysis of Driving Distances to Genetic Counselors in the U.S.
    • Bellaiche MM, Fan W, Walbert HJ, McClave EH, Goodnight BL, Sieling FH, Moore RA, Meng W, Black CM.
    • Front Oncol. 2021 May 26;10:689927. doi: 10.3389/fonc.2021.689927.
    • Risk-Adjusted Prevention. Perspectives on the Governance of Entitlements to Benefits in the Case of Genetic (Breast Cancer) Risks.
    • Meier F, Harney A, Rhiem K, Neusser S, Neumann A, Braun M, Wasem J, Huster S, Dabrock P, Schmutzler RK.
    • Recent Results Cancer Res. 2021 [First Online: 22 May 2021];218:47-66. doi: 10.1007/978-3-030-63749-1_5.
    • eBook chapter
    • Perthera, Side-Out Foundation Partner to Advance Precision Oncology in Breast Cancer.
    • [No author given]
    • Precision Oncology News. Cancer Specialties. Breast Cancer. 2021 May 21.
    • Oncologists, Patients Still Face Unpredictable Payor Coverage for Broad Tissue NGS Panels.
    • Hopkins C.
    • Precision Oncology News. Business & Policy. 2021 May 17.
    • News
    • Oncologists' perspectives of telephone genetic counseling to facilitate germline BRCA1/2 testing for their patients with high-grade serous ovarian cancer.
    • Hemming P, Kaur R, Meiser B, McKinley J, Young MA, James PA, Forrest LE.
    • J Community Genet. 2021 May 6. doi: 10.1007/s12687-021-00530-7. Epub ahead of print.
    • Novel Approach Using Administrative Claims to Evaluate Trends in Oncology Multigene Panel Testing for Patients Enrolled in Medicare Advantage Health Plans.
    • Caplan EO, Wong WB, Ferries E, Hulinsky R, Brown VT, Bordenave K, Suehs BT.
    • JCO Precis Oncol. 2021;5:792. doi: 10.1200/PO.20.00422. Epub 2021 May 5.
    • Understanding patients' views and willingness toward the use of telehealth in a cancer genetics service in Asia.
    • Sim J, Shaw T, Li STCourtney E, Yuen J, Chiang J, Nazir M, Tan R, Ngeow J.
    • J Genet Couns. 2021 May 1. doi: 10.1002/jgc4.1432. Epub ahead of print.
    • Screening High-Risk Women Veterans for Breast Cancer.
    • Park YA, Keller A, Hsu TM, Bidassie B, Venne V, Hawley D, Hoffman-Högg L, Heron B, Colonna S, Aggarwal A.
    • Fed Pract. 2021 May;38(Suppl 2):S35-S41. doi: 10.12788/fp.0122.
    • Hérédité et cancer [Heredity and cancer].
    • Docampo E, Martin M, Gangolf M, Harvengt J, Bulk S, Segers K, Leroi N, Lete C, Palmariciotti V, Freire Chadrina V, Lambert F, Bours V.
    • Rev Med Liege. 2021 May;76(5-6):327-336. French.
    • Baseline knowledge and receptiveness to genetic testing for hereditary breast and ovarian cancer syndromes in Chinese high-risk females.
    • Chu AT, Tse DM, Suen DTK, Kwong A.
    • J Community Genet. 2021 Apr 30. doi: 10.1007/s12687-021-00518-3. Epub ahead of print.
    • Use of a Standardized Tool to Identify Women at Risk for Hereditary Breast and Ovarian Cancer.
    • Nurs Womens Health. 2021 Apr 29:S1751-4851(21)00080-5. doi: 10.1016/j.nwh.2021.03.008. Epub ahead of print.
    • Real-world genetic testing patterns in metastatic castration-resistant prostate cancer.
    • Shore N, Ionescu-Ittu R, Yang L, Laliberté F, Mahendran M, Lejeune D, Yu L, Burgents J, Duh MS, Ghate SR.
    • Future Oncol. 2021 Apr 28. doi: 10.2217/fon-2021-0153. Epub ahead of print.
    • High-risk women are facing barriers to preventive breast cancer care.
    • Branigin A.
    • Washington Post. The Lily. 2021 Apr 27.

    Related:

    Original research:

    Financial constraints on genetic counseling and further risk-management decisions among U.S. women at elevated breast cancer risk.

    • Effect of a health literacy training program for surgical oncologists and specialized nurses on disparities in referral to breast cancer genetic testing.
    • van der Giessen JAM, van Dulmen S, Velthuizen ME, van den Muijsenbergh METC, van Engelen K, Collée M, van Dalen T, Aalfs CM, Hooning MJ, Spreeuwenberg PMM, Fransen MP, Ausems MGEM.
    • Breast. 2021 Apr 22:S0960-9776(21)00367-2. doi: 10.1016/j.breast.2021.04.008. Epub ahead of print.
    • Factors Influencing Discussion of Cancer Genetic Testing with Health-Care Providers in a Population-Based Survey.
    • Makhnoon S, Yu R, Cunningham SA, Peterson SK, Shete S.
    • Public Health Genomics. 2021 Apr 22:1-11. doi: 10.1159/000515465. Epub ahead of print.
    • Value of a genetics clinic evaluation in identifying women at risk for hereditary breast-ovarian cancer syndrome.
    • Hinshaw JC, Zhao LP, Brimm JE, Payne TH, Hisama FM.
    • J Genet Couns. 2021 Apr 21. doi: 10.1002/jgc4.1425. Epub ahead of print.
    • Universal access to genetic counseling for women with epithelial ovarian cancer in Nova Scotia: Evaluating a new collaborative care model.
    • Warias A, Ferguson M, Chamberlain E, Currie L, Snow N, Matheson K, Penney LS, Kieser K.
    • J Genet Couns. 2021 Apr 19. doi: 10.1002/jgc4.1416. Epub ahead of print.
    • The Screen Project: Guided Direct-To-Consumer Genetic Testing for Breast Cancer Susceptibility in Canada.
    • Narod SA, Gojska N, Sun P, Tryon A, Kotsopoulos J, Metcalfe K, Akbari MR.
    • Cancers (Basel). 2021 Apr 15;13(8):E1894. doi: 10.3390/cancers13081894.
    • The Prevent Ovarian Cancer Program (POCP): Identification of women at risk for ovarian cancer using complementary recruitment approaches.
    • Tone AA, McCuaig JM, Ricker N, Boghosian T, Romagnuolo T, Stickle N, Virtanen C, Zhang T, Kim RH, Ferguson SE, May T, Laframboise S, Armel S, Demsky R, Volenik A, Stuart-McEwan T, Shaw P, Oza A, Kamel-Reid S, Stockley T, Bernardini MQ.
    • Gynecol Oncol. 2021 Apr 13:S0090-8258(21)00321-8. doi: 10.1016/j.ygyno.2021.04.011. Epub ahead of print.
    • Management and outcomes of men diagnosed with primary breast cancer.
    • Johnson AE, Coopey SB, Spring LM, Horick NK, Leone JP, Lin NU, Dominici LS, Hughes KS, Jimenez RB.
    • Breast Cancer Res Treat. 2021 Apr 8. doi: 10.1007/s10549-021-06174-y. Epub ahead of print.
    • A Comparison of Patient-Reported Outcomes Following Consent for Genetic Testing Using an Oncologist- or Genetic Counselor-Mediated Model of Care.
    • McCuaig JM, Thain E, Malcolmson J, Keshavarzi S, Armel SR, Kim RH.
    • Curr Oncol. 2021 Apr 8;28(2):1459-1471. doi: 10.3390/curroncol28020138.
    • Development of a culturally sensitive narrative intervention to promote genetic counseling among African American women at risk for hereditary breast cancer.
    • Henderson V, Chukwudozie IB, Comer-Hagans D, Coffey V, Grumbach G, Spencer S, Rodgers C, Kaur R, Newsome J, Balay L, Maga T, Kendall L, Balthazar C, Watson K, Winn R, Odoms-Young A, Hoskins KF.
    • Cancer. 2021 Apr 1. doi: 10.1002/cncr.33525. Epub ahead of print.
    • Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.
    • Cobain EF, Wu YM, Vats P, Chugh R, Worden F, Smith DC, Schuetze SM, Zalupski MM, Sahai V, Alva A, Schott AF, Caram MEV, Hayes DF, Stoffel EM, Jacobs MF, Kumar-Sinha C, Cao X, Wang R, Lucas D, Ning Y, Rabban E, Bell J, Camelo-Piragua S, Udager AM, Cieslik M, Lonigro RJ, Kunju LP, Robinson DR, Talpaz M, Chinnaiyan AM.
    • JAMA Oncol. 2021 Apr 1;7(4):525-533. doi: 10.1001/jamaoncol.2020.7987.

    Related:

    Editorial:

    Precision Medicine in Oncology-Toward the Integrated Targeting of Somatic and Germline Genomic Aberrations.

    Letter, Comment:

    Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?

    Letter, Reply:

    Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?-Reply.

    • O'Neal Comprehensive Cancer Center, My Gene Counsel Partner for Digital Genetic Testing Support.
    • [No author given]
    • Precision Oncology News. Technology. 2021 Mar 26.
    • Germline evaluation of patients undergoing tumor genomic profiling: An academic cancer center's experience with implementing a germline review protocol.
    • Stachowiak S, Jacquart A, Zimmermann MT, George B, Dong H, Geurts JL.
    • J Genet Couns. 2021 Mar 22. doi: 10.1002/jgc4.1392. Epub ahead of print.
    • Cisplatin +/- rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer.
    • Kalra M, Tong Y, Jones DR, Walsh T, Danso MA, Ma CX, Silverman P, King MC, Badve SS, Perkins SM, Miller KD.
    • NPJ Breast Cancer. 2021 Mar 22;7(1):29. doi: 10.1038/s41523-021-00240-w.
    • Financial constraints on genetic counseling and further risk-management decisions among U.S. women at elevated breast cancer risk.
    • Meadows RJ, Padamsee TJ.
    • J Genet Couns. 2021 Mar 21. doi: 10.1002/jgc4.1413. Epub ahead of print.

    Related:

    Press: High-risk women are facing barriers to preventive breast cancer care. (Washington Post / The Lily)

    • Clinical implementation of an oncology-specific family health history risk assessment tool.
    • Fung SM, Wu RR, Myers RA, Goh J, Ginsburg GS, Matchar D, Orlando LA, Ngeow J.
    • Hered Cancer Clin Pract. 2021 Mar 20;19(1):20. doi: 10.1186/s13053-021-00177-y.
    • Correspondence on "Assessing relatives' readiness for hereditary cancer cascade genetic testing" by Bednar et al.
    • Carlson J.
    • Genet Med. 2021 Mar 19. doi: 10.1038/s41436-020-01094-6. Epub ahead of print.
    • Letter

    Related:

    Original research:

    Assessing relatives' readiness for hereditary cancer cascade genetic testing.

    • Clinical and community genetics services in the Dutch Caribbean.
    • Verberne EA, Ecury-Goossen GM, Manshande ME, Ponson-Wever M, de Vroomen M, Tilanus M, Mannens MMAM, Henneman L, van Haelst MM.
    • J Community Genet. 2021 Mar 10:1-5. doi: 10.1007/s12687-021-00515-6. Epub ahead of print.

    Related:

    Duplicate:

    Clinical and community genetics services in the Dutch Caribbean.

    • Foundation Medicine, InformedDNA Partner to Expand Genetic Counseling for Cancer Patients.
    • [No author given]
    • GenomeWeb. Business & Policy. Business News. 2021 Mar 9.
    • Genetic Testing for Breast and Ovarian Cancer: What Has Changed and What Still Needs To Change?
    • Lyss AP.
    • Medscape. News & Perspective. 2021 Mar 8.

    Related:

    Original research:

    Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.

    • Clinical Utility of Next-Generation Sequencing-Based Panel Testing under the Universal Health-Care System in Japan: A Retrospective Analysis at a Single University Hospital.
    • Inagaki C, Maeda D, Hatake K, Sato Y, Hashimoto K, Sakai D, Yachida S, Nonomura I, Satoh T.
    • Cancers (Basel). 2021 Mar 5;13(5):E1121. doi: 10.3390/cancers13051121.
    • Myriad Genetics, Intermountain Healthcare Collaborate for Cancer Testing Service.
    • [No author given]
    • GenomeWeb. Business & Policy. Business News. 2021 Mar 2.
    • Assessment of genetic referrals and outcomes for women with triple negative breast cancer in regional cancer centres in Australia.
    • Hallenstein LG, Sorensen C, Hodgson L, Wen S, Westhuyzen J, Hansen C, Last ATJ, Amalaseelan JV, Salindera S, Ross W, Spigelman AD, Shakespeare TP, Aherne NJ.
    • Hered Cancer Clin Pract. 2021 Feb 26;19(1):19. doi: 10.1186/s13053-021-00176-z.
    • The Knowledge and Attitude of Patients Diagnosed with Epithelial Ovarian Cancer towards Genetic Testing.
    • Shin W, Jeong G, Son Y, Seo SS, Kang S, Park SY, Lim MC.
    • Int J Environ Res Public Health. 2021 Feb 26;18(5):2312. doi: 10.3390/ijerph18052312.
    • Globally Rare BRCA2 Variants With Founder Haplotypes in the South African Population: Implications for Point-of-Care Testing Based on a Single-Institution BRCA1/2 Next-Generation Sequencing Study.
    • Oosthuizen J, Kotze MJ, Van Der Merwe N, Myburgh EJ, Bester P, van der Merwe NC.
    • Front Oncol. 2021 Feb 12;10:619469. doi: 10.3389/fonc.2020.619469.
    • Update: variable implementation of the 2018 UKCGG/UKGTN guidelines for breast cancer gene panel tests offered by UK genetics services.
    • Wedderburn S, Archer S, Tischkowitz M, Hanson H, on behalf of UKCGG.
    • J Med Genet. 2021 Feb 10:jmedgenet-2020-107529. doi: 10.1136/jmedgenet-2020-107529. Epub ahead of print.
    • Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.
    • Kurian AW, Ward KC, Abrahamse P, Bondarenko I, Hamilton AS, Deapen D, Morrow M, Berek JS, Hofer TP, Katz SJ.
    • J Clin Oncol. 2021 Feb 9:JCO2002785. doi: 10.1200/JCO.20.02785. Epub ahead of print.

    Related:

    Research news: Genetic Testing for Breast and Ovarian Cancer: What Has Changed and What Still Needs To Change? (Medscape)

    • Downstream Revenue Generated by a Cancer Genetic Counselor.
    • Mauer CB, Reys BD, Hall RE, Campbell CL, Pirzadeh-Miller SM.
    • JCO Oncol Pract. 2021 Feb 8:OP2000464. doi: 10.1200/OP.20.00464. Epub ahead of print.
    • Implementing genomic screening in diverse populations.
    • Abul-Husn NS, Soper ER, Braganza GT, Rodriguez JE, Zeid N, Cullina S, Bobo D, Moscati A, Merkelson A, Loos RJF, Cho JH, Belbin GM, Suckiel SA, Kenny EE.
    • Genome Med. 2021 Feb 5;13(1):17. doi: 10.1186/s13073-021-00832-y.
    • Preliminary Screening for Hereditary Breast and Ovarian Cancer Using a Chatbot Augmented Intelligence Genetic Counselor: Development and Feasibility Study.
    • Sato A, Haneda E, Suganuma N, Narimatsu H.
    • JMIR Form Res. 2021 Feb 5;5(2):e25184. doi: 10.2196/25184.
    • Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers in Hokkaido, Japan.
    • Kikuchi J, Ohhara Y, Takada K, Tanabe H, Hatanaka K, Amano T, C Hatanaka K, Hatanaka Y, Mitamura T, Kato M, Shibata Y, Yabe I, Endoh A, Komatsu Y, Matsuno Y, Sugiyama M, Manabe A, Sakurai A, Takahashi M, Naruse H, Torimoto Y, Dosaka-Akita H, Kinoshita I.
    • Jpn J Clin Oncol. 2021 Feb 3:hyaa277. doi: 10.1093/jjco/hyaa277. Epub ahead of print.
    • Bringing Onco-Innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine.
    • Horgan D, Ciliberto G, Conte P, Curigliano G, Seijo L, Montuenga LM, Garassino M, Penault-Llorca F, Galli F, Ray-Coquard I, Querleu D, Riegman P, Kerr K, Van Poppel H, Bjartell A, Codacci-Pisanelli G, Koeva-Balabanova J, Paradiso A, Maravic Z, Fotaki V, Malats N, Bernini C, Buglioni S, Kent A, Munzone E, Belina I, Van Meerbeeck J, Duffy M, Jagielska B, Capoluongo E.
    • Cancers (Basel). 2021 Feb 2;13(3):583. doi: 10.3390/cancers13030583.
    • Barriers and strategies to integrate medical genetics and primary care in underserved populations: a scoping review.
    • Chou AF, Duncan AR, Hallford G, Kelley DM, Dean LW.
    • J Community Genet. 2021 Feb 1. doi: 10.1007/s12687-021-00508-5. Epub ahead of print.
    • Oncologist-led BRCA counselling improves access to cancer genetic testing in middle-income Asian country, with no significant impact on psychosocial outcomes.
    • Yoon SY, Wong SW, Lim J, Ahmad S, Mariapun S, Padmanabhan H, Hassan NT, Lau SY, Ch'ng GS, Haniffa M, Ong WP, Rethanavelu K, Moey LH, Keng WT, Omar J, Mohd Abas MN, Yong CM, Ramasamy V, Md Noor MR, Aliyas I, Lim MCK, Suberamaniam A, Mat Adenan NA, Ahmad ZA, Ho GF, Abdul Malik R, Subramaniam S, Khoo BP, Raja A, Chin YS, Sim WW, Teh BH, Kho SK, Ong ESE, Voon PJ, Ismail G, Lee CL, Abdullah BZ, Loo KS, Lim CS, Lee SJ, Lim KJL, Shafiee MN, Ismail F, Latiff ZA, Ismail MP, Mohamed Jamli MF, Kumarasamy S, Leong KW, Low J, Md Yusof M, Ahmad Mustafa AM, Mat Ali NH, Makanjang M, Tayib S, Cheah N, Lim BK, Fong CK, Foo YC, Mellor Abdullah M, Tan TS, Chow DSY, Ho KF, Raman R, Radzi A, Deniel A, Teoh DCY, Ang SF, Joseph JK, Ng PHO, Tho LM, Ahmad AR, Muin I, Bleiker E, George A, Thong MK, Woo YL, Teo SH.
    • J Med Genet. 2021 Feb 1:jmedgenet-2020-107416. doi: 10.1136/jmedgenet-2020-107416. Epub ahead of print.
    • SARS-CoV-2 Testing Survey Results - Cancer Diagnostic Testing Amidst COVID-19 Pandemic.
    • [No author given]
    • Association for Medical Pathology. Advocacy. 2021 Feb?.

    Related:

    Press: AMP Survey Finds Significant Decline in Molecular Cancer Testing Due to COVID-19 Pandemic. (GenomeWeb)

    • Implementation of a High-Risk Breast Clinic for Comprehensive Care of Women With Elevated Breast Cancer Risk Identified by Risk Assessment Models in the Community.
    • Laws A, Mulvey TM.
    • JCO Oncol Pract. 2021 Feb;17(2):e217-e225. doi: 10.1200/OP.20.00256. Epub 2020 Aug 21.
    • Implementing Systematic Genetic Counseling and Multigene Germline Testing for Individuals With Pancreatic Cancer.
    • Chittenden A, Haraldsdottir S, Ukaegbu C, Underhill-Blazey M, Gaonkar S, Uno H, Brais LK, Perez K, Wolpin BM, Syngal S, Yurgelun MB.
    • JCO Oncol Pract. 2021 Feb;17(2):e236-e247. doi: 10.1200/OP.20.00678. Epub 2021 Jan 13.
    • Disclosure of familial implications of pathogenic variants in breast-cancer genes to patients: Opportunity for prompting family communication.
    • Makhnoon S, Smith HS, Bednar EM, Bhatt A, Turner L, Arun B, Volk RJ, Peterson SK.
    • J Community Genet. 2021 Jan 22. doi: 10.1007/s12687-021-00504-9. Epub ahead of print.
    • Recontacting non-BRCA1/2 breast cancer patients for germline CHEK2 c.1100del pathogenic variant testing: uptake and patient experiences.
    • Velthuizen ME, van der Luijt RB, de Vries BJ, Koudijs MJ, Bleiker EMA, Ausems MGEM.
    • Hered Cancer Clin Pract. 2021 Jan 19;19(1):9. doi: 10.1186/s13053-021-00166-1.
    • Challenges of Genomic Testing for Hereditary Breast and Ovarian Cancers.
    • McAlarnen L, Stearns K, Uyar D.
    • Appl Clin Genet. 2021 Jan 14;14:1-9. doi: 10.2147/TACG.S245021.
    • FLABRA, frontline approach for BRCA testing in an ovarian cancer population: a Latin America epidemiologic study.
    • Giornelli G, Gallardo D, Hegg R, Abuin GG, La Vega M, Lim-Law M, Caceres V, Trujillo L, Pilar Estevez-Diz MD, Pacheco C, Sganga L, Goncalves S.
    • Future Oncol. 2021 Jan 8. doi: 10.2217/fon-2020-1152. Epub ahead of print.
    • What improves the likelihood of people receiving genetic test results communicating to their families about genetic risk?
    • Bowen DJ, Makhnoon S, Shirts BH, Fullerton SM, Larson E, Ralston JD, Leppig K, Crosslin DR, Veenstra D, Jarvik GP.
    • Patient Educ Couns. 2021 Jan 7:S0738-3991(21)00001. doi: 10.1016/j.pec.2021.01.001. Epub ahead of print.
    • BRCA testing and outcomes in women with breast cancer.
    • Stenehjem DD, Telford C, Unni SK, Bauer H, Sainski A, Deka R, Schauerhamer MB, Ye X, Tak CR, Ma J, Dalvi TB, Gutierrez L, Kaye JA, Tyczynski JE, Brixner DI, Biskupiak JE.
    • Breast Cancer Res Treat. 2021 Jan 3. doi: 10.1007/s10549-020-06038-x. Epub ahead of print.
    • Increased ease of access to genetic counseling for low-income women with breast cancer using a point of care screening tool.
    • Rao SK, Thomas KA, Singh R, Biltibo E, Lammers PE, Wiesner GL.
    • J Community Genet. 2021 Jan 3. doi: 10.1007/s12687-020-00499-9. Epub ahead of print.
    • Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer.
    • Loeb S, Giri VN.
    • Eur Urol Oncol. 2020 Dec 31:S2588-9311(20)30207-8. doi: 10.1016/j.euo.2020.11.011. Epub ahead of print.
    • Motivations and barriers to pursue cancer genomic testing: a systematic review.
    • Smith-Uffen M, Bartley N, Davies G, Best M.
    • Patient Educ Couns. 2020 Dec 25:S0738-3991(20)306881. doi: 10.1016/j.pec.2020.12.024. Epub ahead of print.
    • Review
    • Facilitated cascade testing (FaCT): a randomized controlled trial.
    • Nitecki R, Moss HA, Watson CH, Urbauer DL, Melamed A, Lu KH, Lipkin SM, Offit K, Rauh-Hain JA, Frey MK.
    • Int J Gynecol Cancer. 2020 Dec 18:ijgc-2020-002118. doi: 10.1136/ijgc-2020-002118. Epub ahead of print.
    • Examining the uptake of predictive BRCA testing in the UK; findings and implications.
    • Martin AP, Downing J, Collins B, Godman B, Alfirevic A, Greenhalgh KL, Pirmohamed M.
    • Eur J Hum Genet. 2020 Dec 16. doi: 10.1038/s41431-020-00783-9. Epub ahead of print.
    • BRCA testing delay during the COVID-19 pandemic: How to act?
    • Minucci A, Scambia G, De Bonis M, De Paolis E, Santonocito C, Fagotti A, Capoluongo E, Concolino P, Urbani A.
    • Mol Biol Rep. 2020 Dec 12. doi: 10.1007/s11033-020-06060-8. Epub ahead of print.
    • Exploring the real-world effect of the SARS-CoV-2 pandemic on the molecular diagnostics for cancer patients and high-risk individuals.
    • Cavic M, Krivokuca A, Boljevic I, Spasic J, Mihajlovic M, Pavlovic M, Damjanovic A, Radosavljevic D, Jankovic R.
    • Expert Rev Mol Diagn. 2020 Dec 5. doi: 10.1080/14737159.2021.1860760. Epub ahead of print.
    • Transition to telephone genetic counseling services during the COVID-19 pandemic.
    • Shannon KM, Emmet MM, Rodgers LH, Wooters M, Seidel ML.
    • J Genet Couns. 2020 Dec 4. doi: 10.1002/jgc4.1365. Epub ahead of print.
    • DNA damage repair gene mutation testing and genetic counseling in men with/without prostate cancer: a systematic review.
    • Armstrong N, Quek RG, Ryder S, Ross J, Titas Buksnys, Forbes C, Fox KM, Castro E.
    • Future Oncol. 2020 Dec 2. doi: 10.2217/fon-2020-0569. Epub ahead of print.
    • Review
    • Genetics and the Gynecologic Patient.
    • Wade KS, Estes JM, Kline RC.
    • Ochsner J. 2020 Winter;20(4):446-451. doi: 10.31486/toj.20.0051.
    • Women’s Intentions to Engage in Risk-Reducing Behaviours after Receiving Personal Ovarian Cancer Risk Information: An Experimental Survey Study.
    • Gallagher A, Waller J, Manchanda R, Jacobs I, Sanderson S.
    • Cancers (Basel). 2020 Nov 27;12(12):E3543. doi: 10.3390/cancers12123543.
    • Communication about positive BRCA1 and BRCA2 genetic test results and uptake of testing in relatives in a diverse Asian setting.
    • Lee DS, Meiser B, Mariapun S, Hassan T, Yip CH, Mohd Taib NA, Teo SH, Thong MK, Yoon SY.
    • J Genet Couns. 2020 Nov 27. doi: 10.1002/jgc4.1360. Epub ahead of print.
    • Tumor phenotype and concordance in synchronous bilateral breast cancer in young women.
    • Pak LM, Gaither R, Rosenberg SM, Ruddy KJ, Tamimi RM, Peppercorn J, Schapira L, Borges VF, Come SE, Warner E, Snow C, Collins LC, King TA, Partridge AH.
    • Breast Cancer Res Treat. 2020 Nov 26. doi: 10.1007/s10549-020-06027-0. Epub ahead of print.
    • Genotype-first approach to the detection of hereditary breast and ovarian cancer risk, and effects of risk disclosure to biobank participants.
    • Leitsalu L, Palover M, Sikka TT, Reigo A, Kals M, Pärn K, Nikopensius T, Esko T, Metspalu A, Padrik P, Tõnisson N.
    • Eur J Hum Genet. 2020 Nov 23. doi: 10.1038/s41431-020-00760-2. Epub ahead of print.
    • BRCA gene testing in women with high-grade serous ovarian carcinoma.
    • Kansu B, Gardner J, Price-Tate R, Murch O, Murray A.
    • J Obstet Gynaecol. 2020 Nov 23:1-4. doi: 10.1080/01443615.2020.1820466. Epub ahead of print.
    • Process evaluation of a culturally targeted video for Latinas at risk of hereditary breast and ovarian cancer.
    • Hurtado-de-Mendoza A, Gómez-Trillos S, Graves KD, Carrera P, Campos C, Anderson L, Gronda A, Orellana H, Peshkin BN, Schwartz MD, Cupertino P, Ostrove N, Luta G, Gonzalez N, Sheppard VB.
    • J Genet Couns. 2020 Nov 22. doi: 10.1002/jgc4.1361. Epub ahead of print.
    • Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer.
    • Rana HQ, Kipnis L, Hehir K, Cronin A, Jaung T, Stokes SM, Fekrmandi F, Vatnick D, Matulonis UA, Garber JE, Wright AA.
    • Gynecol Oncol. 2020 Nov 21:S0090-8258(20)34111-1. doi: 10.1016/j.ygyno.2020.11.003. Epub ahead of print.
    • Cancer Previvors in an Active Duty Service Women Population: An Opportunity for Prevention and Increased Force Readiness.
    • Lovejoy LA, Turner CE, Shriver CD, Ellsworth RE.
    • Mil Med. 2020 Nov 18:usaa485. doi: 10.1093/milmed/usaa485. Epub ahead of print.
    • Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic.
    • Benusiglio PR, Korenbaum C, Vibert R, Ezenfis J, Geoffron S, Paul C, Richard S, Byrde V, Lejeune M, Guillerm E, Basset N, Lotz JP, Chabbert-Buffet N, Gligorov J, Coulet F.
    • Eur J Med Genet. 2020 Nov 10;63(12):104098. doi: 10.1016/j.ejmg.2020.104098. Epub ahead of print.
    • BRCA-Related Cancer Genetic Counseling is Indicated in Many Women Seeking Primary Care.
    • Parente DJ.
    • J Am Board Fam Med. 2020 Nov-Dec;33(6):885-893. doi: 10.3122/jabfm.2020.06.190461.
    • Doing a Better Job at Reaching LatinX People and Families about Hereditary Cancer.
    • Gómez Trillos S, Hurtado de Mendoza A.
    • FORCE. Blog. 2020 Oct 21.
    • Clinically Actionable Findings Derived From Predictive Genomic Testing Offered in a Medical Practice Setting.
    • Anderson JL, Kruisselbrink TM, Lisi EC, Hughes TM, Steyermark JM, Winkler EM, Berg CM, Vierkant RA, Gupta R, Ali AH, Faubion SS, Aoudia SL, McAllister TM, Farrugia G, Stewart AK, Lazaridis KN.
    • Mayo Clin Proc. 2020 Oct 21:S0025-6196(20)31119-8. doi: 10.1016/j.mayocp.2020.08.051. Epub ahead of print.
    • Stay at home: implementation and impact of virtualising cancer genetic services during COVID-19.
    • Norman ML, Malcolmson J, Armel SR, Gillies B, Ou B, Thain E, McCuaig JM, Kim RH.
    • J Med Genet. 2020 Oct 16:jmedgenet-2020-107418. doi: 10.1136/jmedgenet-2020-107418. Epub ahead of print.
    • The mediating effects of public genomic knowledge in precision medicine implementation: A structural equation model approach.
    • Mogaka JJO, Chimbari MJ.
    • PLoS One. 2020 Oct 14;15(10):e0240585. doi: 10.1371/journal.pone.0240585.
    • Pfizer, Invitae Focus on Expanding Global BRCA1/2 Test Access Amid Treatment, Screening Barriers.
    • Hopkins C.
    • Precision Oncology News. 2020 Oct 14.
    • News
    • Experiences and attitudes of hereditary cancer screening patients in a consumer directed testing model.
    • Greve V, Garner M, Odom K, Cooper SJ, East KM.
    • Patient Educ Couns. 2020 Oct 11:S0738-3991(20)305498. doi: 10.1016/j.pec.2020.10.014. Epub ahead of print.
    • Knowledge and Attitudes About Genetic Testing Among Black and White Women with Breast Cancer.
    • McCall MK, Ibikunle S, Murphy Y, Hunter K, Rosenzweig MQ.
    • J Racial Ethn Health Disparities. 2020 Oct 6. doi: 10.1007/s40615-020-00878-5. Epub ahead of print.
    • Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation.
    • Loeb S, Byrne N, Walter D, Makarov DV, Wise DR, Becker D, Giri VN.
    • Cancer Treat Res Commun. 2020 Sep 28;25:100212. doi: 10.1016/j.ctarc.2020.100212. Epub ahead of print.
    • "I think that a brief conversation from their provider can go a very long way": Patient and provider perspectives on barriers and facilitators of genetic testing after ovarian cancer.
    • Mallen AR, Conley CC, Fuzzell L, Ketcher D, Augusto BM, McIntyre M, Barton LV, Townsend MK, Fridley BL, Tworoger SS, Wenham RM, Vadaparampil ST.
    • Support Care Cancer. 2020 Sep 25. doi: 10.1007/s00520-020-05779-1. Epub ahead of print.
    • Evaluation of a Mainstream Model of Genetic Testing for Men With Prostate Cancer.
    • Scheinberg T, Goodwin A, Ip E, Linton A, Mak B, Smith DP, Stockler MR, Strach MC, Tran B, Young AL, Zhang AY, Mahon KL, Horvath LG.
    • JCO Oncol Pract. 2020 Sep 24:OP2000399. doi: 10.1200/OP.20.00399. Epub ahead of print.
    • The Impact of the Number of Tests Presented and a Provider Recommendation on Decisions about Genetic Testing for Cancer Risk.
    • Schwartz MLB, Klein WMP, Erby LAH, Smith CH, Roter DL.
    • Patient Educ Couns. 2020 Sep 18:S0738-3991(20)305188. doi: 10.1016/j.pec.2020.09.020. Epub ahead of print.
    • Electronic health records contain dispersed risk factor information that could be used to prevent breast and ovarian cancer.
    • Payne TH, Zhao LP, Le C, Wilcox P, Yi T, Hinshaw J, Hussey D, Kostrinsky-Thomas A, Hale M, Brimm J, Hisama FM.
    • J Am Med Inform Assoc. 2020 Sep 17:ocaa152. doi: 10.1093/jamia/ocaa152. Epub ahead of print.
    • Implementing Cancer Genomics in State Health Agencies: Mapping Activities to an Implementation Science Outcome Framework.
    • Green RF, Kumerow MT, Rodriguez JL, Addie S, Beachy SH, Senier L.
    • Public Health Genomics. 2020 Sep 17:1-12. doi: 10.1159/000510336. Epub ahead of print.

    Related:

    Original research:

    Proposed outcomes measures for state public health genomic programs.

    • A pilot randomized trial of an educational intervention to increase genetic counseling and genetic testing among Latina breast cancer survivors.
    • Conley CC, Castro-Figueroa EM, Moreno L, Dutil J, García JD, Burgos C, Ricker C, Kim J, Graves KD, Ashing KT, Quinn GP, Soliman H, Vadaparampil ST.
    • J Genet Couns. 2020 Sep 16. doi: 10.1002/jgc4.1324. Epub ahead of print.
    • Adherence to NCCN Guidelines for Genetic Testing in Breast Cancer Patients: Who Are We Missing?
    • Alberty-Oller JJ, Weltz S, Santos A, Pisapati K, Ru M, Weltz C, Schmidt H, Port E.
    • Ann Surg Oncol. 2020 Sep 11. doi: 10.1245/s10434-020-09123-z. Epub ahead of print.
    • BRCA1/2 Testing in Massachusetts Among Women With Private Insurance or Medicaid, 2011-2015.
    • Pace LE, Baum CF, Horvath K, Raja SC, Cohen J, Hawkins SS.
    • Med Care. 2020 Sep 10. doi: 10.1097/MLR.0000000000001405. Epub ahead of print.
    • Relaunched Canadian BRCA1/2 Screening Project Aims to ID High-Risk Carriers, Intervene Early.
    • Anderson A.
    • Precision Oncology News. 2020 Sep 8.
    • News
    • Genetic Testing and Surveillance of Young Breast Cancer Survivors and Blood Relatives: A Cluster Randomized Trial.
    • Katapodi MC, Ming C, Northouse LL, Duffy SA, Duquette D, Mendelsohn-Victor KE, Milliron KJ, Merajver SD, Dinov ID, Janz NK.
    • Cancers (Basel). 2020 Sep 5;12(9):E2526. doi: 10.3390/cancers12092526.
    • Healthcare Disparities and the Demand for Expanding Hereditary Breast Cancer Screening Guidelines in African Americans.
    • Ciuro J, Beyer A, Fritzler J, Jackson N, Ahsan S.
    • Clin Breast Cancer. 2020 Sep 2:S1526-8209(20)30215-9. doi: 10.1016/j.clbc.2020.08.010. Epub ahead of print.
    • Disparities in Genetic Testing and Care among Black women with Hereditary Breast Cancer.
    • Reid S, Cadiz S, Pal T.
    • Curr Breast Cancer Rep. 2020 Sep;12(3):125-131. doi: 10.1007/s12609-020-00364-1. Epub 2020 May 19.
    • Review
    • Strategies to enhance identification of hereditary breast cancer gene carriers.
    • Reid S, Spalluto LB, Pal T.
    • Expert Rev Mol Diagn. 2020 Aug 28. doi: 10.1080/14737159.2020.1816829. Epub ahead of print.
    • Germline mutations and prostate cancer: is it time to change treatment algorithms?
    • Telvizian T, Mukherji D.
    • Chin Clin Oncol. 2020 Aug 27:cco-19-207. doi: 10.21037/cco-19-207. Epub ahead of print.
    • The management of BRCA1 and BRCA2 carriers in Singapore.
    • Chiang J, Ngeow J.
    • Chin Clin Oncol. 2020 Aug 17:cco-20-104. doi: 10.21037/cco-20-104. Epub ahead of print.
    • Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors-proceedings from breast cancer expert group meeting.
    • Dawood S, Konstantinova M, Perazzo F, Kim SB, Villarreal-Garza C, Franco SX, Simon SD, El-Nahas T.
    • Chin Clin Oncol. 2020 Aug 17:cco-20-138. doi: 10.21037/cco-20-138. Epub ahead of print.
    • From Probands to Relatives: Communication of Genetic Risk for Hereditary Breast-Ovarian Cancer and Its Influence on Subsequent Testing.
    • Seven M, Shah LL, Yazici H, Daack-Hirsch S.
    • Cancer Nurs. 2020 Aug 13. doi: 10.1097/NCC.0000000000000876. Epub ahead of print.
    • Uptake of Family-Specific Mutation Genetic Testing Among Relatives of Patients with Ovarian Cancer with BRCA1 or BRCA2 Mutation.
    • Jeong GW, Shin W, Lee DO, Seo SS, Kang S, Park SY, Lim MC.
    • Cancer Res Treat. 2020 Aug 11. doi: 10.4143/crt.2020.364. Epub ahead of print.
    • Streamlining genetic testing for women with ovarian cancer in a Northern California health care system.
    • Powell CB, Laurent C, Ciaravino G, Garcia C, Han L, Hoodfar E, Karlea A, Kobelka C, Lee J, Littell RD, Roh J, Vay A, Kushi LH.
    • Gynecol Oncol. 2020 Aug 7:S0090-8258(20)33662-3. doi: 10.1016/j.ygyno.2020.07.027. Epub ahead of print.
    • BRCA testing in women with high-grade serous ovarian cancer: gynecologic oncologist-initiated testing compared with genetics referral.
    • Piedimonte S, Power J, Foulkes WD, Weber E, Palma L, Schiavi A, Ambrosio E, Konci R, Gilbert L, Jardon K, Baret L, Zeng X.
    • Int J Gynecol Cancer. 2020 Aug 5:ijgc-2020-001261. doi: 10.1136/ijgc-2020-001261. Epub ahead of print.
    • Breast imaging, breast surgery, and cancer genetics in the age of COVID-19.
    • Yin K, Singh P, Drohan B, Hughes KS.
    • Cancer. 2020 Aug 4. doi: 10.1002/cncr.33113. Epub ahead of print.
    • Patterns of cancer family history and genetic counseling eligibility among African Americans with breast, prostate, lung, and colorectal cancers: A Detroit Research on Cancer Survivors cohort study.
    • Purrington KS, Schwartz AG, Ruterbusch JJ, Manning MA, Nair M, Wenzlaff AS, Pandolfi SS, Simon MS, Beebe-Dimmer J.
    • Cancer. 2020 Aug 4. doi: 10.1002/cncr.33126. Epub ahead of print.
    • Ancestry-specific hereditary cancer panel yields: Moving toward more personalized risk assessment.
    • Roberts ME, Susswein LR, Janice Cheng W, Carter NJ, Carter AC, Klein RT, Hruska KS, Marshall ML.
    • J Genet Couns. 2020 Aug;29(4):598-606. doi: 10.1002/jgc4.1257. Epub 2020 Mar 30.
    • Clinicopathological characteristics of gene-positive breast cancer in the United Arab Emirates.
    • Altinoz A, Al Ameri M, Qureshi W, Boush N, Nair SC, Abdel-Aziz A.
    • Breast. 2020 Jul 27;53:119-124. doi: 10.1016/j.breast.2020.07.005. Epub ahead of print.
    • Racial and Ethnic Disparities in Genetic Testing at a Hereditary Breast and Ovarian Cancer Center.
    • Chapman-Davis E, Zhou ZN, Fields JC, Frey MK, Jordan B, Sapra KJ, Chatterjee-Paer S, Carlson AD, Holcomb KM.
    • J Gen Intern Med. 2020 Jul 27. doi: 10.1007/s11606-020-06064-x. Epub ahead of print.
    • Population genetic screening efficiently identifies carriers of autosomal dominant diseases.
    • Grzymski JJ, Elhanan G, Morales Rosado JA, Smith E, Schlauch KA, Read R, Rowan C, Slotnick N, Dabe S, Metcalf WJ, Lipp B, Reed H, Sharma L, Levin E, Kao J, Rashkin M, Bowes J, Dunaway K, Slonim A, Washington N, Ferber M, Bolze A, Lu JT.
    • Nat Med. 2020 Jul 27. doi: 10.1038/s41591-020-0982-5. Epub ahead of print.
    • Disclosure of secondary findings in exome sequencing of 2480 Japanese cancer patients.
    • Horiuchi Y, Matsubayashi H, Kiyozumi Y, Nishimura S, Higashigawa S, Kado N, Nagashima T, Mizuguchi M, Ohnami S, Arai M, Urakami K, Kusuhara M, Yamaguchi K.
    • Hum Genet. 2020 Jul 24. doi: 10.1007/s00439-020-02207-6. Epub ahead of print.
    • Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health Systems.
    • Manchanda R, Sun L, Patel S, Evans O, Wilschut J, De Freitas Lopes AC, Gaba F, Brentnall A, Duffy S, Cui B, Coelho De Soarez P, Husain Z, Hopper J, Sadique Z, Mukhopadhyay A, Yang L, Berkhof J, Legood R.
    • Cancers (Basel). 2020 Jul 17;12(7):E1929. doi: 10.3390/cancers12071929.

    Related:

    Press: BRCA1/2 Population Screening Predicted to be Cost-Effective in Countries With Different Income Levels (GenomeWeb)

    • Utilization of clinical genetic counseling among childhood and young adult cancer survivors in a registry trial.
    • Anderson N, Delavar A, Friedman DN, Joseph V, Mubdi N, Oeffinger KC, Sklar CA, Offit K, Matasar M, Raghunathan N, Antal Z, Straus D, Walsh M, Latham A, Tonorezos ES.
    • J Community Genet. 2020 Jul 16. doi: 10.1007/s12687-020-00478-0. Epub ahead of print.
    • Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system.
    • McCuaig JM, Care M, Ferguson SE, Kim RH, Stockley TL, Metcalfe KA.
    • Gynecol Oncol. 2020 Jul 13:S0090-8258(20)32333-7. doi: 10.1016/j.ygyno.2020.06.507. Epub ahead of print.
    • Mechanisms to increase cascade testing in hereditary breast and ovarian cancer: Impact of introducing standardized communication aids into genetic counseling.
    • Garcia C, Sullivan MW, Lothamer H, Harrison KM, Chatfield L, Thomas MH, Modesitt SC.
    • J Obstet Gynaecol Res. 2020 Jul 12. doi: 10.1111/jog.14366. Epub ahead of print.
    • Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England.
    • Flaum N, Morgan RD, Burghel GJ, Bulman M, Clamp AR, Hasan J, Mitchell CL, Badea D, Moon S, Hogg M, Hadjiyiannakis D, Clancy T, Schlecht H, Woodward ER, Crosbie EJ, Edmondson RJ, Wallace AJ, Jayson GC, Lalloo FI, Harkness EF, Evans DGR.
    • Eur J Hum Genet. 2020 Jul 10. doi: 10.1038/s41431-020-0692-y. Epub ahead of print.
    • Presymptomatic Awareness of Germline Pathogenic BRCA Variants and Associated Outcomes in Women With Breast Cancer.
    • Hadar T, Mor P, Amit G, Lieberman S, Gekhtman D, Rabinovitch R, Levy-Lahad E.
    • JAMA Oncol. 2020 Jul 9. doi: 10.1001/jamaoncol.2020.2059. Epub ahead of print.

    Related:

    Research news: Study Sees Survival Boost For BRCA1/2 Carriers Tested Before Breast Cancer Diagnosis. (GenomeWeb)

    • Breast Cancer Diagnosed in Young Women = Age 35: Effects of Germline Pathogenic Variants, Cancer Subtypes, Tumor-Related Characteristics, and Pregnancy-Associated Diagnosis on Outcomes.
    • Tsai ML, Knaack M, Martone P, Krueger J, Baldinger SR, Lillemoe TJ, Susnik B, Grimm E, Olet S, Rueth N, Swenson KK.
    • Clin Breast Cancer. 2020 Jul 8:S1526-8209(20)30169-5. doi: 10.1016/j.clbc.2020.07.003. Epub ahead of print.
    • Variations in the Referral Pattern for Genetic Counseling of Patients with Early-Onset Breast Cancer: A Population-Based Study in Southern Sweden.
    • Augustinsson A, Ellberg C, Kristoffersson U, Olsson H, Ehrencrona H.
    • Public Health Genomics. 2020 Jul 8:1-10. doi: 10.1159/000508684. Epub ahead of print.
    • Genetic Counseling, Testing, and Management of HBOC in India: An Expert Consensus Document from Indian Society of Medical and Pediatric Oncology.
    • Malhotra H, Kowtal P, Mehra N, Pramank R, Sarin R, Rajkumar T, Gupta S, Bapna A, Bhattacharyya GS, Gupta S, Maheshwari A, Mannan AU, Reddy Kundur R, Sekhon R, Singhal M, Smruti BK, Sp S, Suryavanshi M, Verma A.
    • JCO Glob Oncol. 2020 Jul;6:991-1008. doi: 10.1200/JGO.19.00381.
    • Genetic testing and results disclosure in diverse populations: what does it take?
    • Horowitz CR.
    • Genet Med. 2020 Jun 22. doi: 10.1038/s41436-020-0874-6. Epub ahead of print.
    • Commentary
    • Genetic counselors' perspectives on population-based screening for BRCA-related hereditary breast and ovarian cancer and Lynch syndrome.
    • De Simone LM, Arjunan A, Vogel Postula KJ, Maga T, Bucheit LA.
    • J Genet Couns. 2020 Jun 20. doi: 10.1002/jgc4.1305. Epub ahead of print.
    • Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach.
    • Marchetti C, Minucci A, D'Indinosante M, Ergasti R, Arcieri M, Capoluongo ED, Pietragalla A, Caricato C, Scambia G, Fagotti A.
    • Gynecol Oncol. 2020 Jun 15:S0090-8258(20)32294-0. doi: 10.1016/j.ygyno.2020.06.479. Epub ahead of print.
    • Improving primary care identification of familial breast cancer risk using proactive invitation and decision support.
    • Qureshi N, Dutton B, Weng S, Sheehan C, Chorley W, Robertson JFR, Kendrick D, Kai J.
    • Fam Cancer. 2020 Jun 11. doi: 10.1007/s10689-020-00188-z. Epub ahead of print.
    • Web-based return of BRCA2 research results: one-year genetic counselling experience in Iceland.
    • Stefansdottir V, Thorolfsdottir E, Hognason HB, Patch C, van El C, Hentze S, Cordier C, Mendes Á, Jonsson JJ.
    • Eur J Hum Genet. 2020 Jun 10. doi: 10.1038/s41431-020-0665-1. Epub ahead of print.
    • Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.
    • Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O'Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG.
    • J Clin Oncol. 2020 Jun 9:JCO2000046. doi: 10.1200/JCO.20.00046. Epub ahead of print.

    Related:

    Press: Cancer Experts Develop Precision Medicine-Based Genetic Testing Framework for Prostate Cancer. (GenomeWeb)

    Press: Consider Genetic Testing in All Metastatic Prostate Cancers. (MedPage Today)

    • How to improve the identification of patients with cancer eligible for genetic counselling?
    • Bracci R, Gasperini B, Capalbo M, Campanelli T, Caimmi E, Mattioli R, Espinosa E, Prospero E.
    • Eur J Cancer Care (Engl). 2020 Jun 8:e13276. doi: 10.1111/ecc.13276. Epub ahead of print.
    • Adherence to National Comprehensive Cancer Network Guidelines for BRCA testing among high risk breast Cancer patients: a retrospective chart review study.
    • Bobbili P, Olufade T, DerSarkissian M, Shenolikar R, Yu H, Duh MS, Tung N.
    • Hered Cancer Clin Pract. 2020 Jun 6;18:13. doi: 10.1186/s13053-020-00144-z.
    • Germline Genetic Mutations in a Multi-center Contemporary Cohort of 550 Phyllodes Tumors: An Opportunity for Expanded Multi-gene Panel Testing.
    • Rosenberger LH, Thomas SM, Nimbkar SN, Hieken TJ, Ludwig KK, Jacobs LK, Miller ME, Gallagher KK, Wong J, Neuman HB, Tseng J, Hassinger TE, Jakub JW.
    • Ann Surg Oncol. 2020 Jun 5. doi: 10.1245/s10434-020-08480-z. Epub ahead of print.
    • Studies Show Potential of Video, Online Education to Expand Cancer Risk Genetic Test Access.
    • Ray T.
    • Precision Oncology News. 2020 Jun 4.
    • Press
    • "It wasn't just for me": Motivations and implications of genetic testing for women at a low risk of hereditary breast and ovarian cancer syndrome.
    • Gill G, Beard C, Storey K, Taylor S, Sexton A.
    • Psychooncology. 2020 Jun 4. doi: 10.1002/pon.5436. Epub ahead of print.
    • Setting a baseline: A 7-year review of referral rates and outcomes for serous ovarian cancer prior to implementation of oncologist mediated genetic testing.
    • Armel SR, Volenik A, Demsky R, Malcolmson J, Maganti M, McCuaig J.
    • Gynecol Oncol. 2020 Jun 3:S0090-8258(20)31082-9. doi: 10.1016/j.ygyno.2020.05.014. Epub ahead of print.
    • BFOR Study Uses Digital Tools to Facilitate Population BRCA Screening in Ashkenazi Jewish Community.
    • Anderson A.
    • Precision Oncology News. 2020 Jun 3.
    • Sequencing technology status of BRCA1/2 testing in Latin American Countries.
    • Solano AR, Palmero EI, Delgado L, Carraro DM, Ortíz-López R, Carranza CL, Santamaria C, Cifuentes L, Jara Sosa LE, Toland AE.
    • NPJ Genom Med. 2020 Jun 2;5(1):22. doi: 10.1038/s41525-020-0126-3.

    Duplicate of:

    • Sequencing technology status of BRCA1/2 testing in Latin American Countries.
    • Solano AR, Palmero EI, Delgado L, Carraro DM, Ortíz-López R, Carranza CL, Santamaria C, Cifuentes L, Jara Sosa LE, Toland AE.
    • NPJ Genom Med. 2020 Jun 2;5:22. doi: 10.1038/s41525-020-0126-3.
    • BRCA testing in a genomic diagnostics referral center during the COVID-19 pandemic.
    • Minucci A, Scambia G, Santonocito C, Concolino P, Urbani A.
    • Mol Biol Rep. 2020 Jun;47(6):4857-4860. doi: 10.1007/s11033-020-05479-3. Epub 2020 May 9.
    • Changing practice: moving to a specialist nurse-led service for BRCA gene testing.
    • Scott N, O'Sullivan J, Asgeirsson K, Macmillan D, Wilson E.
    • Br J Nurs. 2020 May 28;29(10):S6-S13. doi: 10.12968/bjon.2020.29.10.S6.
    • How can Australia integrate routine genetic sequencing in oncology: a qualitative study through an implementation science lens.
    • O'Shea R, Rankin NM, Kentwell M, Gleeson M, Salmon L, Tucker KM, Lewis S, Taylor N.
    • Genet Med. 2020 May 28. doi: 10.1038/s41436-020-0838-x. Epub ahead of print.
    • Population Study of Ovarian Cancer Risk Prediction for Targeted Screening and Prevention.
    • Gaba F, Blyuss O, Liu X, Goyal S, Lahoti N, Chandrasekaran D, Kurzer M, Kalsi J, Sanderson S, Lanceley A, Ahmed M, Side L, Gentry-Maharaj A, Wallis Y, Wallace A, Waller J, Luccarini C, Yang X, Dennis J, Dunning A, Lee A, Antoniou AC, Legood R, Menon U, Jacobs I, Manchanda R.
    • Cancers (Basel). 2020 May 15;12(5):E1241. doi: 10.3390/cancers12051241.
    • Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry.
    • Tennen RI, Laskey SB, Koelsch BL, McIntyre MH, Tung JY.
    • Sci Rep. 2020 May 6;10(1):7669. doi: 10.1038/s41598-020-63466-x.
    • Utilization of genetic testing in breast cancer treatment after implementation of comprehensive multi-disciplinary care.
    • Doe S, Petersen S, Swain M.
    • Breast J. 2020 May;26(5):911-916. doi: 10.1111/tbj.13747. Epub 2020 Jan 9.
    • Positive impact of genetic counseling assistants on genetic counseling efficiency, patient volume, and cost in a cancer genetics clinic.
    • Hallquist MLG, Tricou EP, Hallquist MN, Savatt JM, Rocha H, Evans AE, Deckard N, Hu Y, Kirchner HL, Pervola J, Rahm AK, Rashkin M, Schmidlen TJ, Schwartz MLB, Williams JL, Williams MS, Buchanan AH.
    • Genet Med. 2020 Apr 30. doi: 10.1038/s41436-020-0797-2. Epub ahead of print.
    • Uptake of pre-symptomatic testing for BRCA1 and BRCA2 is age, gender, offspring and time-dependent.
    • Forde C, Brunstrom K, Woodward E, Bowers N, Pereira M, Wallace AJ, Lalloo F, Harkness EF, Evans DG.
    • J Med Genet. 2020 Apr 30. pii: jmedgenet-2019-106544. doi: 10.1136/jmedgenet-2019-106544. [Epub ahead of print]
    • Predictors of genetic testing uptake in newly diagnosed breast cancer patients.
    • Ladd MK, Peshkin BN, Isaacs C, Hooker G, Willey S, Valdimarsdottir H, DeMarco T, O'Neill S, Binion S, Schwartz MD; other members of the Surgery After Genetic Evaluation Study Group.
    • J Surg Oncol. 2020 Apr 28. doi: 10.1002/jso.25956. [Epub ahead of print]
    • Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer.
    • Krepline AN, Geurts JL, Akinola I, Christians KK, Clarke CN, George B, Ritch PS, Khan AH, Hall WA, Erickson BA, Griffin MO, Evans DB, Tsai S.
    • HPB (Oxford). 2020 Apr 27. pii: S1365-182X(20)30109-X. doi: 10.1016/j.hpb.2020.03.022. [Epub ahead of print]
    • Acceptability and outcomes of multigene panel testing among young Black breast cancer survivors.
    • Conley CC, Garcia JD, Radford C, Reich RR, Monteiro AN, Pal T, Vadaparampil ST.
    • Breast J. 2020 Apr 22. doi: 10.1111/tbj.13848. Epub ahead of print.
    • Commentary
    • Systematic development of a training program for healthcare professionals to improve communication about breast cancer genetic counseling with low health literate patients.
    • van der Giessen JAM, Ausems MGEM, van den Muijsenbergh METC, van Dulmen S, Fransen MP.
    • Fam Cancer. 2020 Apr 22. doi: 10.1007/s10689-020-00176-3. [Epub ahead of print]
    • Population Screening for Inherited Predisposition to Breast and Ovarian Cancer.
    • Manchanda R, Lieberman S, Gaba F, Lahad A, Levy-Lahad E.
    • Annu Rev Genomics Hum Genet. 2020 Apr 21. doi: 10.1146/annurev-genom-083118-015253. [Epub ahead of print]
    • Unanswered Questions: Hereditary breast and gynecological cancer risk assessment in transgender adolescents and young adults.
    • Sutherland N, Espinel W, Grotzke M, Colonna S.
    • J Genet Couns. 2020 Apr 18. doi: 10.1002/jgc4.1278. [Epub ahead of print]
    • The uptake of predictive DNA testing in 40 families with a pathogenic BRCA1/BRCA2 variant. An evaluation of the proband-mediated procedure.
    • Menko FH, Jeanson KN, Bleiker EMA, van Tiggelen CWM, Hogervorst FBL, Ter Stege JA, Ait Moha D, van der Kolk LE.
    • Eur J Hum Genet. 2020 Apr 16. doi: 10.1038/s41431-020-0618-8. [Epub ahead of print]
    • A road map for the future: An exploration of attitudes, perceptions, and beliefs among African Americans to tailor health promotion of cancer-related genetic counseling and testing.
    • Lumpkins CY, Philp A, Nelson KL, Miller LM, Greiner KA.
    • J Genet Couns. 2020 Apr 15. doi: 10.1002/jgc4.1277. [Epub ahead of print]
    • Adventist Health, CancerIQ Collaboration Identifying More Patients for Guidelines-Supported Genetic Testing.
    • Versel N.
    • GenomeWeb. 2020 Apr 3.
    • News
    • A regional population-based hereditary breast cancer screening tool in Italy: First 5-year results.
    • Cortesi L, Baldassarri B, Ferretti S, Razzaboni E, Bella M, Bucchi L, Canuti D, De Iaco P, De Santis G, Falcini F, Galli V, Godino L, Leoni M, Perrone AM, Pignatti M, Saguatti G, Santini D, Sassoli de'Bianchi P, Sebastiani F, Taffurelli M, Tazzioli G, Turchetti D, Zamagni C, Naldoni C.
    • Cancer Med. 2020 Apr;9(7):2579-2589. doi: 10.1002/cam4.2824. Epub 2020 Feb 11.
    • Longitudinal outcomes with cancer multigene panel testing in previously tested BRCA1/2 negative patients.
    • Bradbury AR, Egleston BL, Patrick-Miller LJ, Rustgi N, Brandt A, Brower J, DiGiovanni L, Fetzer D, Berkelbach C, Long JM, Powers J, Stopfer JE, Domchek SM.
    • Clin Genet. 2020 Apr;97(4):601-609. doi: 10.1111/cge.13716.
    • Assessing relatives' readiness for hereditary cancer cascade genetic testing.
    • Bednar EM, Sun CC, McCurdy S, Vernon SW.
    • Genet Med. 2020 Apr;22(4):719-726. doi: 10.1038/s41436-019-0735-3. Epub 2019 Dec 20.

    Related:

    Letter:

    Correspondence on "Assessing relatives' readiness for hereditary cancer cascade genetic testing" by Bednar et al.

    • Facilitated referral pathway for genetic testing at the time of ovarian cancer diagnosis: uptake of genetic counseling and testing and impact on patient-reported stress, anxiety and depression.
    • Frey MK, Lee SS, Gerber D, Schwartz ZP, Martineau J, Lutz K, Reese E, Dalton E, Olsen A, Girdler J, Pothuri B, Boyd L, Curtin JP, Levine DA, Blank SV.
    • Gynecol Oncol. 2020 Apr;157(1):280-286. doi: 10.1016/j.ygyno.2020.01.007. Epub 2020 Feb 11.
    • Uptake of Risk Appropriate Behaviors After Breast Cancer Risk Stratification in the Mammography Screening Population.
    • Conley CC, Niell BL, Augusto BM, McIntyre M, Roetzheim R, Funaro K, Vadaparampil ST.
    • J Am Coll Radiol. 2020 Mar 27. pii: S1546-1440(20)30240-4. doi: 10.1016/j.jacr.2020.02.019. [Epub ahead of print]

    Related:

    Press: Mailed Notices of High Breast Cancer Risk Do Not Often Translate Into Behavior Changes. (Medscape/Reuters)

    • Public perception of predictive cancer genetic testing and research in Oregon.
    • Alvord TW, Marriott LK, Nguyen PT, Shafer A, Brown K, Stoller W, Volpi JL, Vandehey-Guerrero J, Ferrara LK, Blakesley S, Solomon E, Kuehl H, Palma AJ, Farris PE, Hamman KJ, Cotter M, Shannon J.
    • J Genet Couns. 2020 Mar 27. doi: 10.1002/jgc4.1262. [Epub ahead of print]
    • Genetic Testing for Cancer Predisposition Syndromes in Adolescents and Young Adults (AYAs)
    • Cullinan N, Capra M, McVeigh TP.
    • Curr Genet Med Rep. 2020 Mar 24. doi: 10.1007/s40142-020-00187-7. [Epub ahead of print]
    • Review
    • Germline Genetic Testing, Counseling Move Remote as Pandemic Limits In-Person Care Capacity.
    • Hu C.
    • GenomeWeb. 2020 Mar 24.
    • Germline BRCA Mutation Rates in Latina Women Presenting for Gynecologic Oncology Care.
    • Hong L, Gonzalez R, Unternaehrer J, Ioffe Y.
    • Gynecol Obstet Invest. 2020 Mar 23:1-8. doi: 10.1159/000506108. [Epub ahead of print]
    • Education on cancer risk assessment and genetic counseling to address cancer health disparities among racial/ethnic groups and rural populations: Implementing culturally tailored outreach through community health educators.
    • San Miguel-Majors SL, Whitaker DE, Davis BC, Bailey LO, Springfield SA.
    • J Genet Couns. 2020 Mar 21. doi: 10.1002/jgc4.1272. [Epub ahead of print]
    • Factors shaping at-risk individuals' decisions to undergo genetic testing for cancer in Asia.
    • Sun S, Li ST, Ngeow J.
    • Health Soc Care Community. 2020 Mar 20. doi: 10.1111/hsc.12981. [Epub ahead of print]
    • Racial disparities in breast cancer hereditary risk assessment referrals.
    • Peterson JM, Pepin A, Thomas R, Biagi T, Stark E, Sparks AD, Johnson K, Kaltman R.
    • J Genet Couns. 2020 Mar 20. doi: 10.1002/jgc4.1250. [Epub ahead of print]
    • Knowledge and attitude of hereditary breast cancer among Japanese university female students.
    • Terui-Kohbata H, Egawa M, Yura K, Yoshida M.
    • J Hum Genet. 2020 Mar 18. doi: 10.1038/s10038-020-0743-9. [Epub ahead of print]
    • Exploring the barriers preventing Indigenous Australians from accessing cancer genetic counseling.
    • Gonzalez T, Harris R, Williams R, Wadwell R, Barlow-Stewart K, Fleming J, Buckman M.
    • J Genet Couns. 2020 Mar 16. doi: 10.1002/jgc4.1251. [Epub ahead of print]
    • Prevalence of Pathogenic Variants in Cancer Susceptibility Genes Among Women With Postmenopausal Breast Cancer.
    • Kurian AW, Bernhisel R, Larson K, Caswell-Jin JL, Shadyab AH, Ochs-Balcom H, Stefanick ML.
    • JAMA. 2020 Mar 10;323(10):995-997. doi: 10.1001/jama.2020.0229.

    Related:

    Press: Inherited Mutations in Postmenopausal Breast Cancer Patients Suggest Genetic Testing Is Warranted. (GenomeWeb)

    Press Release: Older women with breast cancer may benefit from genetic testing. (Stanford Medicine)

    Press: Genetic testing may benefit some postmenopausal women with breast cancer. (Healio)

    • Use of an Online Breast Cancer Risk Assessment and Patient Decision Aid in Primary Care Practices.
    • Eden KB, Ivlev I, Bensching KL, Franta G, Hersh AR, Case J, Fu R, Nelson HD.
    • J Womens Health (Larchmt). 2020 Mar 10. doi: 10.1089/jwh.2019.8143. [Epub ahead of print]
    • Pioneering Informed Consent for Return of Research Results to Breast Cancer Patients Facing Barriers to Implementation of Genomic Medicine: The Kenyan BRCA1/2 Testing Experience Using Whole Exome Sequencing.
    • Torrorey-Sawe R, van der Merwe N, Mining SK, Kotze MJ.
    • Front Genet. 2020 Mar 6;11:170. doi: 10.3389/fgene.2020.00170. eCollection 2020.
    • Genetic Counseling and Germline Testing in the Era of Tumor Sequencing: A Cohort Study.
    • Klek S, Heald B, Milinovich A, Ni Y, Abraham J, Mahdi H, Estfan B, Khorana AA, Bolwell BJ, Grivas P, Sohal DPS, Funchain P.
    • JNCI Cancer Spectr. 2020 Mar 5;4(3):pkaa018. doi: 10.1093/jncics/pkaa018.

    Related:

    Editorial:

    A Clinical Approach to Detecting Germline Pathogenic Variants From Tumor-Only Sequencing.

    • The Provision of Genetic Testing and Related Services in Quebec, Canada.
    • Unim B, De Vito C, Hagan J, Villari P, Knoppers BM, Zawati M.
    • Front Genet. 2020 Mar 4;11:127. doi: 10.3389/fgene.2020.00127. eCollection 2020.
    • Involving patients and their families in deciding to use next generation sequencing: Results from a nationally representative survey of U.S. oncologists.
    • Spees LP, Roberts MC, Freedman AN, Butler EN, Klein WMP, Prabhu Das I, de Moor JS.
    • Patient Educ Couns. 2020 Mar 3. pii: S0738-3991(20)30116-6. doi: 10.1016/j.pec.2020.03.001. [Epub ahead of print]
    • Breast Cancer in Men: A Single Center Experience Over a Period of 22 years.
    • Hoffman A, Ben Ishay O, Horesh N, Shabtai M, Forschmidt E, Rosin D, Gutman M, Ram E.
    • Isr Med Assoc J. 2020 Mar;22(3):160-163.
    • Recommendations for Advancing the Diagnosis and Management of Hereditary Breast and Ovarian Cancer in Brazil.
    • Achatz MI, Caleffi M, Guindalini R, Marques RM, Nogueira-Rodrigues A, Ashton-Prolla P.
    • JCO Glob Oncol. 2020 Mar;6:439-452. doi: 10.1200/JGO.19.00170.
    • Precision Prevention: The Current State and Future of Genomically Guided Cancer Prevention.
    • Kassem N, Stout LA, Hunter C, Schneider B, Radovich M.
    • JCO Precis Oncol. 2020;4:96. doi: 10.1200/PO.19.00278. Epub 2020 Feb 26.
    • Review
    • Survey on the current gynaecological approach of ovarian cancer patients: The utility of HIPEC.
    • Iavazzo C, Fotiou A, Tsiatas M, Christopoulou A, Spiliotis J, Sugarbaker P.
    • Pleura Peritoneum. 2020 Feb 26;5(1):20190029. doi: 10.1515/pp-2019-0029.
    • Oncologist-led BRCA 'mainstreaming' in the ovarian cancer clinic: A study of 255 patients and its impact on their management.
    • Rumford M, Lythgoe M, McNeish I, Gabra H, Tookman L, Rahman N, George A, Krell J.
    • Sci Rep. 2020 Feb 25;10(1):3390. doi: 10.1038/s41598-020-60149-5.
    • Group plus "mini" individual pre-test genetic counselling sessions for hereditary cancer shorten provider time and improve patient satisfaction.
    • Hynes J, MacMillan A, Fernandez S, Jacob K, Carter S, Predham S, Etchegary H, Dawson L.
    • Hered Cancer Clin Pract. 2020 Feb 19;18:3. doi: 10.1186/s13053-020-0136-2. eCollection 2020.
    • Evaluation of Triple-Negative Breast Cancer Early Detection via Mammography Screening and Outcomes in African American and White American Patients.
    • Chen Y, Susick L, Davis M, Bensenhaver J, Nathanson SD, Burns J, Newman LA.
    • JAMA Surg. 2020 Feb 19. doi: 10.1001/jamasurg.2019.6032. [Epub ahead of print]
    • Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial.
    • Golan T, Kindler HL, Park JO, Reni M, Macarulla T, Hammel P, Van Cutsem E, Arnold D, Hochhauser D, McGuinness D, Locker GY, Goranova T, Schatz P, Liu YZ, Hall MJ.
    • J Clin Oncol. 2020 Feb 19:JCO1901890. doi: 10.1200/JCO.19.01890. [Epub ahead of print]
    • Disparities in BRCA counseling across providers in a diverse population of young breast cancer survivors.
    • Reid S, Cragun D, Tezak A, Weidner A, Moore J, Mayer IA, Shu XO, Ye F, Fan R, Vadaparampil S, Pal T.
    • Genet Med. 2020 Feb 18. doi: 10.1038/s41436-020-0762-0. [Epub ahead of print]
    • Despite Barriers, Labs Starting to Report Suspected Cancer Risk Mutations Seen in Tumor Testing.
    • Ray T.
    • GenomeWeb. 2020 Feb 6.
    • Healthcare Utilization and Costs after Receiving a Positive BRCA1/2 Result from a Genomic Screening Program.
    • Hao J, Hassen D, Manickam K, Murray MF, Hartzel DN, Hu Y, Liu K, Rahm AK, Williams MS, Lazzeri A, Buchanan A, Sturm A, Snyder SR.
    • J Pers Med. 2020 Feb 3;10(1). pii: E7. doi: 10.3390/jpm10010007.
    • Health Care Provider Perceptions of Caring for Individuals with Inherited Pancreatic Cancer Risk.
    • Underhill ML, Pozzar R, Chung D, Sawhney M, Yurgelun M.
    • J Cancer Educ. 2020 Feb;35(1):194-203. doi: 10.1007/s13187-019-01623-1.
    • Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition.
    • Vos JR, Fakkert IE, de Hullu JA, van Altena AM, Sie AS, Ouchene H, Willems RW, Nagtegaal ID, Jongmans MCJ, Mensenkamp AR, Woldringh GH, Bulten J, Leter EM, Kets CM, Simons M, Ligtenberg MJL, Hoogerbrugge N; OPA Working Group.
    • J Natl Cancer Inst. 2020 Feb 1;112(2):161-169. doi: 10.1093/jnci/djz080.

    Related:

    Letter:

    RE: Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.

    • Mainstreamed genetic testing of breast cancer patients in two hospitals in South Eastern Norway.
    • Grindedal EM, Jørgensen K, Olsson P, Gravdehaug B, Lurås H, Schlichting E, Vamre T, Wangensteen T, Heramb C, Mæhle L.
    • Fam Cancer. 2020 Jan 30. doi: 10.1007/s10689-020-00160-x. [Epub ahead of print]
    • Medicare to Cover Gene Tests in Inherited Breast and Ovarian Cancer.
    • Young KD.
    • Medscape Oncology. 2020 Jan 29.

    Related:

    Decision Memo: Decision Memo for Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer (CAG-00450R) (Centers for Medicare & Medicaid Services)

    • Decision Memo for Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer (CAG-00450R)
    • Syrek Jensen T, Chin J, Evans MA, Ashby L, Ward A, Rollins J, Li C, Long K.
    • Centers for Medicare & Medicaid Services. 2020 Jan 27.
    • CMS to Cover FDA-Approved, -Cleared NGS Germline Tests for Breast, Ovarian Cancer Patients.
    • [No author given]
    • GenomeWeb. 2020 Jan 27.

    Related:

    Decision Memo: Decision Memo for Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer (CAG-00450R) (Centers for Medicare & Medicaid Services)

    • Characteristics predicting recommendation for familial breast cancer referral in a cohort of women from primary care.
    • Lee SI, Qureshi N, Dutton B, Kai J, Weng S.
    • J Community Genet. 2020 Jan 22. doi: 10.1007/s12687-020-00452-w. [Epub ahead of print]
    • As Home Genetic Tests Flood Market, Are Physicians Being Left Behind?
    • Miller KD, Domchek S.
    • Medscape Oncology. 2020 Jan 22.
    • Should Genetic Testing for Cancer Predisposition Be Standard-of-Care for Women with Invasive Breast Cancer? The Murtha Cancer Center Experience.
    • Rummel SK, Lovejoy LA, Turner CE, Shriver CD, Ellsworth RE.
    • Cancers (Basel). 2020 Jan 17;12(1). pii: E234. doi: 10.3390/cancers12010234.
    • Prospective Feasibility Trial of a Novel Strategy of Facilitated Cascade Genetic Testing Using Telephone Counseling.
    • Frey MK, Kahn RM, Chapman-Davis E, Tubito F, Pires , Christos P, Anderson S, Mukherjee S, Jordan B, Blank , Caputo TA, Sharaf , Offit K, Holcomb K, Lipkin S.
    • J Clin Oncol. 2020 Jan 10:JCO1902005. doi: 10.1200/JCO.19.02005. [Epub ahead of print]
    • Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening.
    • Offit K, Tkachuk KA, Stadler ZK, Walsh MF, Diaz-Zabala H, Levin JD, Steinsnyder Z, Ravichandran V, Sharaf RN, Frey MK, Lipkin SM, Robson ME, Hamilton JG, Vijai J, Mukherjee S.
    • J Clin Oncol. 2020 Jan 10:JCO1902010. doi: 10.1200/JCO.19.02010. [Epub ahead of print]
    • Implications of celebrity endorsement of prostate cancer awareness in a tertiary referral unit- The "Fry-Turnbull" Effect.
    • Lovegrove CE, Musbahi O, Ranasinha N, Omer A, Lopez F, Campbell A, Bryant RJ, Leslie T, Bell R, Brewster S, Hamdy FC, Wright B, Lamb AD.
    • BJU Int. 2020 Jan 7. doi: 10.1111/bju.14992. [Epub ahead of print]
    • Commentary
    • Mental Illness and BRCA1/2 Genetic Testing Intention Among Multiethnic Women Undergoing Screening Mammography.
    • Jones T, Freeman K, Ackerman M, Trivedi MS, Silverman T, Shapiro P, Kukafka R, Crew KD.
    • Oncol Nurs Forum. 2020 Jan 1;47(1):E13-E24. doi: 10.1188/20.ONF.E13-E24.
    • Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank.
    • Abul-Husn NS, Soper ER, Odgis JA, Cullina S, Bobo D, Moscati A, Rodriguez JE; CBIPM Genomics Team; Regeneron Genetics Center, Loos RJF, Cho JH, Belbin GM, Suckiel SA, Kenny EE.
    • Genome Med. 2019 Dec 31;12(1):2. doi: 10.1186/s13073-019-0691-1.
    • Latinas' knowledge of and experiences with genetic cancer risk assessment: Barriers and facilitators.
    • Gómez-Trillos S, Sheppard VB, Graves KD, Song M, Anderson L, Ostrove N, Lopez K, Campos C, Gonzalez N, Hurtado-de-Mendoza A.
    • J Genet Couns. 2019 Dec 27. doi: 10.1002/jgc4.1201. [Epub ahead of print]
    • Online BRCA1/2 screening in the Australian Jewish community: a qualitative study.
    • Yuen J, Cousens N, Barlow-Stewart K, O'Shea R, Andrews L.
    • J Community Genet. 2019 Dec 26. doi: 10.1007/s12687-019-00450-7. [Epub ahead of print]
    • The changing surgical treatment of breast cancer in the United States: The tipping point.
    • Carlson GW.
    • Breast J. 2019 Dec 22. doi: 10.1111/tbj.13725. [Epub ahead of print]
    • Review
    • Black Women's Confidence in the Genetic Information Nondiscrimination Act.
    • Sutton AL, Henderson A, Hurtado-de-Mendoza A, Tanner E, Khan M, Quillin J, Sheppard VB.
    • Int J Environ Res Public Health. 2019 Dec 14;16(24). pii: E5112. doi: 10.3390/ijerph16245112.
    • Uptake of Polygenic Risk Information among Women at Increased Risk of Breast Cancer.
    • Yanes T, Meiser B, Kaur R, Scheepers-Joynt M, McInerny S, Taylor S, Barlow-Stewart K, Antill Y, Salmon L, Smyth C, Young MA, James PA.
    • Clin Genet. 2019 Dec 12. doi: 10.1111/cge.13687. [Epub ahead of print]
    • Racial and Ethnic Differences in BRCA1/2 and Multigene Panel Testing Among Young Breast Cancer Patients.
    • Jones T, Trivedi MS, Jiang X, Silverman T, Underhill M, Chung WK, Kukafka R, Crew KD.
    • J Cancer Educ. 2019 Dec 4. doi: 10.1007/s13187-019-01646-8. [Epub ahead of print]

    Related:

    Research news: Study: Racial and ethnic differences in genetic testing among young breast cancer survivors. (FORCE. XRAYS.)

    • Culturally Targeted Video Improves Psychosocial Outcomes in Latina Women at Risk of Hereditary Breast and Ovarian Cancer.
    • Hurtado-de-Mendoza A, Graves KD, Gómez-Trillos S, Carrera P, Campos C, Anderson L, Luta G, Peshkin BN, Schwartz MD, Cupertino AP, Gonzalez N, Sheppard VB.
    • Int J Environ Res Public Health. 2019 Nov 29;16(23). pii: E4793. doi: 10.3390/ijerph16234793.
    • Reducing Disparities in Receipt of Genetic Counseling for Underserved Women at Risk of Hereditary Breast and Ovarian Cancer.
    • Sutton AL, Hurtado-de-Mendoza A, Quillin J, Rubinsak L, Temkin SM, Gal T, Sheppard VB.
    • J Womens Health (Larchmt). 2019 Nov 27. doi: 10.1089/jwh.2019.7984. [Epub ahead of print]
    • Low rates of cascade genetic testing among families with hereditary gynecologic cancer: An opportunity to improve cancer prevention.
    • Griffin NE, Buchanan TR, Smith SH, Leon AA, Meyer MF, Liu J, Tabak RG, Fuh KC, Thaker PH, Powell MA, Mutch DG, Massad LS, Colditz GA, Hagemann AR.
    • Gynecol Oncol. 2019 Nov 25. pii: S0090-8258(19)31626-9. doi: 10.1016/j.ygyno.2019.11.005. [Epub ahead of print]
    • As Genetic Testing Access Grows, Travel Time Remains Barrier to In-Person Counseling.
    • Ray T.
    • GenomeWeb. 2019 Nov 20.
    • Employee Benefits Programs Share Early Experiences Implementing Genetic Testing.
    • Ray T.
    • GenomeWeb. 2019 Nov 15.
    • Knowledge and opinions regarding BRCA1 and BRCA2 genetic testing among primary care physicians.
    • Dekanek EW, Thull DL, Massart M, Grubs RE, Rajkovic A, Mai PL.
    • J Genet Couns. 2019 Nov 14. doi: 10.1002/jgc4.1189. [Epub ahead of print]
    • Germline Testing for Patients With BRCA1/2 Mutations on Somatic Tumor Testing.
    • Vlessis K, Purington N, Chun N, Haraldsdottir S, Ford JM.
    • JNCI Cancer Spectr. 2019 Nov 11;4(1):pkz095. doi: 10.1093/jncics/pkz095. eCollection 2020 Feb.
    • Impact of Genetic Testing on Risk-Management Behavior of Black Breast Cancer Survivors: A Longitudinal, Observational Study.
    • Conley CC, Kasting ML, Augusto BM, Garcia JD, Cragun D, Gonzalez BD, Kim J, Ashing KT, Knott CL, Hughes-Halbert C, Pal T, Vadaparampil ST.
    • Ann Surg Oncol. 2019 Nov 1. doi: 10.1245/s10434-019-07982-9. [Epub ahead of print]
    • Mainstreaming genetic counseling for BRCA testing into oncology clinics - Indian perspective.
    • Verma A, Nag S, Hasan Q, Selvakumar VPP.
    • Indian J Cancer. 2019 Nov;56(Supplement):S38-S47. doi: 10.4103/ijc.IJC_458_19.
    • Calling on Primary Care to Prevent BRCA-Related Cancers.
    • Armstrong K.
    • J Gen Intern Med. 2019 Oct 21. doi: 10.1007/s11606-019-05469-7. [Epub ahead of print]
    • Decision Making About Genetic Testing Among Women With a Personal and Family History of Breast Cancer.
    • Scott D, Friedman S, Telli ML, Kurian AW.
    • J Oncol Pract. 2019 Oct 15:JOP1900221. doi: 10.1200/JOP.19.00221. [Epub ahead of print]
    • Patterns and Predictors of Genetic Referral among Ovarian Cancer Patients at a National Cancer Institute Comprehensive Cancer Center.
    • Mallen AR, Conley CC, Townsend MK, Wells A, Boac BM, Todd S, Gandhi A, Kuznicki M, Augusto BM, McIntyre M, Fridley BL, Tworoger SS, Wenham RM, Vadaparampil ST.
    • Clin Genet. 2019 Oct 10. doi: 10.1111/cge.13654. [Epub ahead of print]
    • BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories.
    • Capoluongo E, Verde N, Barberis M, Bella MA, Buttitta F, Carrera P, Colombo N, Cortesi L, Gion M, Guarneri V, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A, Gori S.
    • Diagnostics (Basel). 2019 Oct 9;9(4). pii: E146. doi: 10.3390/diagnostics9040146.
    • All For BRCA, BRCA For All?
    • Resta R.
    • The DNA Exchange. 2019 Oct 7.
    • Genetic testing in ovarian cancer - clinical impact and current practices.
    • Knabben L, Imboden S, Mueller MD.
    • Horm Mol Biol Clin Investig. 2019 Oct 2. pii: /j/hmbci.ahead-of-print/hmbci-2019-0025/hmbci-2019-0025.xml. doi: 10.1515/hmbci-2019-0025. [Epub ahead of print]
    • Review
    • Genetic counseling and oncology: proposed approaches for collaborative care delivery.
    • Powers J, Spielman K, Mueller R, Batson M, Pundock S, Arutyunova A, Symecko H, Domchek S.
    • Can J Urol. 2019 Oct;26(5S2):57-59.
    • Integrating a Next Generation Sequencing Panel into Clinical Practice in Ovarian Cancer.
    • Lee YJ, Kim D, Kim HS, Na K, Lee JY, Nam EJ, Kim SW, Kim S, Kim YT.
    • Yonsei Med J. 2019 Oct;60(10):914-923. doi: 10.3349/ymj.2019.60.10.914.
    • BRCA testing in unaffected young women in the United States, 2006-2017.
    • Guo F, Scholl M, Fuchs EL, Berenson AB, Kuo YF.
    • Cancer. 2019 Sep 30. doi: 10.1002/cncr.32536. [Epub ahead of print]
    • Recontacting patients for multigene panel testing in hereditary cancer: Efficacy and insights.
    • Sawyer L, Creswick H, Lewandowski R, Quillin J.
    • J Genet Couns. 2019 Sep 25. doi: 10.1002/jgc4.1173. [Epub ahead of print]
    • Patients' willingness to reconsider cancer genetic testing after initially declining: Mention it again.
    • Halverson CME, Wessinger BC, Clayton EW, Wiesner GL.
    • J Genet Couns. 2019 Sep 25. doi: 10.1002/jgc4.1174. [Epub ahead of print]
    • Inequities in multi-gene hereditary cancer testing: lower diagnostic yield and higher VUS rate in individuals who identify as Hispanic, African or Asian and Pacific Islander as compared to European.
    • Ndugga-Kabuye MK, Issaka RB.
    • Fam Cancer. 2019 Sep 17. doi: 10.1007/s10689-019-00144-6. [Epub ahead of print]
    • Germline BRCA1 and BRCA2 testing for breast cancer survivors.
    • Wiggins J, McLoughlin A, George A, Ring A, Kemp Z.
    • J Med Genet. 2019 Sep 11. pii: jmedgenet-2019-106420. doi: 10.1136/jmedgenet-2019-106420. [Epub ahead of print]
    • A family pedigree of malignancies associated with BRCA1 pathogenic variants: a reflection of the state of art in China.
    • Li W, Li L, Wu M.
    • Hered Cancer Clin Pract. 2019 Sep 10;17:26. doi: 10.1186/s13053-019-0126-4. eCollection 2019.
    • Understanding Medical Mistrust in Black Women at Risk of BRCA 1/2 Mutations.
    • Sutton AL, He J, Tanner E, Edmonds MC, Henderson A, Hurtado de Mendoza A, Sheppard VB.
    • J Health Dispar Res Pract. 2019 Fall;12(3):35-47.
    • Cancer: more genetic BRCA testing for men.
    • Marabelli M, Calvello M, Bonanni B.
    • Nature. 2019 Sep;573(7774):346. doi: 10.1038/d41586-019-02775-2.

    Related:

    Commentary:

    New name for breast-cancer syndrome could help to save lives.

    • Universal Genetic Testing for All Breast Cancer Patients.
    • Copur MS.
    • Oncology (Williston Park). 2019 Aug 23;33(8). pii: 683731.
    • USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan.
    • Rajagopal PS, Nielsen S, Olopade OI.
    • JAMA Netw Open. 2019 Aug 20;2(8.10):e1910142. doi: 10.1001/jamanetworkopen.2019.10142.

    Related:

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • BRCA mutation in high grade epithelial ovarian cancers.
    • Manchana T, Phoolcharoen N, Tantbirojn P.
    • Gynecol Oncol Rep. 2019 Aug 13;29:102-105. doi: 10.1016/j.gore.2019.07.007. eCollection 2019 Aug.
    • The Genetic Education for Men (GEM) Trial: Development of Web-Based Education for Untested Men in BRCA1/2-Positive Families.
    • Peshkin BN, Ladd MK, Isaacs C, Segal H, Jacobs A, Taylor KL, Graves KD, O'Neill SC, Schwartz MD.
    • J Cancer Educ. 2019 Aug 11. doi: 10.1007/s13187-019-01599-y. [Epub ahead of print]
    • The budgetary impact of genetic testing for hereditary breast cancer for the statutory health insurance.
    • Neusser S, Lux B, Barth C, Pahmeier K, Rhiem K, Schmutzler R, Engel C, Wasem J, Neumann A.
    • Curr Med Res Opin. 2019 Aug 8:1. doi: 10.1080/03007995.2019.1654689. [Epub ahead of print]
    • Strategies for Improving Access to Hereditary Cancer Testing: Recommendations from Stakeholders.
    • Ready K, Johansen Taber KA, Bonhomme N, Lichtenfeld JL.
    • Genet Med. 2019 Aug;21(8):1702-1704. doi: 10.1038/s41436-018-0430-9. Epub 2019 Jan 28.
    • Assessing the effectiveness of the National Comprehensive Cancer Network genetic testing guidelines in identifying African American breast cancer patients with deleterious genetic mutations.
    • Ademuyiwa FO, Salyer P, Ma Y, Fisher S, Colditz G, Weilbaecher K, Bierut LJ.
    • Breast Cancer Res Treat. 2019 Jul 19. doi: 10.1007/s10549-019-05359-w. [Epub ahead of print]
    • Insurance coverage does not predict outcomes of genetic testing: The search for meaning in payer decisions for germline cancer tests.
    • Amendola LM, Hart MR, Bennett RL, Horike-Pyne M, Dorschner M, Shirts B, Jarvik GP.
    • J Genet Couns. 2019 Jul 17. doi: 10.1002/jgc4.1155. [Epub ahead of print]
    • Uptake of genetic counseling among adult children of BRCA1/2 mutation carriers in France.
    • Gauna Cristaldo FB, Touzani R, Apostolidis T, Mouret-Fourme E, Stoppa-Lyonnet D, Lasset C, Fricker JP, Berthet P, Julian-Reynier C, Mancini J, Noguès C, Bouhnik AD.
    • Psychooncology. 2019 Jul 5. doi: 10.1002/pon.5169. [Epub ahead of print]
    • Moving into the mainstream: healthcare professionals' views of implementing treatment focussed genetic testing in breast cancer care.
    • Hallowell N, Wright S, Stirling D, Gourley C, Young O, Porteous M.
    • Fam Cancer. 2019 Jul;18(3):293-301. doi: 10.1007/s10689-019-00122-y.
    • Knowledge, attitudes, and perceived barriers towards genetic testing across three rural Illinois communities.
    • Fogleman AJ, Zahnd WE, Lipka AE, Malhi RS, Ganai S, Delfino KR, Jenkins WD.
    • J Community Genet. 2019 Jul;10(3):417-423. doi: 10.1007/s12687-019-00407-w. Epub 2019 Jan 23.
    • New name for breast-cancer syndrome could help to save lives.
    • Pritchard CC.
    • Nature. 2019 Jul;571(7763):27-29. doi: 10.1038/d41586-019-02015-7.

    Related:

    Letter:

    Cancer: more genetic BRCA testing for men.

    Press: New Name of 'King Syndrome' for Hereditary BRCA Mutations. (Medscape Oncology)

    • Genetic Testing for Breast Cancer Susceptibility Should Be Offered before Unilateral Abdominally Based Free Flap Breast Reconstruction.
    • Dayan E, Chittenden A, Garber JE, Wo L, Caterson SA, Carty MJ, Erdmann-Sager J.
    • Plast Reconstr Surg. 2019 Jul;144(1):12-20. doi: 10.1097/PRS.0000000000005693.
    • Barriers to the utilization of genetic testing and genetic counseling in patients with suspected hereditary breast and ovarian cancers.
    • Swink A, Nair A, Hoof P, Matthews A, Burden C, Johnson K, Blum JL.
    • Proc (Bayl Univ Med Cent). 2019 Jun 11;32(3):340-344. doi: 10.1080/08998280.2019.1612702. eCollection 2019 Jul.
    • CancerIQ, GeneMatters Integrate Technology to Widen Access to Genetic Counselors.
    • [No author given]
    • GenomeWeb. 2019 Jun 27.
    • Current Genetic Service Delivery Models for the Provision of Genetic Testing in Europe: A Systematic Review of the Literature.
    • Unim B, Pitini E, Lagerberg T, Adamo G, De Vito C, Marzuillo C, Villari P.
    • Front Genet. 2019 Jun 19;10:552. doi: 10.3389/fgene.2019.00552. eCollection 2019.
    • Differences in referral patterns based on race for women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.
    • Boitano TKL, Barrington DA, Batra S, McGwin G Jr, Turner TB, Farmer MB, Brown AM, Straughn MJ Jr, Leath CA 3rd.
    • Gynecol Oncol. 2019 Jun 10. pii: S0090-8258(19)31275-2. doi: 10.1016/j.ygyno.2019.05.031. [Epub ahead of print]
    • Genetic testing and eHealth usage among Deaf women.
    • Kushalnagar P, Holcomb J, Sadler GR.
    • J Genet Couns. 2019 Jun 10. doi: 10.1002/jgc4.1134. [Epub ahead of print]
    • Genetic counseling of patients with ovarian carcinoma: acceptance, timing, and psychological wellbeing.
    • Van de Beek I, Smets EMA, Legdeur MA, de Hullu JA, Lok CAR, Buist MR, Mourits MJE, Kets CM, van der Kolk LE, Oosterwijk JC, Aalfs CM.
    • J Community Genet. 2019 Jun 5. doi: 10.1007/s12687-019-00427-6. [Epub ahead of print]
    • Understanding Factors Associated with Uptake of BRCA1/2 Genetic Testing among Orthodox Jewish Women in the USA Using a Mixed-Methods Approach.
    • Trivedi MS, Colbeth H, Yi H, Vanegas A, Starck R, Chung WK, Appelbaum PS, Kukafka R, Schechter I, Crew KD.
    • Public Health Genomics. 2019 Jun 4:1-11. doi: 10.1159/000499852. [Epub ahead of print]
    • Psychosocial and clinical factors of probands impacting intrafamilial disclosure and uptake of genetic testing among 103 French families with BRCA1/2 or MMR gene mutations.
    • Alegre N, Vande Perre P, Bignon YJ, Michel A, Galibert V, Mophawe O, Corsini C, Coupier I, Chiesa J, Robert L, Bernhard L, Picot MC, Bertet H, Macioce V, Bastide N, Solassol J, Rey JM, Thomas F, Carton S, Pujol P.
    • Psychooncology. 2019 Jun 1. doi: 10.1002/pon.5142. [Epub ahead of print]
    • Referral patterns for genetic counselling of women diagnosed with tubo-ovarian or peritoneal high-grade serous carcinoma (HGSC) within the Auckland Gynaecological Oncology Centre.
    • Burling MJ, Gamet K, Eva L, Tan AL.
    • Aust N Z J Obstet Gynaecol. 2019 Jun;59(3):444-449. doi: 10.1111/ajo.12964. Epub 2019 Mar 18.
    • Disparities in genetic services utilization in a random sample of young breast cancer survivors.
    • Nikolaidis C, Duquette D, Mendelsohn-Victor KE, Anderson B, Copeland G, Milliron KJ, Merajver SD, Janz NK, Northouse LL, Duffy SA, Katapodi MC.
    • Genet Med. 2019 Jun;21(6):1363-1370. doi: 10.1038/s41436-018-0349-1. Epub 2018 Nov 2.
    • Genetic counseling, genetic testing, and risk perceptions for breast and colorectal cancer: Results from the 2015 National Health Interview Survey.
    • Turbitt E, Roberts MC, Taber JM, Waters EA, McNeel TS, Biesecker BB, Klein WMP.
    • Prev Med. 2019 Jun;123:12-19. doi: 10.1016/j.ypmed.2019.02.027. Epub 2019 Feb 25.
    • Challenges in Managing Patients with Hereditary Cancer at Gynecological Services.
    • Ueda M, Tsubamoto H, Kashima-Morii M, Torii Y, Kamihigashi M, Wakimoto Y, Nakagomi N, Hashimoto-Tamaoki T, Sawai H, Shibahara H.
    • Obstet Gynecol Int. 2019 May 27;2019:4365754. doi: 10.1155/2019/4365754. eCollection 2019.
    • Developing a culturally targeted video to enhance the use of genetic counseling in Latina women at increased risk for hereditary breast and ovarian cancer.
    • Hurtado-de-Mendoza A, Graves KD, Gómez-Trillos S, Song M, Anderson L, Campos C, Carrera P, Ostrove N, Peshkin BN, Schwartz MD, Ficca N, Cupertino AP, Gonzalez N, Otero A, Huerta E, Sheppard VB.
    • J Community Genet. 2019 May 18. doi: 10.1007/s12687-019-00423-w. [Epub ahead of print]
    • Uptake of testing for germline BRCA mutations in patients with non-mucinous epithelial ovarian cancers in Western Australia: a comparison of different genetic counseling methods.
    • Stearnes G, Nichols CB, Schofield L, O'Sullivan S, Pachter N, Cohen PA.
    • Int J Gynecol Cancer. 2019 May 17. pii: ijgc-2019-000389. doi: 10.1136/ijgc-2019-000389. [Epub ahead of print]
    • Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.
    • Vos JR, Fakkert IE, de Hullu JA, van Altena AM, Sie AS, Ouchene H, Willems RW, Nagtegaal ID, Jongmans MCJ, Mensenkamp AR, Woldringh GH, Bulten J, Leter EM, Kets CM, Simons M, Ligtenberg MJL, Hoogerbrugge N.
    • J Natl Cancer Inst. 2019 May 11. pii: djz080. doi: 10.1093/jnci/djz080. [Epub ahead of print]

    Related:

    Letter, Comment:

    RE: Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.

    • Exploring Predictors of Genetic Counseling and Testing for Hereditary Breast and Ovarian Cancer: Findings from the 2015 U.S. National Health Interview Survey.
    • Allen CG, Roberts M, Guan Y.
    • J Pers Med. 2019 May 10;9(2). pii: E26. doi: 10.3390/jpm9020026.
    • Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics services.
    • Moss CA, Cojocaru E, Hanwell J, Ward S, Xu W, van Zyl M, O'Leary L, de Bono JS, Banerji U, Kaye SB, Minchom A, George AJ, Lopez J, McVeigh TP.
    • Eur J Cancer. 2019 May 9;114:97-106. doi: 10.1016/j.ejca.2019.04.009. [Epub ahead of print]
    • Effectiveness of interventions to identify and manage patients with familial cancer risk in primary care: a systematic review.
    • Lee SI, Patel M, Dutton B, Weng S, Luveta J, Qureshi N.
    • J Community Genet. 2019 May 6. doi: 10.1007/s12687-019-00419-6. [Epub ahead of print]
    • Review
    • Trends in BRCA testing and socioeconomic deprivation.
    • Martin AP, Pedra G, Downing J, Collins B, Godman B, Alfirevic A, Pirmohamed M, Lynn Greenhalgh K.
    • Eur J Hum Genet. 2019 May 3. doi: 10.1038/s41431-019-0424-3. [Epub ahead of print]
    • Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
    • Kemp Z, Turnbull A, Yost S, Seal S, Mahamdallie S, Poyastro-Pearson E, Warren-Perry M, Eccleston A, Tan MM, Teo SH, Turner N, Strydom A, George A, Rahman N.
    • JAMA Netw Open. 2019 May 3;2(5):e194428. doi: 10.1001/jamanetworkopen.2019.4428.
    • Attitude towards and factors affecting uptake of population-based BRCA testing in the Ashkenazi Jewish population: a cohort study.
    • Manchanda R, Burnell M, Gaba F, Sanderson S, Loggenberg K, Gessler S, Wardle J, Side L, Desai R, Brady AF, Dorkins H, Wallis Y, Chapman C, Jacobs C, Tomlinson I, Beller U, Menon U, Jacobs I.
    • BJOG. 2019 May;126(6):784-794. doi: 10.1111/1471-0528.15654. Epub 2019 Mar 18.
    • Identifying disparities in germline and somatic testing for ovarian cancer.
    • Huang M, Kamath P, Schlumbrecht M, Miao F, Driscoll D, Oldak S, Slomovitz B, Koru-Sengul T, George S.
    • Gynecol Oncol. 2019 May;153(2):297-303. doi: 10.1016/j.ygyno.2019.03.007. Epub 2019 Mar 16.
    • A randomized controlled intervention to promote readiness to genetic counseling for breast cancer survivors.
    • Kasting ML, Conley CC, Hoogland AI, Scherr CL, Kim J, Thapa R, Reblin M, Meade CD, Lee MC, Pal T, Quinn GP, Vadaparampil ST.
    • Psychooncology. 2019 May;28(5):980-988. doi: 10.1002/pon.5059. Epub 2019 Apr 11.
    • Global Disparities in Breast Cancer Genetics Testing, Counselling and Management.
    • Yip CH, Evans DG, Agarwal G, Buccimazza I, Kwong A, Morant R, Prakash I, Song CY, Taib NA, Tausch C, Ung O, Meterissian S.
    • World J Surg. 2019 May;43(5):1264-1270. doi: 10.1007/s00268-018-04897-6.
    • Shared-patient physician networks and their impact on the uptake of genomic testing in breast cancer.
    • Rotter J, Wilson L, Greiner MA, Pollack CE, Dinan M.
    • Breast Cancer Res Treat. 2019 Apr 26. doi: 10.1007/s10549-019-05248-2. [Epub ahead of print]
    • Scientific supremacy as an obstacle to establishing and sustaining interdisciplinary dialogue across knowledge paradigms in health medicine.
    • Gripsrud BH, Solbrække KN.
    • Med Health Care Philos. 2019 Apr 25. doi: 10.1007/s11019-019-09901-x. [Epub ahead of print]

    Related:

    Commentary:

    Our genes, our selves: hereditary breast cancer and biological citizenship in Norway.

    Our genes, our selves: hereditary breast cancer and biological citizenship in Norway.

    • Uptake of genetic testing for germline BRCA1/2 pathogenic variants in a predominantly Hispanic population.
    • McGuinness JE, Trivedi MS, Silverman T, Marte A, Mata J, Kukafka R, Crew KD.
    • Cancer Genet. 2019 Apr 24. pii: S2210-7762(19)30059-6. doi: 10.1016/j.cancergen.2019.04.063. [Epub ahead of print]
    • Improving access to cancer genetic services: perspectives of high-risk clients in a community-based setting.
    • Miller I, Greenberg S, Yashar BM, Marvin ML.
    • J Community Genet. 2019 Apr 24. doi: 10.1007/s12687-019-00420-z. [Epub ahead of print]
    • The Burden of Breast Cancer Predisposition Variants Across The Age Spectrum Among 10 000 Patients.
    • Chavarri-Guerra Y, Hendricks CB, Brown S, Marcum C, Hander M, Segota ZE, Hake C, Sand S, Slavin TP, Hurria A, Soto-Perez-de-Celis E, Nehoray B, Blankstein KB, Blazer KR, Weitzel JN; Clinical Cancer Genomics Community Research Network.
    • J Am Geriatr Soc. 2019 Apr 23. doi: 10.1111/jgs.15937. [Epub ahead of print]
    • Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.
    • Paller CJ, Antonarakis ES, Beer TM, Borno HT, Carlo MI, George DJ, Graff JN, Gupta S, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Petrylak DP, Rettig MB, Ryan C, Taplin ME, Whang YE, Vinson J, Cheng HH, Giri VN; PCCTC Germline Genetics Working Group.
    • Clin Genitourin Cancer. 2019 Apr 18. pii: S1558-7673(19)30139-9. doi: 10.1016/j.clgc.2019.04.013. [Epub ahead of print]
    • Genetic counseling referral for ovarian cancer patients: a call to action.
    • Garcia C, Harrison K, Ring KL, Sullivan MW, Rauh LA, Modesitt SC.
    • Fam Cancer. 2019 Apr 16. doi: 10.1007/s10689-019-00129-5. [Epub ahead of print]
    • Hereditary Breast Cancer Risk Analysis in Uninsured Mexican-Origin Women Living in the U.S.-Mexico Border Region.
    • Salinas JJ, Roy R, Dwivedi AK, Shokar NK.
    • Hisp Health Care Int. 2019 Apr 12:1540415319837850. doi: 10.1177/1540415319837850. [Epub ahead of print]
    • Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.
    • Kurian AW, Ward KC, Howlader N, Deapen D, Hamilton AS, Mariotto A, Miller D, Penberthy LS, Katz SJ.
    • J Clin Oncol. 2019 Apr 9:JCO1801854. doi: 10.1200/JCO.18.01854. [Epub ahead of print]

    Related:

    Press: Genetic Testing Under-Utilized in Ovarian Cancer. (Medscape Oncology)

    • Evaluation of telephone genetic counselling to facilitate germline BRCA1/2 testing in women with high-grade serous ovarian cancer.
    • Tutty E, Petelin L, McKinley J, Young MA, Meiser B, Rasmussen VM, Forbes Shepherd R, James PA, Forrest LE.
    • Eur J Hum Genet. 2019 Apr 8. doi: 10.1038/s41431-019-0390-9. [Epub ahead of print]
    • Racial/Ethnic Disparities in BRCA Counseling and Testing: a Narrative Review.
    • Williams CD, Bullard AJ, O'Leary M, Thomas R, Redding TS 4th, Goldstein K.
    • J Racial Ethn Health Disparities. 2019 Apr 8. doi: 10.1007/s40615-018-00556-7. [Epub ahead of print]
    • Review
    • 23andMe DTC Breast and Ovarian Cancer Risk Test Misses Almost 90 Percent of BRCA Mutation Carriers.
    • Karow J.
    • Precision Oncology News. 2019 Apr 5.
    • Benchmarking of a checklist for the identification of familial risk for breast and ovarian cancers in a prospective cohort.
    • Rhiem K, Bücker-Nott HJ, Hellmich M, Fischer H, Ataseven B, Dittmer-Grabowski C, Latos K, Pelzer V, Seifert M, Schmidt A, Rezek D, Groh U, Meinerz W, Crommelinck D, Hahnen E, Wesselmann S, Schmutzler RK.
    • Breast J. 2019 Apr 5. doi: 10.1111/tbj.13257. [Epub ahead of print]
    • Direct Genetics Referral Pathway for High-Grade Serous Ovarian Cancer Patients: The "Opt-Out" Process.
    • McGee J, Peart TM, Foley N, Bertrand M, Prefontaine M, Sugimoto A, Ettler H, Welch S, Panabaker K.
    • J Oncol. 2019 Apr 2;2019:6029097. doi: 10.1155/2019/6029097. eCollection 2019.
    • A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.
    • Donenberg T, George S, Ali J, Bravo G, Hernandez K, Sookar N, Ashing KT, Narod SA, Akbari MR, Hurley J.
    • Breast Cancer Res Treat. 2019 Apr;174(2):469-477. doi: 10.1007/s10549-018-5045-y. Epub 2018 Dec 4.
    • Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma.
    • Walker EJ, Carnevale J, Pedley C, Blanco A, Chan S, Collisson EA, Tempero MA, Ko AH.
    • Fam Cancer. 2019 Apr;18(2):241-251. doi: 10.1007/s10689-018-0106-2.
    • Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility.
    • Rowley SM, Mascarenhas L, Devereux L, Li N, Amarasinghe KC, Zethoven M, Lee JEA, Lewis A, Morgan JA, Limb S, Young MA, James PA, Trainer AH, Campbell IG.
    • Genet Med. 2019 Apr;21(4):913-922. doi: 10.1038/s41436-018-0277-0. Epub 2018 Sep 26.
    • A patient-centered mobile health application to motivate use of genetic counseling among women with ovarian cancer: A pilot randomized controlled trial.
    • Vogel RI, Niendorf K, Petzel S, Lee H, Teoh D, Blaes AH, Argenta P, Rivard C, Winterhoff B, Lee HY, Geller MA.
    • Gynecol Oncol. 2019 Apr;153(1):100-107. doi: 10.1016/j.ygyno.2019.01.019. Epub 2019 Feb 1.
    • Disparities in gynecologic cancer genetics evaluation.
    • Hinchcliff EM, Bednar EM, Lu KH, Rauh-Hain JA.
    • Gynecol Oncol. 2019 Apr;153(1):184-191. doi: 10.1016/j.ygyno.2019.01.024. Epub 2019 Jan 31.
    • Review
    • Current Approaches to Cancer Genetic Counseling Services for Spanish-Speaking Patients.
    • Augusto B, Kasting ML, Couch FJ, Lindor NM, Vadaparampil ST.
    • J Immigr Minor Health. 2019 Apr;21(2):434-437. doi: 10.1007/s10903-018-0772-z.
    • Breast surgeons recommend genetic testing for all breast cancer patients.
    • [No author given]
    • FORCE. XRAYS. 2019 Mar 25.

    Related:

    Guideline: Consensus Guideline on Genetic Testing for Hereditary Breast Cancer. (PDF) (American Society of Breast Surgeons.)

    • Discoveries beyond BRCA1/2: Multigene testing in an Asian multi-ethnic cohort suspected of hereditary breast cancer syndrome in the real world.
    • Ow SGW, Ong PY, Lee SC.
    • PLoS One. 2019 Mar 15;14(3):e0213746. doi: 10.1371/journal.pone.0213746. eCollection 2019.
    • Gaps in information about breast cancer risk and prevention impact African American women.
    • [No author given]
    • FORCE. XRAYS. 2019 Mar 14.

    Related:

    Original research:

    Layers of information: interacting constraints on breast cancer risk-management by high-risk African American women.

    • Impact of Implementing B-RSTTM to Screen for Hereditary Breast and Ovarian Cancer on Risk Perception and Genetic Counseling Uptake Among Women in an Academic Safety Net Hospital.
    • Wernke K, Bellcross C, Gabram S, Ali N, Stanislaw C.
    • Clin Breast Cancer. 2019 Mar 11. pii: S1526-8209(18)30730-4. doi: 10.1016/j.clbc.2019.02.014. [Epub ahead of print]
    • RE: Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative.
    • Peshkin BN, Isaacs C, Schwartz MD.
    • J Natl Cancer Inst. 2019 Mar 5. pii: djz028. doi: 10.1093/jnci/djz028. [Epub ahead of print]

    Related:

    Letter, reply:

    Response to Peshkin, Isaacs, and Schwartz.

    Original research:

    Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative.

    • Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
    • Quek RGW, Mardekian J.
    • Adv Ther. 2019 Mar;36(3):708-720. doi: 10.1007/s12325-018-0867-x. Epub 2019 Jan 17.
    • BRCA mutation testing for ovarian cancer in the context of available targeted therapy: Survey and consensus of Hong Kong specialists.
    • Kwong A, Cheng KD, Hsue CV, Hui SK, Leung CR, Leung KA, Ngan KR, Soong SI.
    • Asia Pac J Clin Oncol. 2019 Mar;15 Suppl 2:20-31. doi: 10.1111/ajco.13116. Epub 2019 Mar 6.
    • Genetic testing and insurance in Australia.
    • Otlowski M, Barlow-Stewart K, Lacaze P, Tiller J.
    • Aust J Gen Pract. 2019 Mar;48(3):96-99.
    • Painting a portrait: Analysis of national health survey data for cancer genetic counseling.
    • Stamp MH, Gordon OK, Childers CP, Childers KK.
    • Cancer Med. 2019 Mar;8(3):1306-1314. doi: 10.1002/cam4.1864. Epub 2019 Feb 7.
    • Author response to "a response to 'personalised medicine and population health: breast and ovarian cancer'".
    • Narod SA.
    • Hum Genet. 2019 Mar;138(3):291-292. doi: 10.1007/s00439-019-01981-2. Epub 2019 Feb 21.
    • Letter, Reply

    Related:

    Letter, Commentary:

    A response to "Personalised medicine and population health: breast and ovarian cancer".

    Review:

    Personalised medicine and population health: breast and ovarian cancer.

    • Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing.
    • Giri VN, Hegarty SE, Hyatt C, O'Leary E, Garcia J, Knudsen KE, Kelly WK, Gomella LG.
    • Prostate. 2019 Mar;79(4):333-339. doi: 10.1002/pros.23739. Epub 2018 Nov 18.
    • Patterns of referral and uptake of BReast CAncer (BRCA) gene testing of eligible women with ovarian cancer in New Zealand.
    • Fraser K, Tan AL, Innes C, Stephens R, Tristram A, Petrich S, Lintott C, Sykes PH, Gamet K, Christian A, Simcock B.
    • N Z Med J. 2019 Feb 22;132(1490):26-35.
    • Psychosocial, attitudinal, and demographic correlates of cancer-related germline genetic testing in the 2017 Health Information National Trends Survey.
    • Roberts MC, Turbitt E, Klein WMP.
    • J Community Genet. 2019 Feb 20. doi: 10.1007/s12687-018-00405-4. [Epub ahead of print]
    • Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice.
    • Fulton AJ, Lamarca A, Nuttall C, McCallum L, Pihlak R, O'Reilly D, Lalloo F, McNamara MG, Hubner RA, Clancy T, Valle JW.
    • World J Gastrointest Oncol. 2019 Feb 15;11(2):102-116. doi: 10.4251/wjgo.v11.i2.102.
    • Consensus Guideline on Genetic Testing for Hereditary Breast Cancer.
    • Manahan ER, Sebastian M, Hughes KS, Boughey JC, Kuerer HM, Euhus DM, Robson ME, Boolbol SK, Arun BK, Taylor WA.
    • American Society of Breast Surgeons. 2019 Feb 10.

    Related:

    Press: ASBrS Calls for Genetic Testing for All Breast Cancer Patients. (Medscape Oncology)

    News: Breast surgeons recommend genetic testing for all breast cancer patients. (FORCE. XRAYS.)

    • The cost of cancer care and impact of financial hardship on treatment.
    • [No author given]
    • FORCE. XRAYS. 2019 Feb 8.

    Related:

    Original research:

    BRCA1 and BRCA2 Testing in Medically Underserved Medicare Beneficiaries With Breast or Ovarian Cancer.

    News: Labs, Advocacy Groups Push Back on Medicare Policy Shift on NGS Testing for Hereditary Cancer Risk. (GenomeWeb)

    News: Pricey Precision Medicine Often Financially Toxic For Cancer Patients. (Kaiser Health News)

    • Trends in BRCA Test Utilization in an Integrated Health System, 2005-2015.
    • Knerr S, Bowles EJA, Leppig KA, Buist DSM, Gao H, Wernli KJ.
    • J Natl Cancer Inst. 2019 Feb 8. doi: 10.1093/jnci/djz008. [Epub ahead of print]

    Related:

    Editorial:

    Persistent underutilization of BRCA1/2 testing suggest the need for new approaches to genetic testing delivery.

    • Genetic Service Delivery Models: Exploring Approaches to Care for Families With Hereditary Cancer Risk.
    • Pierle JM, Mahon SM.
    • Clin J Oncol Nurs. 2019 Feb 1;23(1):60-67. doi: 10.1188/19.CJON.60-67.
    • Concordance with BRCA1/2 testing guidelines among women in The Health of Women (HOW) Study®.
    • Silver MI, Klein W, Samimi G, Minasian L, Loud J, Roberts MC.
    • Breast Cancer Res Treat. 2019 Feb;173(3):719-726. doi: 10.1007/s10549-018-5035-0. Epub 2018 Nov 9.
    • A Pragmatic Testing-Eligibility Framework for Population Mutation Screening: The Example of BRCA1/2.
    • Best AF, Tucker MA, Frone MN, Greene MH, Peters JA, Katki HA.
    • Cancer Epidemiol Biomarkers Prev. 2019 Feb;28(2):293-302. doi: 10.1158/1055-9965.EPI-18-0584. Epub 2019 Jan 28.
    • Genetic Testing Across Young Hispanic and Non-Hispanic White Breast Cancer Survivors: Facilitators, Barriers, and Awareness of the Genetic Information Nondiscrimination Act.
    • Cragun D, Weidner A, Kechik J, Pal T.
    • Genet Test Mol Biomarkers. 2019 Feb;23(2):75-83. doi: 10.1089/gtmb.2018.0253. Epub 2019 Jan 24.
    • Disseminating universal genetic testing to a diverse, indigent patient population at a county hospital gynecologic oncology clinic.
    • Bednar EM, Sun CC, Camacho B, Terrell J, Rieber AG, Ramondetta LM, Freedman RS, Lu KH.
    • Gynecol Oncol. 2019 Feb;152(2):328-333. doi: 10.1016/j.ygyno.2018.12.001. Epub 2018 Dec 8.
    • Challenges and Opportunities for Cancer Predisposition Cascade Screening for Hereditary Breast and Ovarian Cancer and Lynch Syndrome in Switzerland: Findings from an International Workshop.
    • Nikolaidis C, Ming C, Pedrazzani C, van der Horst T, Kaiser-Grolimund A, Ademi Z, Bührer-Landolt R, Bürki N, Caiata-Zufferey M, Champion V, Chappuis PO, Kohler C, Erlanger TE, Graffeo R, Hampel H, Heinimann K, Heinzelmann-Schwarz V, Kurzeder C, Monnerat C, Northouse LL, Pagani O, Probst-Hensch N, Rabaglio M, Schoenau E, Sijbrands EJG, Taborelli M, Urech C, Viassolo V, Wieser S, Katapodi MC; for the CASCADE Consortium.
    • Public Health Genomics. 2019 Jan 29:1-12. doi: 10.1159/000496495. [Epub ahead of print]
    • Overestimation of the Benefit-to-Harm Ratio of Risk-Based Mammography Screening in the United Kingdom.
    • Autier P.
    • JAMA Oncol. 2019 Jan 17. doi: 10.1001/jamaoncol.2018.6501. [Epub ahead of print]
    • Letter, Comment

    Related:

    Letter, Reply:

    Overestimation of the Benefit-to-Harm Ratio of Risk-Based Mammography Screening in the United Kingdom-Reply.

    Original research:

    Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model.

    • Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative.
    • Caswell-Jin JL, Zimmer AD, Stedden W, Kingham KE, Zhou AY, Kurian AW.
    • J Natl Cancer Inst. 2019 Jan 1;111(1):95-98. doi: 10.1093/jnci/djy147.

    Related:

    Letter, comment:

    RE: Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative.

    Letter, reply:

    Response to Peshkin, Isaacs, and Schwartz.

    • [Knowledge and attitude among general practitioners in Andalusia (Spain) on the identification of subjects at high risk of breast and colorectal cancer].
    • Sánchez Pérez MR, Sánchez Pérez MJ, Lorente Acosta JA, Bayo Lozano E, Mancera Romero J.
    • Semergen. 2019 Jan - Feb;45(1):6-14. doi: 10.1016/j.semerg.2018.07.006. Epub 2018 Oct 24.
    • High patient satisfaction with a simplified BRCA1/2 testing procedure: long-term results of a prospective study.
    • Nilsson MP, Nilsson ED, Borg Å, Brandberg Y, Silfverberg B, Loman N.
    • Breast Cancer Res Treat. 2019 Jan;173(2):313-318. doi: 10.1007/s10549-018-5000-y. Epub 2018 Oct 11.
    • European Breast Cancer Council manifesto 2018: Genetic risk prediction testing in breast cancer.
    • Rutgers E, Balmana J, Beishon M, Benn K, Evans DG, Mansel R, Pharoah P, Perry Skinner V, Stoppa-Lyonnet D, Travado L, Wyld L.
    • Eur J Cancer. 2019 Jan;106:45-53. doi: 10.1016/j.ejca.2018.09.019. Epub 2018 Nov 22.
    • The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice.
    • Menko FH, Ter Stege JA, van der Kolk LE, Jeanson KN, Schats W, Moha DA, Bleiker EMA.
    • Fam Cancer. 2019 Jan;18(1):127-135. doi: 10.1007/s10689-018-0089-z.
    • Review
    • Written pretest information and germline BRCA1/2 pathogenic variant testing in unselected breast cancer patients: predictors of testing uptake.
    • Nilsson MP, Nilsson ED, Silfverberg B, Borg Å, Loman N.
    • Genet Med. 2019 Jan;21(1):89-96. doi: 10.1038/s41436-018-0021-9. Epub 2018 Jun 6.
    • Challenges in the identification of inherited risk of ovarian cancer: where should we go from here?
    • Norquist BM.
    • Gynecol Oncol. 2019 Jan;152(1):3-6. doi: 10.1016/j.ygyno.2018.12.003. Epub 2018 Dec 8.
    • Inequities in genetic testing for hereditary breast cancer: implications for public health practice.
    • Sayani A.
    • J Community Genet. 2019 Jan;10(1):35-39. doi: 10.1007/s12687-018-0370-8. Epub 2018 May 20.
    • Evaluating and improving the implementation of a community-based hereditary cancer screening program.
    • Greenberg S, Yashar BM, Pearlman M, Duquette D, Milliron K, Marvin M.
    • J Community Genet. 2019 Jan;10(1):51-60. doi: 10.1007/s12687-018-0357-5. Epub 2018 Mar 5.
    • BRCA Testing Dichotomy in Saudi Arabia.
    • Abusanad A.
    • J Glob Oncol. 2019 Jan;(5):1-2. doi: 10.1200/JGO.18.00188.
    • Identification and Confirmation of Potentially Actionable Germline Mutations in Tumor-Only Genomic Sequencing.
    • Clark DF, Maxwell KN, Powers J, Lieberman DB, Ebrahimzadeh J, Long JM, McKenna D, Shah P, Bradbury A, Morrissette JJD, Nathanson KL, Domchek SM.
    • JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00076. Epub 2019 Aug 19.
    • Layers of information: interacting constraints on breast cancer risk-management by high-risk African American women.
    • Padamsee TJ, Meadows R, Hils M.
    • Ethn Health. 2018 Dec 27:1-24. doi: 10.1080/13557858.2018.1562053. [Epub ahead of print]

    Related:

    Research news: Gaps in information about breast cancer risk and prevention impact African American women (FORCE. XRAYS.)

    • Cancer communication research in the era of genomics and precision medicine: a scoping review.
    • Kaphingst KA, Peterson E, Zhao J, Gaysynsky A, Elrick A, Hong SJ, Krakow M, Pokharel M, Ratcliff CL, Klein WMP, Khoury MJ, Chou WS.
    • Genet Med. 2018 Dec 21. doi: 10.1038/s41436-018-0402-0. [Epub ahead of print]
    • Review
    • Use and Patient-Reported Outcomes of Clinical Multigene Panel Testing for Cancer Susceptibility in the Multicenter Communication of Genetic Test Results by Telephone Study.
    • Hall MJ, Patrick-Miller LJ, Egleston BL, Domchek SM, Daly MB, Ganschow P, Grana G, Olopade OI, Fetzer D, Brandt A, Chambers R, Clark DF, Forman A, Gaber R, Gulden C, Horte J, Long JM, Lucas T, Madaan S, Mattie K, McKenna D, Montgomery S, Nielsen S, Powers J, Rainey K, Rybak C, Savage M, Seelaus C, Stoll J, Stopfer JE, Yao XS, Bradbury AR.
    • JCO Precis Oncol. 2018;2. doi: 10.1200/PO.18.00199. Epub 2018 Dec 18.
    • Response to "Male Patients With Breast Cancer: Addressing Needs Using an Educational Task Force".
    • Mahon SM.
    • Clin J Oncol Nurs. 2018 Dec 1;22(6):610. doi: 10.1188/18.CJON.610.

    Related:

    Original Research: Male Patients With Breast Cancer: Addressing Needs Using an Educational Task Force. (Clinical Journal of Oncology Nursing)

    • Impact of Appointment Waiting Time on Attendance Rates at a Clinical Cancer Genetics Service.
    • Shaw T, Metras J, Ting ZAL, Courtney E, Li ST, Ngeow J.
    • J Genet Couns. 2018 Dec;27(6):1473-1481. doi: 10.1007/s10897-018-0259-z. Epub 2018 May 24.
    • Creation and Implementation of an Environmental Scan to Assess Cancer Genetics Services at Three Oncology Care Settings.
    • Bednar EM, Walsh MT Jr, Baker E, Muse KI, Oakley HD, Krukenberg RC, Dresbold CS, Jenkinson SB, Eppolito AL, Teed KB, Klein MH, Morman NA, Bowdish EC, Russ P, Wise EE, Cooper JN, Method MW, Henson JW, Grainger AV, Arun BK, Lu KH.
    • J Genet Couns. 2018 Dec;27(6):1482-1496. doi: 10.1007/s10897-018-0262-4. Epub 2018 May 24.
    • The influence of Malay cultural beliefs on breast cancer screening and genetic testing: A focus group study.
    • Shaw T, Ishak D, Lie D, Menon S, Courtney E, Li ST, Ngeow J.
    • Psychooncology. 2018 Dec;27(12):2855-2861. doi: 10.1002/pon.4902. Epub 2018 Oct 16.
    • 9 Myths About Men and Hereditary Cancer.
    • [No author given]
    • My Gene Counsel. 2018 Nov 19.
    • Next-Generation Service Delivery: A Scoping Review of Patient Outcomes Associated with Alternative Models of Genetic Counseling and Genetic Testing for Hereditary Cancer.
    • McCuaig JM, Armel SR, Care M, Volenik A, Kim RH, Metcalfe KA.
    • Cancers (Basel). 2018 Nov 13;10(11). pii: E435. doi: 10.3390/cancers10110435.
    • Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model.
    • Pashayan N, Morris S, Gilbert FJ, Pharoah PDP.
    • JAMA Oncol. 2018 Nov 1;4(11):1504-1510. doi: 10.1001/jamaoncol.2018.1901.

    Related:

    Editorial:

    Implementation Challenges for Risk-Stratified Screening in the Era of Precision Medicine.

    Audio Interview: Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Breast Cancer Screening. (JAMA Oncology)

    Press: Breast Cancer Screening Only for Women at Higher Risk. (Medscape)

    Letter, Comment:

    Overestimation of the Benefit-to-Harm Ratio of Risk-Based Mammography Screening in the United Kingdom

    Letter, Reply:

    Overestimation of the Benefit-to-Harm Ratio of Risk-Based Mammography Screening in the United Kingdom—Reply.

    • Familial communication and cascade testing among relatives of BRCA population screening participants.
    • Lieberman S, Lahad A, Tomer A, Koka S, BenUziyahu M, Raz A, Levy-Lahad E.
    • Genet Med. 2018 Nov;20(11):1446-1454. doi: 10.1038/gim.2018.26. Epub 2018 Mar 29.
    • Hereditary Cancer Risk Assessment and Genetic Testing in the Community-Practice Setting.
    • DeFrancesco MS, Waldman RN, Pearlstone MM, Karanik D, Bernhisel R, Logan J, Alico L, Adkins RT.
    • Obstet Gynecol. 2018 Nov;132(5):1121-1129. doi: 10.1097/AOG.0000000000002916.
    • Knowledge regarding and patterns of genetic testing in patients newly diagnosed with breast cancer participating in the iCanDecide trial.
    • Gornick MC, Kurian AW, An LC, Fagerlin A, Jagsi R, Katz SJ, Hawley ST.
    • Cancer. 2018 Oct 15;124(20):4000-4009. doi: 10.1002/cncr.31731. Epub 2018 Oct 5.
    • Surgeon attitude impacts rate of genetic testing after a breast cancer diagnosis.
    • [No author given]
    • FORCE. XRAYS. 2018 Oct 6.

    Related:

    Association of Attending Surgeon With Variation in the Receipt of Genetic Testing After Diagnosis of Breast Cancer.

    • Association of Attending Surgeon With Variation in the Receipt of Genetic Testing After Diagnosis of Breast Cancer.
    • Katz SJ, Bondarenko I, Ward KC, Hamilton AS, Morrow M, Kurian AW, Hofer TP.
    • JAMA Surg. 2018 Oct 1;153(10):909-916. doi: 10.1001/jamasurg.2018.2001.

    Related:

    Commentary:

    Consideration of Population-Based BRCA Testing as a Strategy to Reduce Disparities in Genetic Counseling Referrals: The Importance of Stating (and Proving) the Obvious.

    Research News: Association of Attending Surgeon With Variation in the Receipt of Genetic Testing After Diagnosis of Breast Cancer. (FORCE, XRAYS)

    Research News: Surgeon Attitudes May Influence Genetic Testing for Patients With Breast Cancer. (Cancer Therapy Advisor)

    • Comparison of gynecologic cancer risk factors, incidence and mortality trends between South Korea and Israel, 1999-2013.
    • Michaan N, Park SY, Won YJ, Lim MC.
    • Jpn J Clin Oncol. 2018 Oct 1;48(10):884-891. doi: 10.1093/jjco/hyy111.
    • Promoting guideline-based cancer genetic risk assessment for hereditary breast and ovarian cancer in ethnically and geographically diverse cancer survivors: Rationale and design of a 3-arm randomized controlled trial.
    • Kinney AY, Howell R, Ruckman R, McDougall JA, Boyce TW, Vicuña B, Lee JH, Guest DD, Rycroft R, Valverde PA, Gallegos KM, Meisner A, Wiggins CL, Stroup A, Paddock LE, Walters ST.
    • Contemp Clin Trials. 2018 Oct;73:123-135. doi: 10.1016/j.cct.2018.09.005. Epub 2018 Sep 18.
    • Mutations in context: implications of BRCA testing in diverse populations.
    • Felix GES, Zheng Y, Olopade OI.
    • Fam Cancer. 2018 Oct;17(4):471-483. doi: 10.1007/s10689-017-0038-2.
    • Personalised medicine and population health: breast and ovarian cancer.
    • Narod SA.
    • Hum Genet. 2018 Oct;137(10):769-778. doi: 10.1007/s00439-018-1944-6. Epub 2018 Oct 17.
    • Review

    Related:

    Letter, Commentary:

    A response to "Personalised medicine and population health: breast and ovarian cancer".

    Letter, Reply:

    Author response to “a response to ‘personalised medicine and population health: breast and ovarian cancer’”.

    • Changing landscape of hereditary breast and ovarian cancer germline genetic testing in Australia.
    • Petelin L, James PA, Trainer AH.
    • Intern Med J. 2018 Oct;48(10):1269-1272. doi: 10.1111/imj.14058.
    • Commentary, Review
    • Provider's Perceptions of Barriers and Facilitators for Latinas to Participate in Genetic Cancer Risk Assessment for Hereditary Breast and Ovarian Cancer.
    • Hurtado-de-Mendoza A, Graves K, Gómez-Trillos S, Anderson L, Campos C, Evans C, Stearns S, Zhu Q, Gonzalez N, Sheppard VB.
    • Healthcare (Basel). 2018 Sep 17;6(3). pii: E116. doi: 10.3390/healthcare6030116.
    • A feasibility study of breast cancer genetic risk assessment in a federally qualified health center.
    • Hoskins KF, Tejeda S, Vijayasiri G, Chukwudozie IB, Remo MH, Shah HA, Abraham IE, Balay LE, Maga TK, Searles ER, Korah VJ, Biggers A, Stolley MR, Warnecke RB.
    • Cancer. 2018 Sep 15;124(18):3733-3741. doi: 10.1002/cncr.31635. Epub 2018 Oct 15.
    • Risk-reducing mastectomy rates in the US: a closer examination of the Angelina Jolie effect.
    • Liede A, Cai M, Crouter TF, Niepel D, Callaghan F, Evans DG.
    • Breast Cancer Res Treat. 2018 Sep;171(2):435-442. doi: 10.1007/s10549-018-4824-9. Epub 2018 May 28.
    • Proposed outcomes measures for state public health genomic programs.
    • Doyle DL, Clyne M, Rodriguez JL, Cragun DL, Senier L, Hurst G, Chan K, Chambers DA.
    • Genet Med. 2018 Sep;20(9):995-1003. doi: 10.1038/gim.2017.229. Epub 2018 Jan 4.

    Related:

    Original research:

    Implementing Cancer Genomics in State Health Agencies: Mapping Activities to an Implementation Science Outcome Framework.

    • Factors Influencing Clinical Follow-Up for Individuals with a Personal History of Breast and/or Ovarian Cancer and Previous Uninformative BRCA1 and BRCA2 Testing.
    • Chadwell SE, He H, Knapke S, Lewis J, Sisson R, Hopper J.
    • J Genet Couns. 2018 Sep;27(5):1210-1219. doi: 10.1007/s10897-018-0241-9. Epub 2018 Mar 17.
    • Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap.
    • McCuaig JM, Stockley TL, Shaw P, Fung-Kee-Fung M, Altman AD, Bentley J, Bernardini MQ, Cormier B, Hirte H, Kieser K, MacMillan A, Meschino WS, Panabaker K, Perrier R, Provencher D, Schrader KA, Serfas K, Tomiak E, Wong N, Young SS, Gotlieb WH, Hoskins P, Kim RH; BRCA TtoT Community of Practice.
    • J Med Genet. 2018 Sep;55(9):571-577. doi: 10.1136/jmedgenet-2018-105472. Epub 2018 Jul 24.
    • Establishment of the Alabama Hereditary Cancer Cohort - strategies for the inclusion of underrepresented populations in cancer genetics research.
    • Bishop MR, Shah A, Shively M, Huskey ALW, Omeler SM, Bilgili EP, Jackson E, Daniell K, Stallworth E, Spina S, Shepp K, Bergstresser S, Davis A, Dean H, Gibson J, Johnson B, Merner ND.
    • Mol Genet Genomic Med. 2018 Sep;6(5):766-778. doi: 10.1002/mgg3.443. Epub 2018 Jul 1.
    • BRCA1 and BRCA2 Testing in Medically Underserved Medicare Beneficiaries With Breast or Ovarian Cancer.
    • Gross AL, Blot WJ, Visvanathan K.
    • JAMA. 2018 Aug 14;320(6):597-598. doi: 10.1001/jama.2018.8258.
    • Study protocol: a cluster randomized controlled trial of web-based decision support tools for increasing BRCA1/2 genetic counseling referral in primary care.
    • Silverman TB, Vanegas A, Marte A, Mata J, Sin M, Ramirez JCR, Tsai WY, Crew KD, Kukafka R.
    • BMC Health Serv Res. 2018 Aug 13;18(1):633. doi: 10.1186/s12913-018-3442-x.
    • Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.
    • Kurian AW, Ward KC, Hamilton AS, Deapen DM, Abrahamse P, Bondarenko I, Li Y, Hawley ST, Morrow M, Jagsi R, Katz SJ.
    • JAMA Oncol. 2018 Aug 1;4(8):1066-1072. doi: 10.1001/jamaoncol.2018.0644.

    Related:

    Press: Multigene Sequencing Rapidly Replacing BRCA Tests. (Medscape Oncology)

    Letter, Comment:

    Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer.

    Letter, Reply:

    Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer-Reply.

    • Uptake of BRCA 1/2 and oncotype DX testing by medical and surgical oncologists.
    • Murciano-Goroff YR, McCarthy AM, Bristol MN, Groeneveld P, Domchek SM, Motanya UN, Armstrong K.
    • Breast Cancer Res Treat. 2018 Aug;171(1):173-180. doi: 10.1007/s10549-018-4810-2. Epub 2018 May 8.
    • Randomized trial of proactive rapid genetic counseling versus usual care for newly diagnosed breast cancer patients.
    • Schwartz MD, Peshkin BN, Isaacs C, Willey S, Valdimarsdottir HB, Nusbaum R, Hooker G, O'Neill S, Jandorf L, Kelly SP, Heinzmann J, Zidell A, Khoury K.
    • Breast Cancer Res Treat. 2018 Aug;170(3):517-524. doi: 10.1007/s10549-018-4773-3. Epub 2018 Apr 2.
    • Beyond BRCA: A Case Series Examining the Advent of Multigene Panel Testing.
    • Reap L, Ahsan S, Saleh M.
    • Clin Breast Cancer. 2018 Aug;18(4):e431-e439. doi: 10.1016/j.clbc.2018.03.015. Epub 2018 Apr 6.
    • Inadequate Rates of BRCA Testing with its Negative Consequences for Women with Epithelial Ovarian Cancer and their Families: an Overview of the Literature.
    • Hoskins PJ.
    • Clin Oncol (R Coll Radiol). 2018 Aug;30(8):472-483. doi: 10.1016/j.clon.2018.04.004. Epub 2018 May 5.
    • Review
    • Engagement with Genetic Information and Uptake of Genetic Testing: the Role of Trust and Personal Cancer History.
    • Roberts MC, Taber JM, Klein WM.
    • J Cancer Educ. 2018 Aug;33(4):893-900. doi: 10.1007/s13187-016-1160-9.
    • Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit.
    • Lobo M, López-Tarruella S, Luque S, Lizarraga S, Flores-Sánchez C, Bueno O, Solera J, Jerez Y, Del Val RG, Palomero MI, Cebollero M, Echavarría I, Torres G, Martín M, Márquez-Rodas I.
    • J Genet Couns. 2018 Aug;27(4):854-862. doi: 10.1007/s10897-017-0187-3. Epub 2017 Dec 15.
    • Breast Cancer Genetics Knowledge and Testing Intentions among Nigerian Professional Women.
    • Ngene SO, Adedokun B, Adejumo P, Olopade O.
    • J Genet Couns. 2018 Aug;27(4):863-873. doi: 10.1007/s10897-017-0194-4. Epub 2017 Dec 19.
    • Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population.
    • Manchanda R, Blyuss O, Gaba F, Gordeev VS, Jacobs C, Burnell M, Gan C, Taylor R, Turnbull C, Legood R, Zaikin A, Antoniou AC, Menon U, Jacobs I.
    • J Med Genet. 2018 Aug;55(8):538-545. doi: 10.1136/jmedgenet-2017-105195. Epub 2018 Apr 5.
    • Clinical genetic testing outcome with multi-gene panel in Asian patients with multiple primary cancers.
    • Chan GHJ, Ong PY, Low JJH, Kong HL, Ow SGW, Tan DSP, Lim YW, Lim SE, Lee SC.
    • Oncotarget. 2018 Jul 17;9(55):30649-30660. doi: 10.18632/oncotarget.25769. eCollection 2018 Jul 17.
    • A qualitative study of barriers to genetic counseling and potential for mobile technology education among women with ovarian cancer.
    • Vogel RI, Niendorf K, Lee H, Petzel S, Lee HY, Geller MA.
    • Hered Cancer Clin Pract. 2018 Jul 4;16:13. doi: 10.1186/s13053-018-0095-z. eCollection 2018.
    • Uptake of risk-reducing surgery in BRCA gene carriers in Wales, UK.
    • Long J, Evans TG, Bailey D, Lewis MH, Gower-Thomas K, Murray A.
    • Breast J. 2018 Jul;24(4):580-585. doi: 10.1111/tbj.12978. Epub 2017 Dec 29.
    • Psychological outcomes and surgical decisions after genetic testing in women newly diagnosed with breast cancer with and without a family history.
    • Meiser B, Quinn VF, Mitchell G, Tucker K, Watts KJ, Rahman B, Peate M, Saunders C, Geelhoed E, Gleeson M, Barlow-Stewart K, Field M, Harris M, Antill YC, Susman R, Bowen MT, Mills L, Kirk J; TFGT Collaborative Group.
    • Eur J Hum Genet. 2018 Jul;26(7):972-983. doi: 10.1038/s41431-017-0057-3. Epub 2018 Mar 30.
    • Increased access to TP53 analysis through breast cancer multi-gene panels: clinical considerations.
    • Azzollini J, Mariani M, Peissel B, Manoukian S.
    • Fam Cancer. 2018 Jul;17(3):317-319. doi: 10.1007/s10689-017-0020-z.

    Related:

    Next generation sequencing is informing phenotype: a TP53 example.

    • A comparison of cancer risk assessment and testing outcomes in patients from underserved vs. tertiary care settings.
    • Rana HQ, Cochrane SR, Hiller E, Akindele RN, Nibecker CM, Svoboda LA, Cronin AM, Garber JE, Lathan CS.
    • J Community Genet. 2018 Jul;9(3):233-241. doi: 10.1007/s12687-017-0347-z. Epub 2017 Nov 18.
    • Clinical Cancer Genetics in a Lower-Middle Income Country: Considerations for Policymaking.
    • Ginsburg O, Narod SA.
    • J Glob Oncol. 2018 Jul;(4):1-3. doi: 10.1200/JGO.18.00081.

    Related:

    Knowledge of Genetic Counseling Among Patients With Breast Cancer and Their Relatives at a Nigerian Teaching Hospital.

    • Direct-to-Consumer Genetic Testing: The Implications of the US FDA's First Marketing Authorization for BRCA Mutation Testing.
    • Gill J, Obley AJ, Prasad V.
    • JAMA. 2018 Jun 19;319(23):2377-2378. doi: 10.1001/jama.2018.5330.
    • Commentary
    • 5-year BRCA SCOTUS Anniversary.
    • [No author given]
    • My Gene Counsel. 2018 Jun 13.
    • National Distribution of Cancer Genetic Testing in the United States: Evidence for a Gender Disparity in Hereditary Breast and Ovarian Cancer.
    • Childers KK, Maggard-Gibbons M, Macinko J, Childers CP.
    • JAMA Oncol. 2018 Jun 1;4(6):876-879. doi: 10.1001/jamaoncol.2018.0340.
    • Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screening.
    • Denu RA.
    • JAMA Oncol. 2018 Jun 1;4(6):883. doi: 10.1001/jamaoncol.2017.5906.

    Related:

    Original Research:

    Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas.

    Letter, Reply:

    Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screening-Reply.

    • Implementation of a quality improvement project for universal genetic testing in women with ovarian cancer.
    • Uyar D, Neary J, Monroe A, Nugent M, Simpson P, Geurts JL.
    • Gynecol Oncol. 2018 Jun;149(3):565-569. doi: 10.1016/j.ygyno.2018.03.059. Epub 2018 Apr 10.
    • [To know or not to know, that is the question - screening for BRCA].
    • Johannsson OT.
    • Laeknabladid. 2018 Jun;104(6):281. doi: 10.17992/lbl.2018.06.187.
    • [Views of Icelandic women towards genetic counseling - and testing of BRCA2 mutations].
    • Jonsdottir T, Valdimarsdottir H, Tryggvadottir L, Lund SH, Thordardottir M, Magnusson MK, Valdimarsdottir U.
    • Laeknabladid. 2018 Jun;104(6):289-296. doi: 10.17992/lbl.2018.06.189.
    • Our genes, our selves: hereditary breast cancer and biological citizenship in Norway.
    • Møller P, Hovig E.
    • Med Health Care Philos. 2018 Jun;21(2):239-242. doi: 10.1007/s11019-017-9803-0.

    Related:

    Our genes, our selves: hereditary breast cancer and biological citizenship in Norway.

    Commentary, Reply:

    Scientific supremacy as an obstacle to establishing and sustaining interdisciplinary dialogue across knowledge paradigms in health medicine.

    • Pervasive genetic testing.
    • Thiruchelvam PTR, Fisher CS, Leff DR, Domchek SM.
    • Lancet. 2018 May 26;391(10135):2089-2091. doi: 10.1016/S0140-6736(18)30997-8. Epub 2018 May 24.
    • Comment
    • Genetics of breast cancer in African populations: a literature review.
    • Abbad A, Baba H, Dehbi H, Elmessaoudi-Idrissi M, Elyazghi Z, Abidi O, Radouani F.
    • Glob Health Epidemiol Genom. 2018 May 11;3:e8. doi: 10.1017/gheg.2018.8. eCollection 2018.
    • Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer.
    • Colombo N, Huang G, Scambia G, Chalas E, Pignata S, Fiorica J, Van Le L, Ghamande S, González-Santiago S, Bover I, Graña Suárez B, Green A, Huot-Marchand P, Bourhis Y, Karve S, Blakeley C.
    • J Clin Oncol. 2018 May 1;36(13):1300-1307. doi: 10.1200/JCO.2017.76.2781. Epub 2018 Mar 20.
    • Accuracy of self-reported family history of cancer, mutation status and tumor characteristics in patients with early onset breast cancer.
    • Augustinsson A, Ellberg C, Kristoffersson U, Borg Å, Olsson H.
    • Acta Oncol. 2018 May;57(5):595-603. doi: 10.1080/0284186X.2017.1404635. Epub 2017 Nov 22.
    • Impact of an embedded genetic counselor on breast cancer treatment.
    • Pederson HJ, Hussain N, Noss R, Yanda C, O'Rourke C, Eng C, Grobmyer SR.
    • Breast Cancer Res Treat. 2018 May;169(1):43-46. doi: 10.1007/s10549-017-4643-4. Epub 2018 Jan 18.
    • Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.
    • Barrington DA, Champion ML, Boitano TKL, Walters-Haygood CL, Farmer MB, Alvarez RD, Estes JM, Leath CA 3rd.
    • Gynecol Oncol. 2018 May;149(2):337-340. doi: 10.1016/j.ygyno.2018.02.014. Epub 2018 Mar 2.
    • Genetic Counseling Referral Rates in Long-Term Survivors of Triple-Negative Breast Cancer.
    • Barcenas CH, Shafaee MN, Sinha AK, Raghavendra A, Saigal B, Murthy RK, Woodson AH, Arun B.
    • J Natl Compr Canc Netw. 2018 May;16(5):518-524. doi: 10.6004/jnccn.2018.7002.
    • Hereditary Cancer Genetic Testing in Community-Based Obstetrics and Gynecology Settings.
    • Obstet Gynecol. 2018 May;131(5):119s. doi: 10.1097/01.AOG.0000533506.01865.a1.
    • Risk Screening for Hereditary Cancer During Obstetrical Care: Barriers to Testing and Health Disparities.
    • Lua LL, Jackson D, Foggia M, Rosenbaum A.
    • Obstet Gynecol. 2018 May;131(5):148s. doi: 10.1097/01.AOG.0000533083.79347.8c.
    • Investigating barriers to genetic counseling and germline mutation testing in women with suspected hereditary breast and ovarian cancer syndrome and Lynch syndrome.
    • Shaw J, Bulsara C, Cohen PA, Gryta M, Nichols CB, Schofield L, O'Sullivan S, Pachter N, Hardcastle SJ.
    • Patient Educ Couns. 2018 May;101(5):938-944. doi: 10.1016/j.pec.2017.12.011. Epub 2017 Dec 12.
    • Challenges in recruiting African-American women for a breast cancer genetics study.
    • Compadre AJ, Simonson ME, Gray K, Runnells G, Kadlubar S, Zorn KK.
    • Hered Cancer Clin Pract. 2018 Apr 24;16:8. doi: 10.1186/s13053-018-0091-3. eCollection 2018.
    • Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer.
    • Katz SJ, Ward KC, Hamilton AS, Mcleod MC, Wallner LP, Morrow M, Jagsi R, Hawley ST, Kurian AW.
    • J Clin Oncol. 2018 Apr 20;36(12):1218-1224. doi: 10.1200/JCO.2017.76.2369. Epub 2018 Mar 12.

    Related:

    Press: Many Breast Cancer Patients Not Receiving Genetic Evaluation. (Medscape)

    • Returning Individual Genetic Research Results to Research Participants: Uptake and Outcomes Among Patients With Breast Cancer.
    • Bradbury AR, Patrick-Miller L, Egleston BL, Maxwell KN, DiGiovanni L, Brower J, Fetzer D, Bennett Gaieski J, Brandt A, McKenna D, Long J, Powers J, Stopfer JE, Nathanson KL, Domchek SM.
    • JCO Precis Oncol. 2018;2. doi: 10.1200/po.17.00250. Epub 2018 Apr 16.
    • Trends in utilization and costs of BRCA testing among women aged 18-64 years in the United States, 2003-2014.
    • Chen Z, Kolor K, Grosse SD, Rodriguez JL, Lynch JA, Green RF, Dotson WD, Bowen MS, Khoury MJ.
    • Genet Med. 2018 Apr;20(4):428-434. doi: 10.1038/gim.2017.118. Epub 2017 Sep 21.
    • Disparities in genetics assessment for women with ovarian cancer: Can we do better?
    • Manrriquez E, Chapman JS, Mak J, Blanco AM, Chen LM.
    • Gynecol Oncol. 2018 Apr;149(1):84-88. doi: 10.1016/j.ygyno.2017.10.034.
    • Increasing genetic counseling referral rates through bundled interventions after ovarian cancer diagnosis.
    • Swanson CL, Kumar A, Maharaj JM, Kemppainen JL, Thomas BC, Weinhold MR, Slaby KM, Mara KC, Wick MJ, Bakkum-Gamez JN.
    • Gynecol Oncol. 2018 Apr;149(1):121-126. doi: 10.1016/j.ygyno.2018.01.033. Epub 2018 Feb 3.
    • Impact of Multigene Panel Testing on Surgical Decision Making in Breast Cancer Patients.
    • Pederson HJ, Gopalakrishnan D, Noss R, Yanda C, Eng C, Grobmyer SR.
    • J Am Coll Surg. 2018 Apr;226(4):560-565. doi: 10.1016/j.jamcollsurg.2017.12.037. Epub 2018 Jan 31.
    • Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan.
    • Arai M, Yokoyama S, Watanabe C, Yoshida R, Kita M, Okawa M, Sakurai A, Sekine M, Yotsumoto J, Nomura H, Akama Y, Inuzuka M, Nomizu T, Enomoto T, Nakamura S.
    • J Hum Genet. 2018 Apr;63(4):447-457. doi: 10.1038/s10038-017-0355-1. Epub 2017 Nov 8.
    • Germline BRCA mutation in male carriers-ripe for precision oncology?
    • Leão RRN, Price AJ, James Hamilton R.
    • Prostate Cancer Prostatic Dis. 2018 Apr;21(1):48-56. doi: 10.1038/s41391-017-0018-5. Epub 2017 Dec 14.
    • Review
    • The Right Not to Know: When Ignorance Is Bliss but Deadly.
    • Clausen AM.
    • Global Health NOW. 2018 Mar 20.

    Related:

    Commentary: The right not to know when not knowing is dangerous. (FORCE. XRAYS.)

    • FDA approves breast cancer test kits: how useful are they?
    • [No author given]
    • FORCE. XRAYS. 2018 Mar 19.

    Related:

    FDA News Release: FDA authorizes, with special controls, direct-to-consumer test that reports three mutations in the BRCA breast cancer genes (U.S. Food & Drug Administration)

    Press: Oncology Community Sees Potential for Patient Harm in FDA OK of 23andMe BRCA Test (GenomeWeb)

    Press: FDA Authorizes 23andMe DTC Test Report for Three BRCA Mutations (GenomeWeb)

    • Medical Strategy or Marketing Strategy?
    • Resta R.
    • The DNA Exchange. 2018 Mar 18.
    • Factors Influencing Clinical Follow-Up for Individuals with a Personal History of Breast and/or Ovarian Cancer and Previous Uninformative BRCA1 and BRCA2 Testing.
    • Chadwell SE, He H, Knapke S, Lewis J, Sisson R, Hopper J.
    • J Genet Couns. 2018 Mar 17. doi: 10.1007/s10897-018-0241-9. [Epub ahead of print]
    • Impact of a genetic counseling requirement prior to genetic testing.
    • Stenehjem DD, Au T, Sainski AM, Bauer H, Brown K, Lancaster J, Stevens V, Brixner DI.
    • BMC Health Serv Res. 2018 Mar 7;18(1):165. doi: 10.1186/s12913-018-2957-5.
    • First DTC Test for Some BRCA Mutations Authorized by FDA.
    • Nelson R.
    • Medscape. Medscape Medical News. 2018 Mar 7.
    • FDA authorizes, with special controls, direct-to-consumer test that reports three mutations in the BRCA breast cancer genes.
    • [No author given]
    • U.S. Food & Drug Administration. FDA News Release. 2018 Mar 6.

    Related:

    Blog post, News: NSGC Responds to U.S. Food and Drug Administration Approval of Direct-to-Consumer Cancer Test that Reports Three BRCA Mutations (NSGC Blog)

    News: FDA approves breast cancer test kits: how useful are they? (FORCE. XRAYS)

    • A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
    • Hanley GE, McAlpine JN, Miller D, Huntsman D, Schrader KA, Blake Gilks C, Mitchell G.
    • BMC Cancer. 2018 Mar 5;18(1):254. doi: 10.1186/s12885-018-4153-8.
    • Genetic assessment wait time indicators in the High Risk Ontario Breast Screening Program.
    • Eisen A, Blackmore KM, Meschino WS, Muradali D, Carroll JC, Majpruz V, Warner E, Rabeneck L, Chiarelli AM.
    • Mol Genet Genomic Med. 2018 Mar;6(2):213-223. doi: 10.1002/mgg3.359. Epub 2018 Jan 25.
    • Clinical testing of BRCA1 and BRCA2: a worldwide snapshot of technological practices.
    • Toland AE, Forman A, Couch FJ, Culver JO, Eccles DM, Foulkes WD, Hogervorst FBL, Houdayer C, Levy-Lahad E, Monteiro AN, Neuhausen SL, Plon SE, Sharan SK, Spurdle AB, Szabo C, Brody LC; BIC Steering Committee.
    • NPJ Genom Med. 2018 Feb 15;3:7. doi: 10.1038/s41525-018-0046-7. eCollection 2018.
    • Adaptation of Genetic Counseling According to an Individual's Literacy Regarding Genomics.
    • Nakamura S, Narimatsu H.
    • J Clin Oncol. 2018 Feb 10;36(5):516-517. doi: 10.1200/JCO.2017.76.3300. Epub 2018 Jan 2.
    • Letter, Comment

    Related:

    National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer.

    Letter, Reply:

    Reply to S. Nakamura et al and S. Narod et al.

    • Population-Based Genetic Testing for BRCA1 and BRCA2.
    • Narod S, Akbari MR.
    • J Clin Oncol. 2018 Feb 10;36(5):517. doi: 10.1200/JCO.2017.75.8490. Epub 2018 Jan 2.
    • Letter

    Related:

    Editorial:

    Genetic Testing: What Problem Are We Trying to Solve?

    National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer.

    Letter, Comment:

    Reply to S. Nakamura et al and S. Narod et al.

    • Genetic Testing: Multiple Problems to Solve.
    • Ramos E, Haidle JL.
    • J Clin Oncol. 2018 Feb 10;36(5):518-519. doi: 10.1200/JCO.2017.76.0942. Epub 2018 Jan 2.

    Related:

    Editorial:

    Genetic Testing: What Problem Are We Trying to Solve?

    Letter, Reply:

    Reply to E. Ramos et al.

    • Provider Discussions of Genetic Tests With U.S. Women at Risk for a BRCA Mutation.
    • Hull LE, Haas JS, Simon SR.
    • Am J Prev Med. 2018 Feb;54(2):221-228. doi: 10.1016/j.amepre.2017.10.015. Epub 2017 Dec 11.
    • BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer.
    • Nilsson MP, Törngren T, Henriksson K, Kristoffersson U, Kvist A, Silfverberg B, Borg Å, Loman N.
    • Breast Cancer Res Treat. 2018 Feb;168(1):117-126. doi: 10.1007/s10549-017-4584-y. Epub 2017 Nov 21.
    • Estimating the number of potential family members eligible for BRCA1 and BRCA2 mutation testing in a "Traceback" approach.
    • Moss HA, Samimi G, Havrilesky LJ, Sherman ME, Myers ER.
    • Genet Epidemiol. 2018 Feb;42(1):117-122. doi: 10.1002/gepi.22095. Epub 2017 Nov 30.
    • Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk.
    • Caswell-Jin JL, Gupta T, Hall E, Petrovchich IM, Mills MA, Kingham KE, Koff R, Chun NM, Levonian P, Lebensohn AP, Ford JM, Kurian AW.
    • Genet Med. 2018 Feb;20(2):234-239. doi: 10.1038/gim.2017.96. Epub 2017 Jul 27.
    • FDA Approval of PARP Inhibitors and the Impact on Genetic Counseling and Genetic Testing Practices.
    • Buchtel KM, Vogel Postula KJ, Weiss S, Williams C, Pineda M, Weissman SM.
    • J Genet Couns. 2018 Feb;27(1):131-139. doi: 10.1007/s10897-017-0130-7. Epub 2017 Aug 5.
    • Cancer Genetic Counseling and Testing: Perspectives of Epithelial Ovarian Cancer Patients and Gynecologic Oncology Healthcare Providers.
    • Liang MI, Wong DH, Walsh CS, Farias-Eisner R, Cohen JG.
    • J Genet Couns. 2018 Feb;27(1):177-186. doi: 10.1007/s10897-017-0135-2. Epub 2017 Aug 7.
    • "I've just never gotten around to doing it": Men's approaches to managing BRCA-related cancer risks.
    • Rauscher EA, Dean M.
    • Patient Educ Couns. 2018 Feb;101(2):340-345. doi: 10.1016/j.pec.2017.07.015. Epub 2017 Jul 23.
    • Examination of the Patient-Focused Impact of Cancer Telegenetics Among a Rural Population: Comparison with Traditional In-Person Services.
    • Solomons NM, Lamb AE, Lucas FL, McDonald EF, Miesfeldt S.
    • Telemed J E Health. 2018 Feb;24(2):130-138. doi: 10.1089/tmj.2017.0073. Epub 2017 Jul 21.
    • Men seeking counselling in a Breast Cancer Risk Evaluation Clinic.
    • Freitas AC1, Opinião A, Fragoso S, Nunes H, Santos M, Clara A, Bento S, Luis A, Silva J, Moura C, Filipe B, Machado P, Santos S, André S, Rodrigues P, Parreira J, Vaz F.
    • Ecancermedicalscience. 2018 Jan 30;12:804. doi: 10.3332/ecancer.2018.804. eCollection 2018.
    • The risk of unjustified BRCA testing after the "Angelina Jolie effect": how can we save (laboratory) medicine from the Internet?
    • Lippi G.
    • Clin Chem Lab Med. 2018 Jan 26;56(2):e33-e35. doi: 10.1515/cclm-2017-0551.
    • Letter
    • Improving attendance to genetic counselling services for gynaecological oncology patients.
    • Pokharel HP, Hacker NF, Andrews L.
    • Gynecol Oncol Res Pract. 2018 Jan 10;5:2. doi: 10.1186/s40661-018-0059-z. eCollection 2018.
    • Evaluation of a 27-gene inherited cancer panel across 630 consecutive patients referred for testing in a clinical diagnostic laboratory.
    • Gardner SA, Weymouth KS, Kelly WS, Bogdanova E, Chen W, Lupu D, Suhl J, Zeng Q, Geigenmüller U, Boles D, Okamoto PM, McDowell G, Hayden MA, Nagan N.
    • Hered Cancer Clin Pract. 2018 Jan 4;16:1. doi: 10.1186/s13053-017-0083-8. eCollection 2018.
    • Genetic Testing for Hereditary Breast Cancer: The Decision to Decline.
    • White VB, Walsh KK, Foss KS, Amacker-North L, Lenarcic S, McNeely L, White RL Jr..
    • Am Surg. 2018 Jan 1;84(1):154-160.
    • Your Genes: One Size Doesn't Fit All.
    • Freivogel ME, Cohen SA.
    • J Natl Compr Canc Netw. 2018 Jan 1;16(1):2-3. doi: 10.6004/jnccn.2017.7055.
    • Commentary

    Related:

    Commentary:

    Your Genes: Getting the Best Fit.

    • Comparing Outcomes of Genetic Counseling Options in Breast and Ovarian Cancer: An Integrative Review.
    • Fournier DM, Bazzell AF, Dains JE.
    • Oncol Nurs Forum. 2018 Jan 1;45(1):96-105. doi: 10.1188/18.ONF.96-105.
    • Review
    • Breadth of Genetic Testing Selected by Patients at Risk of Hereditary Breast and Ovarian Cancer.
    • Szender JB, Kaur J, Clayback K, Hutton ML, Mikkelson J, Odunsi K, Dresbold C.
    • Int J Gynecol Cancer. 2018 Jan;28(1):26-33. doi: 10.1097/IGC.0000000000001122.
    • Preferences for multigene panel testing for hereditary breast cancer risk among ethnically diverse BRCA-uninformative families.
    • Vicuña B, Delaney HD, Flores KG, Ballinger L, Royce M, Dayao Z, Pal T, Kinney AY.
    • J Community Genet. 2018 Jan;9(1):81-92. doi: 10.1007/s12687-017-0322-8. Epub 2017 Oct 2.
    • ACOG Committee Opinion No. 727: Cascade Testing: Testing Women for Known Hereditary Genetic Mutations Associated With Cancer.
    • [No authors listed]
    • Obstet Gynecol. 2018 Jan;131(1):e31-e34. doi: 10.1097/AOG.0000000000002457.

    Related:

    Summary:

    ACOG Committee Opinion No. 727 Summary: Cascade Testing: Testing Women For Known Hereditary Genetic Mutations Associated With Cancer.

    Press: 'Cascade Testing' Important for Hereditary Gynecologic Cancers: ACOG (Medscape/Reuters)

    • Variability in the therapeutic management of advanced ovarian cancer patients: a five-country survey of oncologists.
    • Audibert C, Perlaky A, Stuntz M, Glass D.
    • Drug Des Devel Ther. 2017 Dec 6;11:3471-3479. doi: 10.2147/DDDT.S151420. eCollection 2017.
    • National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer.
    • Childers CP, Childers KK, Maggard-Gibbons M, Macinko J.
    • J Clin Oncol. 2017 Dec 1;35(34):3800-3806. doi: 10.1200/JCO.2017.73.6314. Epub 2017 Aug 18.

    Related:

    Editorial:

    Genetic Testing: What Problem Are We Trying to Solve?

    Letter:

    Population-Based Genetic Testing for BRCA1 and BRCA2.

    Press: Huge Underuse of Genetic Testing Among Cancer Survivors. (Medscape Oncology)

    • Genetic Testing in a Population-Based Sample of Breast and Ovarian Cancer Survivors from the REACH Randomized Trial: Cost Barriers and Moderators of Counseling Mode.
    • Steffen LE, Du R, Gammon A, Mandelblatt JS, Kohlmann WK, Lee JH, Buys SS, Stroup AM, Campo RA, Flores KG, Vicuña B, Schwartz MD, Kinney AY.
    • Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1772-1780. doi: 10.1158/1055-9965.EPI-17-0389. Epub 2017 Sep 29.
    • Insights into BRCA1/2 Genetic Counseling from Ethnically Diverse Latina Breast Cancer Survivors.
    • Rajpal N, Muñoz J, Peshkin BN, Graves KD.
    • J Genet Couns. 2017 Dec;26(6):1221-1237. doi: 10.1007/s10897-017-0096-5. Epub 2017 Apr 4.
    • Identification and management of familial breast cancer in Austria.
    • Singer CF, Tan YY, Rappaport C.
    • Horm Mol Biol Clin Investig. 2017 Nov 30;32(2). pii: /j/hmbci.2017.32.issue-2/hmbci-2017-0025/hmbci-2017-0025.xml. doi: 10.1515/hmbci-2017-0025.
    • Review
    • Genetics of Breast and Gynecologic Cancers (PDQ®): Health Professional Version. Psychosocial Issues in Inherited Breast and Ovarian Cancer Syndromes. Uptake of Genetic Counseling and Genetic Testing.
    • PDQ Cancer Genetics Editorial Board.
    • PDQ Cancer Information Summaries [Internet]. Bethesda, MD: National Cancer Institute. Updated 2017 Nov 30. Accessed 2017 Dec 8.
    • [A survey of willingness about genetic counseling and tests in patients of epithelial ovarian cancer].
    • Li L, Qiu L, Wu M.
    • Zhonghua Yi Xue Za Zhi. 2017 Nov 21;97(43):3412-3415. doi: 10.3760/cma.j.issn.0376-2491.2017.43.011.
    • English Abstract, [Article in Chinese]
    • Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature.
    • Hoskins PJ, Gotlieb WH.
    • CA Cancer J Clin. 2017 Nov;67(6):493-506. doi: 10.3322/caac.21408. Epub 2017 Sep 7.
    • Traceback: leveraging archived biospecimens to identify mutation carriers.
    • Samimi G, Sherman ME.
    • Oncotarget. 2017 Oct 11;8(53):90628-90629. doi: 10.18632/oncotarget.21742. eCollection 2017 Oct 31.
    • Recent Patterns in Genetic Testing for Breast and Ovarian Cancer Risk in the U.S.
    • Han X, Jemal A.
    • Am J Prev Med. 2017 Oct;53(4):504-507. doi: 10.1016/j.amepre.2017.04.014. Epub 2017 Jun 29.
    • Genetic consultation embedded in a gynecologic oncology clinic improves compliance with guideline-based care.
    • Senter L, O'Malley DM, Backes FJ, Copeland LJ, Fowler JM, Salani R, Cohn DE.
    • Gynecol Oncol. 2017 Oct;147(1):110-114. doi: 10.1016/j.ygyno.2017.07.141. Epub 2017 Aug 8.
    • Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol.
    • Katapodi MC, Viassolo V, Caiata-Zufferey M, Nikolaidis C, Bührer-Landolt R5, Buerki N, Graffeo R, Horváth HC, Kurzeder C, Rabaglio M, Scharfe M, Urech C, Erlanger TE, Probst-Hensch N, Heinimann K, Heinzelmann-Schwarz V, Pagani O, Chappuis PO.
    • JMIR Res Protoc. 2017 Sep 20;6(9):e184. doi: 10.2196/resprot.8138.
    • Hereditary gynaecologic cancers in Nepal: a proposed model of care to serve high risk populations in developing countries.
    • Pokharel HP, Hacker NF, Andrews L.
    • Hered Cancer Clin Pract. 2017 Sep 18;15:12. doi: 10.1186/s13053-017-0072-y. eCollection 2017.
    • BRCA Genetic Testing and Receipt of Preventive Interventions Among Women Aged 18-64 Years with Employer-Sponsored Health Insurance in Nonmetropolitan and Metropolitan Areas - United States, 2009-2014.
    • Kolor K, Chen Z, Grosse SD, Rodriguez JL, Green RF, Dotson WD, Bowen MS, Lynch JA, Khoury MJ.
    • MMWR Surveill Summ. 2017 Sep 8;66(15):1-11. doi: 10.15585/mmwr.ss6615a1.
    • Referral to cancer genetic counseling: do migrant status and patients’ educational background matter?
    • van der Giessen JAM, van Riel E, Velthuizen ME, van Dulmen AM, Ausems MGEM.
    • J Community Genet. 2017 Sep 4. doi: 10.1007/s12687-017-0326-4. [Epub ahead of print]
    • The Impact of Mental Illness on Uptake of Genetic Counseling for Hereditary Breast Cancer and Ovarian Cancer in a Multiethnic Cohort of Breast Cancer Patients.
    • Ackerman MG, Shapiro PA, Coe A, Trivedi MS, Crew KD.
    • Breast J. 2017 Sep;23(5):519-524. doi: 10.1111/tbj.12791. Epub 2017 Mar 21.
    • Barriers and Facilitating Factors for Implementation of Genetic Services: A Public Health Perspective.
    • Cornel MC, van El CG.
    • Front Public Health. 2017 Aug 4;5:195. doi: 10.3389/fpubh.2017.00195. eCollection 2017.
    • Multi-disciplinary summit on genetics services for women with gynecologic cancers: A Society of Gynecologic Oncology White Paper.
    • Randall LM, Pothuri B, Swisher EM, Diaz JP, Buchanan A, Witkop CT, Bethan Powell C, Smith EB, Robson ME, Boyd J, Coleman RL, Lu K.
    • Gynecol Oncol. 2017 Aug;146(2):217-224. doi: 10.1016/j.ygyno.2017.06.002. Epub 2017 Jun 7.
    • A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.
    • Bednar EM, Oakley HD, Sun CC, Burke CC, Munsell MF, Westin SN, Lu KH.
    • Gynecol Oncol. 2017 Aug;146(2):399-404. doi: 10.1016/j.ygyno.2017.05.037. Epub 2017 Jun 10.
    • Why Is Cancer Genetic Counseling Underutilized by Women Identified as at Risk for Hereditary Breast Cancer? Patient Perceptions of Barriers Following a Referral Letter.
    • Kne A, Zierhut H, Baldinger S, Swenson KK, Mink P, Veach PM, Tsai ML.
    • J Genet Couns. 2017 Aug;26(4):697-715. doi: 10.1007/s10897-016-0040-0. Epub 2016 Nov 8.
    • Large, Prospective Analysis of the Reasons Patients Do Not Pursue BRCA Genetic Testing Following Genetic Counseling.
    • Hayden S, Mange S, Duquette D, Petrucelli N, Raymond VM; BRCA Clinical Network Partners.
    • J Genet Couns. 2017 Aug;26(4):859-865. doi: 10.1007/s10897-016-0064-5. Epub 2017 Jan 16.
    • Genetic Testing in Patients With Newly Diagnosed Breast Cancer: Room for Improvement.
    • Ahn S, Port ER.
    • J Clin Oncol. 2017 Jul 10;35(20):2221-2223. doi: 10.1200/JCO.2017.72.8816. Epub 2017 Apr 14.
    • Identification of BRCA1 and BRCA2 Mutation Carriers Through a Traceback Framework: Consent, Privacy, and Autonomy.
    • Schwartz MD.
    • J Clin Oncol. 2017 Jul 10;35(20):2226-2228. doi: 10.1200/JCO.2017.72.8774. Epub 2017 May 2.

    Related:

    Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.

    • Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer.
    • Kurian AW, Li Y, Hamilton AS, Ward KC, Hawley ST, Morrow M, McLeod MC, Jagsi R, Katz SJ.
    • J Clin Oncol. 2017 Jul 10;35(20):2232-2239. doi: 10.1200/JCO.2016.71.6480. Epub 2017 Apr 12.

    Related:

    Press: Lack of Understanding of Genetic Breast Cancer Testing. (Medscape)

    • Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.
    • Samimi G, Bernardini MQ, Brody LC, Caga-Anan CF, Campbell IG, Chenevix-Trench G, Couch FJ, Dean M, de Hullu JA, Domchek SM, Drapkin R, Spencer Feigelson H, Friedlander M, Gaudet MM, Harmsen MG, Hurley K, James PA, Kwon JS, Lacbawan F, Lheureux S, Mai PL, Mechanic LE, Minasian LM, Myers ER, Robson ME, Ramus SJ, Rezende LF, Shaw PA, Slavin TP, Swisher EM, Takenaka M, Bowtell DD, Sherman ME.
    • J Clin Oncol. 2017 Jul 10;35(20):2329-2337. doi: 10.1200/JCO.2016.70.3439. Epub 2017 Apr 11.

    Related:

    Editorial:

    Identification of BRCA1 and BRCA2 Mutation Carriers Through a Traceback Framework: Consent, Privacy, and Autonomy.

    • Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors.
    • Cragun D, Weidner A, Lewis C, Bonner D, Kim J, Vadaparampil ST, Pal T.
    • Cancer. 2017 Jul 1;123(13):2497-2505. doi: 10.1002/cncr.30621. Epub 2017 Feb 9.
    • Barriers to genetic testing in newly diagnosed breast cancer patients: do surgeons limit testing?
    • Hafertepen L, Pastorino A, Morman N, Snow J, Halaharvi D, Byrne L, Cripe M.
    • Am J Surg. 2017 Jul;214(1):105-110. doi: 10.1016/j.amjsurg.2016.08.012. Epub 2016 Sep 9.
    • Predictors of BRCA1/2 genetic testing among Black women with breast cancer: a population-based study.
    • Jones T, McCarthy AM, Kim Y, Armstrong K.
    • Cancer Med. 2017 Jul;6(7):1787-1798. doi: 10.1002/cam4.1120. Epub 2017 Jun 19.
    • Population screening for BRCA1/BRCA2 founder mutations in Ashkenazi Jews: proactive recruitment compared with self-referral.
    • Lieberman S, Tomer A, Ben-Chetrit A, Olsha O, Strano S, Beeri R, Koka S, Fridman H, Djemal K, Glick I, Zalut T, Segev S, Sklair M, Kaufman B, Lahad A, Raz A, Levy-Lahad E.
    • Genet Med. 2017 Jul;19(7):754-762. doi: 10.1038/gim.2016.182. Epub 2016 Dec 8.
    • Current condition of genetic medicine for hereditary breast cancer.
    • Terui-Kohbata H, Yoshida M.
    • Mol Clin Oncol. 2017 Jul;7(1):98-102. doi: 10.3892/mco.2017.1260. Epub 2017 May 12.
    • 4 Years Post-Gene Patents: How Has Life Changed In The Genomics World?
    • [No author given]
    • My Gene Counsel. 2017 Jun 13.
    • High-risk patients with breast cancer may not receive genetic testing.
    • Printz C
    • Cancer. 2017 Jun 1;123(11):1887. doi: 10.1002/cncr.30774.

    Related:

    Letter, Comment:

    Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer.

    • Use of BRCA Mutation Test in the U.S., 2004-2014.
    • Guo F, Hirth JM, Lin YL, Richardson G, Levine L, Berenson AB, Kuo YF.
    • Am J Prev Med. 2017 Jun;52(6):702-709. doi: 10.1016/j.amepre.2017.01.027. Epub 2017 Mar 22.

    Related:

    Press: BRCA Testing Has Skyrocketed, but Misses High-Risk Women. (Medscape)

    Letter, Comment:

    Increased Use of BRCA Mutation Test in Unaffected Women Over the Period 2004-2014 in the U.S.: Further Evidence of the "Angelina Jolie Effect"?

    Letter, Reply:

    Authors' Response: "Angelina Jolie Effect" on the Shifting Role of BRCA Testing in the U.S.

    • Online self-test identifies women at high familial breast cancer risk in population-based breast cancer screening without inducing anxiety or distress.
    • van Erkelens A, Sie AS, Manders P, Visser A, Duijm LE, Mann RM, Ten Voorde M, Kroeze H, Prins JB, Hoogerbrugge N.
    • Eur J Cancer. 2017 Jun;78:45-52. doi: 10.1016/j.ejca.2017.03.014. Epub 2017 Apr 14.
    • Practice Patterns of Hereditary Ovarian Cancer Management in Korea.
    • Choi MC, Lim MC, Lee M, Kim MK, Suh DH, Song YJ, Kim TJ, Chang SJ, Kim JW.
    • Int J Gynecol Cancer. 2017 Jun;27(5):895-899. doi: 10.1097/IGC.0000000000000964.
    • Influence of the Angelina Jolie Announcement and Insurance Reimbursement on Practice Patterns for Hereditary Breast Cancer.
    • Lee J, Kim S, Kang E, Park S, Kim Z, Lee MH; Korean Breast Cancer Society.
    • J Breast Cancer. 2017 Jun;20(2):203-207. doi: 10.4048/jbc.2017.20.2.203. Epub 2017 Jun 26.
    • Clinical Cancer Genetics Disparities among Latinos.
    • Cruz-Correa M, Pérez-Mayoral J, Dutil J, Echenique M, Mosquera R, Rivera-Román K, Umpierre S, Rodriguez-Quilichini S, Gonzalez-Pons M, Olivera MI, Pardo S; Puerto Rico Clinical Cancer Genetics Consortia.
    • J Genet Couns. 2017 Jun;26(3):379-386. doi: 10.1007/s10897-016-0051-x. Epub 2016 Dec 12.
    • Review
    • Familial breast cancer: Genetic counseling over time, including patients´ expectations and initiators considering the Angelina Jolie effect.
    • Evers C, Fischer C, Dikow N, Schott S.
    • PLoS One. 2017 May 25;12(5):e0177893. doi: 10.1371/journal.pone.0177893. eCollection 2017.
    • Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer.
    • Masuda K, Hirasawa A, Irie-Kunitomi H, Akahane T, Ueki A, Kobayashi Y, Yamagami W, Nomura H, Kataoka F, Tominaga E, Banno K, Susumu N, Aoki D.
    • Jpn J Clin Oncol. 2017 May 1;47(5):401-406. doi: 10.1093/jjco/hyx019.
    • Population-Based Study of Attitudes toward BRCA Genetic Testing among Orthodox Jewish Women.
    • Tang EY, Trivedi MS, Kukufka R, Chung WK, David R, Respler L, Leifer S, Schechter I, Crew KD.
    • Breast J. 2017 May;23(3):333-337. doi: 10.1111/tbj.12736. Epub 2016 Nov 30.
    • Experiences from a pilot program bringing BRCA1/2 genetic screening to theUS Ashkenazi Jewish population.
    • Wiesman C, Rose E, Grant A, Zimilover A, Klugman S, Schreiber-Agus N.
    • Genet Med. 2017 May;19(5):529-536. doi: 10.1038/gim.2016.154. Epub 2016 Oct 13.

    Related:

    Press: New Study Highlights the Benefits of BRCA Testing for All People of Ashkenazi Jewish Descent. (Newswise, Montefiore Health System)

    • Optimization of quality assurance to increase clinical utility and cost effectiveness of hereditary cancer testing.
    • Smith S, Marino I, Schaller J, Arnell C, Moyes K, Manley S.
    • Per Med. 2017 May;14(3):213-220. doi: 10.2217/pme-2016-0091. Epub 2017 Mar 29.
    • Deficit of Risk-Reducing Salpingo-Oophorectomies in BRCA1/2 Mutation Carriers After Telephone Genetic Counseling.
    • Benusiglio PR, Caron O.
    • J Clin Oncol. 2017 Apr 10;35(11):1255. doi: 10.1200/JCO.2016.70.5780. Epub 2017 Jan 23.

    Related:

    Randomized Noninferiority Trial of Telephone Delivery of BRCA1/2 Genetic Counseling Compared With In-Person Counseling: 1-Year Follow-Up.

    • Impact of self-reported data on the acquisition of multi-generational family history and lifestyle factors among women seen in a high-risk breast screening program: a focus on modifiable risk factors and genetic referral.
    • Rosenberger LH, Weber R, Sjoberg D, Vickers AJ, Mangino DA, Morrow M, Pilewskie ML.
    • Breast Cancer Res Treat. 2017 Apr;162(2):275-282. doi: 10.1007/s10549-017-4115-x. Epub 2017 Jan 28.
    • Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer.
    • Nilsson MP, Winter C, Kristoffersson U, Rehn M, Larsson C, Saal LH, Loman N.
    • Fam Cancer. 2017 Apr;16(2):187-193. doi: 10.1007/s10689-016-9953-x.
    • Breast cancer genetic counseling among Dutch patients from Turkish and Moroccan descent: participation determinants and perspectives of patients and healthcare professionals.
    • Baars JE, van Dulmen AM, Velthuizen ME, van Riel E, Ausems MG.
    • J Community Genet. 2017 Apr;8(2):97-108. doi: 10.1007/s12687-016-0290-4. Epub 2017 Jan 12.
    • The effect of a celebrity health disclosure on demand for health care: trends in BRCA testing and subsequent health services use.
    • Roberts MC, Dusetzina SB.
    • J Community Genet. 2017 Apr;8(2):141-146. doi: 10.1007/s12687-017-0295-7. Epub 2017 Mar 15.
    • Genetic Counselling, BRCA1/2 Status and Clinico-pathologic Characteristics of Patients with Ovarian Cancer before 50 Years of Age.
    • Cvelbar M, Hocevar M, Novakovic S, Stegel V, Perhavec A, Krajc M.
    • Radiol Oncol. 2017 Mar 16;51(2):187-194. doi: 10.1515/raon-2017-0013. eCollection 2017 Jun.
    • Genetic Cancer Risk Assessment for Breast Cancer in Latin America.
    • Chavarri-Guerra Y, Blazer KR, Weitzel JN.
    • Rev Invest Clin. 2017 Mar-Apr;69(2):94-102.
    • Genetics Consultation Rates Following a Diagnosis of High-Grade Serous Ovarian Carcinoma in the Canadian Province of Ontario.
    • McGee J, Panabaker K, Leonard S, Ainsworth P, Elit L, Shariff SZ.
    • Int J Gynecol Cancer. 2017 Mar;27(3):437-443. doi: 10.1097/IGC.0000000000000907.
    • Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature.
    • Frey MK, Pothuri B.
    • Gynecol Oncol Res Pract. 2017 Feb 22;4:4. doi: 10.1186/s40661-017-0039-8. eCollection 2017.
    • Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer .
    • Kurian AW, Griffith KA, Hamilton AS, Ward KC, Morrow M, Katz SJ, Jagsi R.
    • JAMA. 2017 Feb 7;317(5):531-534. doi: 10.1001/jama.2016.16918.
    • Letter, Comment

    Related:

    Viewpoint:

    Multigene Panel Testing in Oncology Practice: How Should We Respond?

    Research news: High-risk patients with breast cancer may not receive genetic testing. (Cancer)

    Press: Shortage of Genetic Counselors in Face of Growing Need. (Medscape Conference News)

    • A Retrospective Exploration of the Impact of the 'Angelina Jolie Effect' on the Single State-Wide Familial Cancer Program in Perth, Western Australia.
    • Freedman R, Mountain H, Karina D, Schofield L.
    • J Genet Couns. 2017 Feb;26(1):52-62. doi: 10.1007/s10897-016-9982-5. Epub 2016 Jun 6.
    • The Role of Knowledge on Genetic Counseling and Testing in Black Cancer Survivors at Increased Risk of Carrying a BRCA1/2 Mutation.
    • Hurtado-de-Mendoza A, Jackson MC, Anderson L, Sheppard VB.
    • J Genet Couns. 2017 Feb;26(1):113-121. doi: 10.1007/s10897-016-9986-1. Epub 2016 Jul 12.
    • BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines.
    • Chun DS, Berse B, Venne VL, DuVall SL, Filipski KK, Kelley MJ, Meyer LJ, Icardi MS, Lynch JA.
    • Fam Cancer. 2017 Jan;16(1):41-49. doi: 10.1007/s10689-016-9921-5.
    • Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab.
    • Li H, Feng B, Miron A, Chen X, Beesley J, Bimeh E, Barrowdale D, John EM, Daly MB, Andrulis IL, Buys SS, Kraft P; kConFab investigators, Thorne H, Chenevix-Trench G, Southey MC, Antoniou AC, James PA, Terry MB, Phillips KA, Hopper JL, Mitchell G, Goldgar DE.
    • Genet Med. 2017 Jan;19(1):30-35. doi: 10.1038/gim.2016.43. Epub 2016 May 12.
    • Impact of Payer Constraints on Access to Genetic Testing.
    • Whitworth P, Beitsch P, Arnell C, Cox HC, Brown K, Kidd J, Lancaster JM.
    • J Oncol Pract. 2017 Jan;13(1):e47-e56. doi: 10.1200/JOP.2016.013581. Epub 2016 Oct 23.
    • Five Years of Multidisciplinary Care in Hereditary Cancer: Our Experience in a Spanish University Hospital.
    • Márquez-Rodas I, Lobo M, Flores-Sanchez C, Sanz M, Luque S, Lizarraga S, González-Asanza C, Pajares JA, Peligros MI, Bueno O, Mata C, Lopez C, López-Tarruella S, Jerez Y, Muñoz-Martin A, Blanco M, Die-Trill M, Justel JP, Solera J, Martin M.
    • Oncology. [2017 Jan;]92(2):68-74. doi: 10.1159/000452280. Epub 2016 Nov 18.
    • [Making better use of the clinical geneticist's expertise; treating physician could request a DNA test for most cancer patients].
    • Aalfs CM, Westermann AM, van El CG.
    • Ned Tijdschr Geneeskd. 2017;161(0):D1525.
    • [Article in Dutch], English Abstract
    • Do celebrity endorsements matter? Observational study of BRCA gene testing and mastectomy rates after Angelina Jolie's New York Times editorial.
    • Desai S, Jena AB.
    • BMJ. 2016 Dec 14;355:i6357. doi: 10.1136/bmj.i6357.

    Related:

    Research News:

    Angelina Jolie's mastectomy triggered sharp rise in gene testing.

    Research News: Angelina Jolie spoke out on BRCA testing: Did genetic testing increase? (FORCE)

    Blog post: "Angelina Jolie Effect”: What Should I Know About Hereditary Cancer and Testing? (NSGC Blog)

    Research News: Were women foolish to follow Angelina Jolie into BRCA cancer gene testing? (STAT)

    Research News: Jolie Effect: BRCA Tests Up but No Change in Mastectomy. (Medscape)

    • Genetic testing in a gynaecological oncology care in developing countries-knowledge, attitudes and perception of Nepalese clinicians.
    • Pokharel HP, Hacker NF, Andrews L.
    • Gynecol Oncol Res Pract. 2016 Dec 5;3:12. eCollection 2016.
    • Increasing Appropriate BRCA1/2 Mutation Testing: The Role of Family History Documentation and Genetic Counseling in a Multidisciplinary Clinic.
    • Kishan AU, Gomez CL, Dawson NA, Dvorak R, Foster NM, Hoyt A, Hurvitz SA, Kusske A, Silver EL, Tseng C, McCloskey SA.
    • Ann Surg Oncol. 2016 Dec;23(Suppl 5):634-641. Epub 2016 Sep 12.
    • Changing patterns of referrals and outcomes of genetic participation in gynaecological-oncology multidisciplinary care.
    • Pokharel HP, Hacker NF, Andrews L.
    • Aust N Z J Obstet Gynaecol. 2016 Dec;56(6):633-638. doi: 10.1111/ajo.12504. Epub 2016 Aug 17.
    • The Impact of Angelina Jolie (AJ)'s Story on Genetic Referral and Testing at an Academic Cancer Centre in Canada.
    • Raphael J, Verma S, Hewitt P, Eisen A.
    • J Genet Couns. 2016 Dec;25(6):1309-1316. Epub 2016 May 26.
    • The effect of referral for genetic counseling on genetic testing and surgical prevention in women at high risk for ovarian cancer: Results from a randomized controlled trial.
    • Drescher CW, Beatty JD, Resta R, Andersen MR, Watabayashi K, Thorpe J, Hawley S, Purkey H, Chubak J, Hanson N, Buist DSM, Urban N.
    • Cancer. 2016 Nov 15;122(22):3509-3518. doi: 10.1002/cncr.30190. Epub 2016 Jul 22.
    • Impact of Payer Constraints on Access to Genetic Testing.
    • Whitworth P, Beitsch P, Arnell C, Cox HC, Brown K, Kidd J, Lancaster JM
    • J Oncol Pract. 2016 Oct 23. doi: 10.1200/JOP.2016.013581.

    Related:

    News: Payers’ Genetic Counselor Mandates Decrease Access to BRCA 1/2 Testing (Clinical Omics)

    • Use of Cancer Genetics Services in African-American Young Breast Cancer Survivors.
    • Jones T, Lockhart JS, Mendelsohn-Victor KE, Duquette D, Northouse LL, Duffy SA, Donley R, Merajver SD, Milliron KJ, Roberts JS, Katapodi MC.
    • Am J Prev Med. 2016 Oct;51(4):427-36. doi: 10.1016/j.amepre.2016.03.016. Epub 2016 Apr 23.
    • Effective Referral of Low-Income Women at Risk for Hereditary Breast and Ovarian Cancer to Genetic Counseling: A Randomized Delayed Intervention Control Trial.
    • Pasick RJ, Joseph G, Stewart S, Kaplan C, Lee R, Luce J, Davis S, Marquez T, Nguyen T, Guerra C.
    • Am J Public Health. 2016 Oct;106(10):1842-1848. Epub 2016 Aug 23.
    • A collaborative approach to cancer risk assessment services using genetic counselor extenders in a multi-system community hospital.
    • Cohen SA, Nixon DM.
    • Breast Cancer Res Treat. 2016 Oct;159(3):527-34. doi: 10.1007/s10549-016-3964-z. Epub 2016 Aug 31.

    Related:

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: Assist physicians with ordering testing?

    • Genomic Disparities in Breast Cancer Among Latinas.
    • Lynce F, Graves KD, Jandorf L, Ricker C, Castro E, Moreno L, Augusto B, Fejerman L, Vadaparampil ST.
    • Cancer Control. 2016 Oct;23(4):359-372.
    • A model for patient-direct screening and referral for familial cancer risk.
    • Niendorf KB, Geller MA, Vogel RI, Church TR, Leininger A, Bakke A, Madoff RD.
    • Fam Cancer. 2016 Oct;15(4):707-16. doi: 10.1007/s10689-016-9912-6.
    • Video-assisted genetic counseling in patients with ovarian, fallopian and peritoneal carcinoma.
    • Watson CH, Ulm M, Blackburn P, Smiley L, Reed M, Covington R, Bokovitz L, Tillmanns T.
    • Gynecol Oncol. 2016 Oct;143(1):109-12. doi: 10.1016/j.ygyno.2016.07.094. Epub 2016 Jul 12.
    • Increasing Appropriate BRCA1/2 Mutation Testing: The Role of Family History Documentation and Genetic Counseling in a Multidisciplinary Clinic.
    • Kishan AU, Gomez CL, Dawson NA, Dvorak R, Foster NM, Hoyt A, Hurvitz SA, Kusske A, Silver EL, Tseng C, McCloskey SA.
    • Ann Surg Oncol. 2016 Sep 12. [Epub ahead of print]
    • Randomized Noninferiority Trial of Telephone Delivery of BRCA1/2 Genetic Counseling Compared With In-Person Counseling: 1-Year Follow-Up.
    • Kinney AY, Steffen LE, Brumbach BH, Kohlmann W, Du R, Lee JH, Gammon A, Butler K, Buys SS, Stroup AM, Campo RA, Flores KG, Mandelblatt JS, Schwartz MD.
    • J Clin Oncol. 2016 Aug 20;34(24):2914-24. doi: 10.1200/JCO.2015.65.9557. Epub 2016 Jun 20.

    Related:

    Letter:

    Deficit of Risk-Reducing Salpingo-Oophorectomies in BRCA1/2 Mutation Carriers After Telephone Genetic Counseling.

    Press: Telephone counseling can help make cancer genetic services more accessible to rural women (News Medical)

    • Health Care Segregation, Physician Recommendation, and Racial Disparities in BRCA1/2 Testing Among Women With Breast Cancer.
    • McCarthy AM, Bristol M, Domchek SM, Groeneveld PW, Kim Y, Motanya UN, Shea JA, Armstrong K.
    • J Clin Oncol. 2016 Aug 1;34(22):2610-8. doi: 10.1200/JCO.2015.66.0019. Epub 2016 May 9.

    Related:

    Research News: Racial disparities in BRCA testing: Why? (FORCE)

    • Adherence Patterns to National Comprehensive Cancer Network Guidelines for Referral of Women With Breast Cancer to Genetics Professionals.
    • Stuckey A, Febbraro T, Laprise J, Wilbur JS, Lopes V, Robison K.
    • Am J Clin Oncol. 2016 Aug;39(4):363-7. doi: 10.1097/COC.0000000000000073.
    • Health Care Disparities in Hereditary Ovarian Cancer: Are We Reaching the Underserved Population?
    • Randall TC, Armstrong K.
    • Curr Treat Options Oncol. 2016 Aug;17(8):39. doi: 10.1007/s11864-016-0417-1.
    • Review
    • Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients.
    • George A, Riddell D, Seal S, Talukdar S, Mahamdallie S, Ruark E, Cloke V, Slade I, Kemp Z, Gore M, Strydom A, Banerjee S, Hanson H, Rahman N.
    • Sci Rep. 2016 Jul 13;6:29506. doi: 10.1038/srep29506.

    Related:

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: Are We Just A Bunch of Health Care Money-Wasters Who Are Indirectly Responsible For People Getting Preventable Cancers?

    News:

    Streamlined genetic testing pathway is developed for women with ovarian cancer.

    Press: Simplified the Process. (GenomeWeb)

    Press: All women with ovarian cancer should be offered genetic testing – so why aren’t they? (Science Blog)

    • Changes of Socio-demographic data of clients seeking genetic counseling for hereditary breast and ovarian cancer due to the "Angelina Jolie Effect".
    • Staudigl C, Pfeiler G, Hrauda K, Renz R, Berger A, Lichtenschopf R, Singer CF, Tea MM.
    • BMC Cancer. 2016 Jul 8;16:436. doi: 10.1186/s12885-016-2472-1.
    • Disparities in Cancer Genetic Risk Assessment and Testing.
    • Underhill ML, Jones T, Habin K.
    • Oncol Nurs Forum. 2016 Jul 1;43(4):519-23. doi: 10.1188/16.ONF.519-523.
    • Willingness of Japanese patients with breast cancer to have genetic testing of BRCA without burden of expenses.
    • Nakagomi H, Sakamoto I, Hirotsu Y, Amemiya K, Mochizuki H, Inoue M, Nakagomi S, Kubota T, Omata M.
    • Breast Cancer. 2016 Jul;23(4):649-53. doi: 10.1007/s12282-015-0618-7. Epub 2015 May 30.

    Related:

    Comments on NSGC Discussion Forum

    Subject: Article request - Breast Cancer

    • Rates of testing for BRCA mutations in young women are on the rise.
    • Barton MK.
    • CA Cancer J Clin. 2016 Jul;66(4):269-70. doi: 10.3322/caac.21306. Epub 2016 May 5.
    • Participation of low-income women in genetic cancer risk assessment and BRCA 1/2 testing: the experience of a safety-net institution.
    • Komenaka IK, Nodora JN, Madlensky L, Winton LM, Heberer MA, Schwab RB, Weitzel JN, Martinez ME.
    • J Community Genet. 2016 Jul;7(3):177-83. doi: 10.1007/s12687-015-0257-x. Epub 2015 Dec 21.
    • [Latest international guidelines for screening, prevention and treatment of familial breast cancer - implications for the relevant practice in Hungary].
    • Romics L, Kocsis J, Ormándi K, Molnár BÁ.
    • Orv Hetil. 2016 Jul;157(28):1117-25. doi: 10.1556/650.2016.30473.
    • The Unbearably Slow Adoption of Genetic Cancer Tests
    • [No author given]
    • The Atlantic. 2016 Jul.

    Related:

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: Are We Just A Bunch of Health Care Money-Wasters Who Are Indirectly Responsible For People Getting Preventable Cancers?

    • Underuse of BRCA testing in patients with breast and ovarian cancer.
    • Wright JD, Chen L, Tergas AI, Accordino M, Ananth CV, Neugut AI, Hershman DL.
    • Am J Obstet Gynecol. 2016 Jun;214(6):761-3. doi: 10.1016/j.ajog.2016.02.011. Epub 2016 Feb 11.

    Trends in Breast Reconstruction by Ethnicity: An Institutional Review Centered on the Treatment of an Urban Population.

    • BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study.
    • Høberg-Vetti H, Bjorvatn C, Fiane BE, Aas T, Woie K, Espelid H, Rusken T, Eikesdal HP, Listøl W, Haavind MT, Knappskog PM, Haukanes BI, Steen VM, Hoogerbrugge N.
    • Eur J Hum Genet. 2016 Jun;24(6):881-8. doi: 10.1038/ejhg.2015.196. Epub 2015 Sep 9.
    • Impact of Clinical Genetics Attendance at a Gynecologic Oncology Tumor Board on Referrals for Genetic Counseling and BRCA Mutation Testing.
    • Cohen PA, Nichols CB, Schofield L, Van Der Werf S, Pachter N.
    • Int J Gynecol Cancer. 2016 Jun;26(5):892-7. doi: 10.1097/IGC.0000000000000689.
    • Testing for Hereditary Predisposition in Patients with Gynecologic Cancers, Quo Vadis?
    • Mitchell G, Schrader KA.
    • Surg Pathol Clin. 2016 Jun;9(2):301-6. doi: 10.1016/j.path.2016.01.009. Epub 2016 Apr 11.
    • Review
    • Oncogenetics service and the Brazilian public health system: the experience of a reference Cancer Hospital.
    • Palmero EI, Galvão HC, Fernandes GC, Paula AE, Oliveira JC, Souza CP, Andrade CE, Romagnolo LG, Volc S, C Neto M, Sabato C, Grasel R, Mauad E, Reis RM, Michelli RA.
    • Genet Mol Biol. 2016 May 13;39(2):168-177. doi: 10.1590/1678-4685-GMB-2014-0364.
    • Fast Screen Identifies Women at Risk for Hereditary Cancers.
    • Ingrid Hein.
    • Medscape Medical News. Conference News. Oncology Nursing Society (ONS) 2016 Annual Congress. 2016 May 3.
    • Discussion: Should We Test Minors For Hereditary Cancer Syndromes?
    • [No author given]
    • My Gene Counsel. 2016 May 2.
    • BRCA1 and BRCA2 Testing Among Young Breast Cancer Survivors.
    • Kehl KL, Giordano SH.
    • JAMA Oncol. 2016 May 1;2(5):688-9. doi: 10.1001/jamaoncol.2016.0976.
    • Letter
    • Migrant breast cancer patients and their participation in genetic counseling: results from a registry-based study.
    • Baars JE, van Dulmen AM, Velthuizen ME, Theunissen EB, Vrouenraets BC, Kimmings AN, van Dalen T, van Ooijen B, Witkamp AJ, van der Aa MA, Ausems MG.
    • Fam Cancer. 2016 Apr;15(2):163-71. doi: 10.1007/s10689-016-9871-y.
    • Public Health Approaches and Barriers to Educating Providers about Hereditary Breast and Ovarian Cancer Syndrome.
    • Trepanier AM, Supplee L, Blakely L, McLosky J, Duquette D.
    • Healthcare (Basel). 2016 Mar 11;4(1). pii: E19. doi: 10.3390/healthcare4010019.
    • Influence of Personal Exposure to the Cancer of a Loved One on the Breast Cancer Prevention Decisions of High Risk Women.
    • Padamsee TJ, Muraveva A, Wills C, Yee L, Paskett E.
    • Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):561. 40th Annual (2016) ASPO meeting. doi: 10.1158/1055-9965.EPI-16-0090.
    • Conference abstract
    • Rates of BRCA1/2 mutation testing among young survivors of breast cancer.
    • Kehl KL, Shen C, Litton JK, Arun B, Giordano SH.
    • Breast Cancer Res Treat. 2016 Jan;155(1):165-73. doi: 10.1007/s10549-015-3658-y. Epub 2015 Dec 26.

    Related:

    Erratum

    Erratum to: Rates of BRCA1/2 mutation testing among young survivors of breast cancer.

    • Acceptance of, inclination for, and barriers in genetic testing for gene mutations that increase the risk of breast and ovarian cancers among female residents of Warsaw.
    • Olejniczak D, Dera P, Religioni U, Duda-Zalewska A, Deptała A.
    • Contemp Oncol (Pozn). 2016;20(1):80-5. doi: 10.5114/wo.2016.58504. Epub 2016 Mar 16.
    • Genetic Testing for BRCA Mutations Today and Tomorrow-About the ABOUT Study.
    • Narod S.
    • JAMA Oncol. 2015 Dec 1;1(9):1225-1226. doi: 10.1001/jamaoncol.2015.3269.
    • Comment

    Related:

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: Dr. Narod's commentary on pre-test genetic counseling

    Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study.

    • Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study.
    • Armstrong J, Toscano M, Kotchko N, Friedman S, Schwartz MD, Virgo KS, Lynch K, Andrews JE, Aguado Loi CX, Bauer JE, Casares C, Bourquardez Clark E, Kondoff MR, Molina AD, Abdollahian M, Walker G, Sutphen R.
    • JAMA Oncol. 2015 Dec 1;1(9):1251-1260. doi: 10.1001/jamaoncol.2015.3048.

    Related:

    Blog post: Rates of Genetic Testing on the Rise While Utilization of Genetic Counseling Plummets (My Gene Counsel)

    Press: Most Women Get No Counseling After BRCA Testing (Medscape Oncology)

    Press: Study of Aetna-Insured Finds Lack of Pre-BRCA Test Counseling Despite Guidelines (GenomeWeb)

    Press: BRCA Testing, Genetic Counseling Utilization in the Community Setting (OncoTherapy Network)

    Press: Too Few Women Get Counseling Before Breast Cancer Gene Test: Study (MedlinePlus)

    Press: Too Few Get Counseling Before BRCA Gene Test (WEbMD / HealthDay News)

    • Beyond BRCA: Testing negative and living in the 'gray zone' for cancer risk.
    • [No author given]
    • My Gene Counsel. 2015 Dec 1.
    • Utilization of Next Generation Multi-gene Panels Versus Single Gene Testing.
    • Zenas Chang, Jenny Backman, Sara Carroll, M. Heather Einstein.
    • Gynecologic Oncology. 2015 Dec;139(3):584. 2015 NEAGO ABSTRACTS. doi: 10.1016/j.ygyno.2015.09.023.
    • Conference abstract
    • Referrals to Genetic Counseling in Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, an Institutional Review.
    • Jenny Backman, Zenas Chang, Sara Carroll, M. Heather Einstein.
    • Gynecologic Oncology. 2015 Dec;139(3):586. 2015 NEAGO ABSTRACTS. doi: 10.1016/j.ygyno.2015.09.029.
    • Conference abstract
    • Identifying Women at Risk for Hereditary Breast and Ovarian Cancer Syndrome Utilizing Breast Care Nurse Navigation at Mammography and Imaging Centers.
    • Appel SJ, Cleiment RJ.
    • J Natl Black Nurses Assoc. 2015 Dec;26(2):17-26.
    • Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2.
    • Dean M, Boland J, Yeager M, Im KM, Garland L, Rodriguez-Herrera M, Perez M, Mitchell J, Roberson D, Jones K, Lee HJ, Eggebeen R, Sawitzke J, Bass S, Zhang X, Robles V, Hollis C, Barajas C, Rath E, Arentz C, Figueroa JA, Nguyen DD, Nahleh Z.
    • Gigascience. 2015 Nov 4;4:50. doi: 10.1186/s13742-015-0088-z. eCollection 2015.
    • Prediction of Cancer Prevention: From Mammogram Screening to Identification of BRCA1/2 Mutation Carriers in Underserved Populations.
    • Robinson LS, Hendrix A, Xie XJ, Yan J, Pirzadeh-Miller S, Pritzlaff M, Read P, Pass S, Euhus D, Ross TS.
    • EBioMedicine. 2015 Oct 21;2(11):1827-33. doi: 10.1016/j.ebiom.2015.10.022. eCollection 2015.

    Related:

    Commentary

    Differences in Uptake of Risk Reduction Strategies Among Underserved Populations.

    • Breast Cancer Genetic Testing: More Than a Medical Management Tool.
    • Schroeder D, Conroy SA.
    • Clin J Oncol Nurs. 2015 Oct 1;19(5):603-7. doi: 10.1188/15.CJON.603-607.
    • Review
    • Why do women not return family history forms when referred to breast cancer genetics services? A mixed-method study.
    • Hanning KA, Steel M, Goudie D, McLeish L, Dunlop J, Myring J, Sullivan F, Berg J, Humphris G, Ozakinci G.
    • Health Expect. 2015 Oct;18(5):1735-43. doi: 10.1111/hex.12166. Epub 2014 Jan 5.
    • Personalized Medicine Through SNP Testing for Breast Cancer Risk: Clinical Implementation.
    • Howe R, Miron-Shatz T, Hanoch Y, Omer ZB, O'Donoghue C, Ozanne EM.
    • J Genet Couns. 2015 Oct;24(5):744-51. doi: 10.1007/s10897-014-9803-7. Epub 2014 Dec 18.
    • Attitudes Toward Breast Cancer Genetic Testing in Five Special Population Groups.
    • Ramirez AG, Chalela P, Gallion KJ, Muñoz E, Holden AE, Burhansstipanov L, Smith SA, Wong-Kim E, Wyatt SW, Suarez L.
    • J Health Dispar Res Pract. 2015 Fall;8(4):124-135.
    • Factors influencing breast cancer screening and risk assessment among young African American women: An integrative review of the literature.
    • Jones TP, Katapodi MC, Lockhart JS.
    • J Am Assoc Nurse Pract. 2015 Sep;27(9):521-9. doi: 10.1002/2327-6924.12223. Epub 2015 Mar 3.
    • Review
    • Strategies for recruitment of relatives of BRCA mutation carriers to a genetic testing program in the Bahamas.
    • Trottier M, Lunn J, Butler R, Curling D, Turnquest T, Royer R, Akbari MR, Donenberg T, Hurley J, Narod SA.
    • Clin Genet. 2015 Aug;88(2):182-6. doi: 10.1111/cge.12468. Epub 2014 Sep 6.
    • Participation of Korean families at high risk for hereditary breast and ovarian cancer in BRCA1/2 genetic testing.
    • Sun Y, Kang E, Baek H, Jung J, Hwang E, Koo , Kim , Kim SW.
    • Jpn J Clin Oncol. 2015 Jun;45(6):527-32. doi: 10.1093/jjco/hyv044. Epub 2015 Apr 2.
    • Concerns about cancer risk and experiences with genetic testing in a diverse population of patients with breast cancer.
    • Jagsi R, Griffith KA, Kurian AW, Morrow M, Hamilton AS, Graff JJ, Katz SJ, Hawley ST.
    • J Clin Oncol. 2015 May 10;33(14):1584-91. doi: 10.1200/JCO.2014.58.5885. Epub 2015 Apr 6.

    Related:

    Comment / Letter:

    Discussing the Implications of Genetic Testing With Patients.

    Comment / Letter:

    Reply to S.M. Sorscher and A.B. Hafeez Bhatti.

    Comment / Letter:

    Discussing Genetic Testing With Patients With Breast Cancer in Developing Countries: Should We Be Judicious?

    Press: Women With Breast Cancer Concerned About Genetic Risk. (Medscape Oncology)

    • Factors associated with genetic counseling and BRCA testing in a population-based sample of young Black women with breast cancer.
    • Cragun D, Bonner D, Kim J, Akbari MR, Narod SA, Gomez-Fuego A, Garcia JD, Vadaparampil ST, Pal T.
    • Breast Cancer Res Treat. 2015 May;151(1):169-76. doi: 10.1007/s10549-015-3374-7. Epub 2015 Apr 14.
    • BRCA Genetic Counseling Among At-Risk Latinas in New York City: New Beliefs Shape New Generation.
    • Sussner KM, Edwards T, Villagra C, Rodriguez MC, Thompson HS, Jandorf L, Valdimarsdottir HB.
    • J Genet Couns. 2015 Feb;24(1):134-48. doi: 10.1007/s10897-014-9746-z. Epub 2014 Aug 15.
    • Characteristics associated with genetic counseling referral and BRCA1/2 testing among women in a large integrated health system.
    • Bellcross CA, Peipins LA, McCarty FA, Rodriguez JL, Hawkins NA, Hensley Alford S, Leadbetter S.
    • Genet Med. 2015 Jan;17(1):43-50. doi: 10.1038/gim.2014.68. Epub 2014 Jun 19.
    • From observation to intervention: development of a psychoeducational intervention to increase uptake of BRCA genetic counseling among high-risk breast cancer survivors.
    • Vadaparampil ST, Malo TL, Nam KM, Nelson A, de la Cruz CZ, Quinn GP.
    • J Cancer Educ. 2014 Dec;29(4):709-19. doi: 10.1007/s13187-014-0643-9.
    • From Autism to Breast Cancer to Prenatal Genetic Testing, Genetic Counselors Can Help
    • Jennifer Malone Hoskovec
    • NSGC blog, 2014 Sep 20
    • Study Finds Counseling, Insurance Coverage, and Personal Preference Impact Decision to Pursue BRCA Testing
    • Christina Izzo
    • Oncology Nursing News, 2014 Sep 19
    • Does perceived risk predict breast cancer screening use? Findings from a prospective cohort study of female relatives from the Ontario site of the breast cancer family registry.
    • Walker MJ, Mirea L, Glendon G, Ritvo P, Andrulis IL, Knight JA, Chiarelli AM.
    • Breast. 2014 Aug;23(4):482-8. doi: 10.1016/j.breast.2014.04.001. Epub 2014 May 10.
    • Improving referral for genetic risk assessment in ovarian cancer using an electronic medical record system.
    • Petzel SV, Vogel RI, McNiel J, Leininger A, Argenta PA, Geller MA.
    • Int J Gynecol Cancer. 2014 Jul;24(6):1003-9. doi: 10.1097/IGC.0000000000000148.
    • Familial breast cancer genetic testing in the West of Ireland.
    • McVeigh TP, Irwin R, Cody N, Miller N, McDevitt T, Sweeney KJ, Green A, Kerin MJ.
    • Ir J Med Sci. 2014 Jun;183(2):199-206. doi: 10.1007/s11845-013-0990-2. Epub 2013 Jul 26.
    • African American Women's Limited Knowledge and Experiences with Genetic Counseling for Hereditary Breast Cancer.
    • Sheppard VB, Graves KD, Christopher J, Hurtado-de-Mendoza A, Talley C, Williams KP.
    • J Genet Couns. 2014 Jun;23(3):311-22. doi: 10.1007/s10897-013-9663-6. Epub 2013 Nov 5.
    • Determinants of genetic counseling uptake and its impact on breast cancer outcome: a population-based study.
    • Ayme A, Viassolo V, Rapiti E, Fioretta G, Schubert H, Bouchardy C, Chappuis PO, Benhamou S.
    • Breast Cancer Res Treat. 2014 Apr;144(2):379-89. doi: 10.1007/s10549-014-2864-3. Epub 2014 Feb 12.
    • Psychosocial approaches to participation in BRCA1/2 genetic risk assessment among African American women: a systematic review.
    • Sherman KA, Miller SM, Shaw LK, Cavanagh K, Sheinfeld Gorin S.
    • J Community Genet. 2014 Apr;5(2):89-98. doi: 10.1007/s12687-013-0164-y. Epub 2013 Aug 10.
    • Patient-reported hereditary breast and ovarian cancer in a primary care practice.
    • Quillin JM, Krist AH, Gyure M, Corona R, Rodriguez V, Borzelleca J, Bodurtha JN.
    • J Community Genet. 2014 Apr;5(2):179-83. doi: 10.1007/s12687-013-0161-1. Epub 2013 Jul 20.

    Related:

    Press: Few women at high-risk for hereditary breast and ovarian cancer receive genetic counseling (EurekAlert!)

    • Inadequate Family History Assessment by Oncologists is an Important Physician Barrier to Referral for Hereditary Breast Cancer Evaluation.
    • Ow SG, Yong YF, Chieng WS, Phyu PS, Lee SC.
    • Clin Oncol (R Coll Radiol). 2014 Mar;26(3):174-5. doi: 10.1016/j.clon.2013.11.029. Epub 2014 Jan 4.
    • Letter
    • Genetic counseling for hereditary breast and ovarian cancer among Puerto Rican women living in the United States.
    • Scherr CL, Vasquez E, Quinn GP, Vadaparampil ST.
    • Rev Recent Clin Trials. 2014;9(4):245-53.
    • Increase in breast cancer gene screening: the Angelina Jolie effect.
    • Deborah Kotz.
    • Boston Globe. 2013 Dec 3.
    • Validity of self-reported genetic counseling and genetic testing use among breast cancer survivors.
    • Hamann HA, Tiro JA, Sanders JM, Melhado TV, Funk RK, Carpentier MY, Bartholomew LK, Argenbright KE, Vernon SW.
    • J Cancer Surviv. 2013 Dec;7(4):624-9. doi: 10.1007/s11764-013-0301-y. Epub 2013 Aug 23.
    • Breast and Ovarian Cancer Family History and Genetic Counseling among Michigan Women.
    • Fussman C, Mange S.
    • Michigan BRFSS Surveillance Brief. Vol. 7, No. 5. Lansing, MI: Michigan Department of Community Health, Lifecourse Epidemiology and Genomics Division, Surveillance and Program Evaluation Section, Chronic Disease Epidemiology Unit. 2013 Nov.
    • Are physician recommendations for BRCA1/2 testing in patients with breast cancer appropriate? A population-based study.
    • McCarthy AM, Bristol M, Fredricks T, Wilkins L, Roelfsema I, Liao K, Shea JA, Groeneveld P, Domchek SM, Armstrong K.
    • Cancer. 2013 Oct 15;119(20):3596-3603. doi: 10.1002/cncr.28268. Epub 2013 Jul 16.
    • Family Communication of BRCA1/2 Results and Family Uptake of BRCA1/2 Testing in a Diverse Population of BRCA1/2 Carriers.
    • Fehniger J, Lin F, Beattie MS, Joseph G, Kaplan C.
    • J Genet Couns. 2013 Oct;22(5):603-12. doi: 10.1007/s10897-013-9592-4. Epub 2013 May 12.
    • Genetic risk assessment for women with epithelial ovarian cancer: referral patterns and outcomes in a university gynecologic oncology clinic.
    • Petzel SV, Vogel RI, Bensend T, Leininger A, Argenta PA, Geller MA.
    • J Genet Couns. 2013 Oct;22(5):662-73. doi: 10.1007/s10897-013-9598-y. Epub 2013 May 16.
    • Breast cancer gene tests may treble on Welsh NHS.
    • Gemma Ryall.
    • BBC News. 2013 Aug 2.
    • Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests.
    • Pujol P, Lyonnet DS, Frebourg T, Blin J, Picot MC, Lasset C, Dugast C, Berthet P, de Paillerets BB, Sobol H, Grandjouan S, Soubrier F, Buecher B, Guimbaud R, Lidereau R, Jonveaux P, Houdayer C, Giraud S, Olschwang S, Nogue E, Galibert V, Bara C, Nowak F, Khayat D, Nogues C.
    • Breast Cancer Res Treat. 2013 Aug;141(1):135-44. doi: 10.1007/s10549-013-2669-9. Epub 2013 Aug 24.
    • Keeping it simple: Genetics referrals for all invasive serous ovarian cancers.
    • Demsky R, McCuaig J, Maganti M, Murphy KJ, Rosen B, Armel SR.
    • Gynecol Oncol. 2013 Aug;130(2):329-33. doi: 10.1016/j.ygyno.2013.05.003. Epub 2013 May 22.
    • Timing of referral for genetic counseling and genetic testing in patients with ovarian, fallopian tube, or primary peritoneal carcinoma.
    • Novetsky AP, Smith K, Babb SA, Jeffe DB, Hagemann AR, Thaker PH, Powell MA, Mutch DG, Massad LS, Zighelboim I.
    • Int J Gynecol Cancer. 2013 Jul;23(6):1016-21. doi: 10.1097/IGC.0b013e3182994365.

    Related:

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: Timing of referral for ovarian patients

    • Barriers and facilitators to BRCA genetic counseling among at-risk Latinas in New York City.
    • Sussner KM, Jandorf L, Thompson HS, Valdimarsdottir HB.
    • Psychooncology. 2013 Jul;22(7):1594-604. doi: 10.1002/pon.3187. Epub 2012 Sep 16.
    • Implementation of a breast cancer genetic service in South Africa - lessons learned.
    • Schoeman M, Apffelstaedt JP, Baatjes K, Urban M.
    • S Afr Med J. 2013 Jun 25;103(8):529-33. doi: 10.7196/samj.6814.
    • Myriad BRCA Patents Nixed: What Happens Next?
    • Roxanne Nelson.
    • Medscape Medical News. Oncology. 2013 Jun 21.
    • Genomic Medicine Just Hit the Accelerator.
    • Eric J. Topol.
    • Medscape Internal Medicine. 2013 Jun 17.
    • Star Power.
    • Robert Resta.
    • The DNA Exchange. 2013 Jun 16.
    • Significant Under-Use of Genetic Testing for Inherited Cancers Puts Health of Entire Families at Risk.
    • [No author given].
    • ScienceDaily. 2013 Jun 7.
    • Acceptance of genetic counseling and testing in a hospital-based series of patients with gynecological cancer.
    • Dekker N, van Dorst EB, van der Luijt RB, van Gijn ME, van Tuil M, Offerhaus JA, Ausems MG.
    • J Genet Couns. 2013 Jun;22(3):345-57. doi: 10.1007/s10897-012-9553-3. Epub 2012 Nov 30.
    • Individual and family characteristics associated with BRCA1/2 genetic testing in high-risk families.
    • Katapodi MC, Northouse LL, Milliron KJ, Liu G, Merajver SD.
    • Psychooncology. 2013 Jun;22(6):1336-43. doi: 10.1002/pon.3139. Epub 2012 Jul 24.
    • The Angelina effect.
    • Kluger J, Park A.
    • Time. 2013 May 27;181(20):28-33.
    • Source
    • BRCA Choices Not Affordable for Many US Women.
    • Roxanne Nelson.
    • Medscape Medical News. Oncology. 2013 May 23.
    • Scotland expands breast cancer predictive genetic testing.
    • Philippa Brice.
    • PHG Foundation. 2013 May 22.
    • Angelina Jolie's Mastectomy: BRCA Testing in the Spotlight.
    • Kate Johnson.
    • Medscape Medical News. Oncology. 2013 May 16.
    • Prevalence and Healthcare Actions of Women in a Large Health System with a Family History Meeting the 2005 USPSTF Recommendation for BRCA Genetic Counseling Referral.
    • Bellcross CA, Leadbetter S, Alford SH, Peipins LA.
    • Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):728-35. doi: 10.1158/1055-9965.EPI-12-1280. Epub 2013 Jan 31.
    • Medical mistrust influences black women's level of engagement in BRCA 1/2 genetic counseling and testing.
    • Sheppard VB, Mays D, LaVeist T, Tercyak KP.
    • J Natl Med Assoc. 2013 Spring;105(1):17-22.
    • Early Onset Breast Cancer in a Registry-based Sample of African-American Women: BRCA Mutation Prevalence, and Other Personal and System-level Clinical Characteristics.
    • Pal T, Bonner D, Kim J, Monteiro AN, Kessler L, Royer R, Narod SA, Vadaparampil ST.
    • Breast J. 2013 Mar;19(2):189-92. doi: 10.1111/tbj.12083. Epub 2013 Jan 16.

    Related:

    Press: Young, Black, Female Breast Cancer Patients Need Genetic Risk Strategies. (Medical News Today)

    • Does the diagnosis of breast or ovarian cancer trigger referral to genetic counseling?
    • Powell CB, Littell R, Hoodfar E, Sinclair F, Pressman A.
    • Int J Gynecol Cancer. 2013 Mar;23(3):431-6. doi: 10.1097/IGC.0b013e318280f2b4.
    • Interest and attitudes of patients, cancer physicians, medical students and cancer researchers towards a spectrum of genetic tests relevant to breast cancer patients.
    • Ngoi N, Lee SC, Hartman M, Khin LW, Wong A.
    • Breast. 2013 Feb;22(1):47-52. doi: 10.1016/j.breast.2012.04.003. Epub 2012 May 4.
    • BRCA1/2 testing and cancer risk management in underserved women at a public hospital.
    • Hamann HA, Robinson LD, Moldrem AW, Golden EP, Mook JA, Pechero Bishop W, Sugg Skinner C, Euhus DM.
    • Commun Oncol 2012 Dec;9(12):369-376.
    • Receipt of Genetic Counseling Recommendations Among Black Women at High Risk for BRCA Mutations.
    • Thompson HS, Sussner K, Schwartz MD, Edwards T, Forman A, Jandorf L, Brown K, Bovbjerg DH, Valdimarsdottir HB.
    • Genet Test Mol Biomarkers. 2012 Nov;16(11):1257-62. doi: 10.1089/gtmb.2012.0114. Epub 2012 Oct 11.
    • Family communication of genetic test results and uptake of genetic testing in a diverse population of BRCA1 and BRCA2 (BRCA1/2) carriers.
    • Fehniger J, Lin F, Beattie M.
    • Gynecol Oncol 2012 Oct;127(1):s22-3. doi: 10.1016/j.ygyno.2012.07.062.
    • Conference abstract
    • Low rates of African American participation in genetic counseling and testing for BRCA1/2 mutations: racial disparities or just a difference?
    • Halbert CH, Kessler L, Collier A, Weathers B, Stopfer J, Domchek S, McDonald JA.
    • J Genet Couns. 2012 Oct;21(5):676-83. doi: 10.1007/s10897-012-9485-y. Epub 2012 Jul 12.
    • Adequacy of family history taking in ovarian cancer patients: a population-based study.
    • van Altena AM, van Aarle S, Kiemeney LA, Hoogerbrugge N, Massuger LF, de Hullu JA.
    • Fam Cancer. 2012 Sep;11(3):343-9. doi: 10.1007/s10689-012-9518-6.
    • Outcomes of a systems-level intervention offering breast cancer risk assessments to low-income underserved women.
    • Mays D, Sharff ME, Demarco TA, Williams B, Beck B, Sheppard VB, Peshkin BN, Eng-Wong J, Tercyak KP.
    • Fam Cancer. 2012 Sep;11(3):493-502. doi: 10.1007/s10689-012-9541-7.
    • Prophylactic oophorectomy rates in relation to a guideline update on referral to genetic counseling.
    • Pocobelli G, Chubak J, Hanson N, Drescher C, Resta R, Urban N, Buist DS.
    • Gynecol Oncol. 2012 Aug;126(2):229-35. doi: 10.1016/j.ygyno.2012.04.046. Epub 2012 May 4.
    • Barriers to genetic testing for breast cancer risk among ethnic minority women: an exploratory study.
    • Glenn BA, Chawla N, Bastani R.
    • Ethn Dis. 2012 Summer;22(3):267-73.
    • Efficient identification and referral of low-income women at high risk for hereditary breast cancer: a practice-based approach.
    • Joseph G, Kaplan C, Luce J, Lee R, Stewart S, Guerra C, Pasick R.
    • Public Health Genomics. [2012 Apr;]15(3-4):172-80. doi: 10.1159/000336419. Epub 2012 Apr 4.
    • Implications for cancer genetics practice of pro-actively assessing family history in a General Practice cohort in North West London.
    • Kohut K, D'Mello L, Bancroft EK, Thomas S, Young MA, Myhill K, Shanley S, Briggs BH, Newman M, Saraf IM, Cox P, Scambler S, Wagman L, Wyndham MT, Eeles RA, Ferris M.
    • Fam Cancer. 2012 Mar;11(1):107-13. doi: 10.1007/s10689-011-9482-6.
    • Will Chinese ovarian cancer patients benefit from knowing the BRCA2 mutation status?
    • Liu GY, Zhang W.
    • Chin J Cancer. 2012 Jan;31(1):1-4. doi: 10.5732/cjc.011.10432. Epub 2011 Dec 16.
    • Differences in US healthcare coverage policies in BRCA testing and potential implications.
    • Beattie MS, Wang G, Phillips KA.
    • Per Med. 2012 Jan;9(1):5-8. doi: 10.2217/pme.11.85.
    • Editorial
    • Barriers and facilitators for utilization of genetic counseling and risk assessment services in young female breast cancer survivors.
    • Anderson B, McLosky J, Wasilevich E, Lyon-Callo S, Duquette D, Copeland G.
    • J Cancer Epidemiol. 2012;2012:298745. doi: 10.1155/2012/298745. Epub 2012 Oct 22.